(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 1 November 2001 (01.11.2001)

PCT

English

(10) International Publication Number WO 01/81346 A2

(51) International Patent Classification⁷: C07D 473/00

(21) International Application Number: PCT/US01/13315

(22) International Filing Date: 24 April 2001 (24.04.2001)

(25) Filing Language:

(26) Publication Language: English

(30) Priority Data: 60/199,655 25 April 2000 (25.04.2000) US 60/238,057 5 October 2000 (05.10.2000) US

- (71) Applicant: ICOS CORPORATION [US/US]; 22021 20th Avenue S.E., Bothell, WA 98021 (US).
- (72) Inventors: SADHU, Chanchal; 903 223rd Street SE, Bothell, WA 98012 (US). DICK, Ken; 22517 1st Place West, Bothell, WA 98021-8321 (US). TREIBERG, Jennifer; 19411 Grannis Road, Bothell, WA 98012 (US). SOWELL, C., Gregory; 9423 61st Avenue W., Makilteo, WA 98275 (US). KESICKI, Edward, A.; 2504 208th Place SE, Bothell, WA 98021 (US). OLIVER, Amy; 23123 15th Avenue, S.E., Bothell, WA 98021 (US).


- (74) Agent: NAPOLI, James, J.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.





(57) Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compound s to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

- 1 -

INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application Serial No. 60/199,655, filed April 25, 2000 and U.S. provisional application Serial No. 60/238,057, filed October 25, 2000.

FIELD OF THE INVENTION

The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods of using such materials.

BACKGROUND OF THE INVENTION

Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a variety of cellular processes, e.g., malignant transformation, growth factor signaling, inflammation, and immunity (see Rameh et al., J. Biol Chem, 274:8347-8350 (1999) for a review). The enzyme responsible for generating these phosphorylated signaling products, phosphatidylinositol 3-kinase (PI 3-kinase; PI3K), was originally identified as an activity associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring

(Panayotou et al., *Trends Cell Biol* 2:358-60 (1992)).

The levels of phosphatidylinositol-3,4,5triphosphate (PIP3), the primary product of PI 3kinase activation, increase upon treatment of cells with a variety of agonists. PI 3-kinase activation, therefore, is believed to be involved in a range of cellular responses including cell growth, differentiation, and apoptosis (Parker et al., Current Biology, 5:577-99 (1995); Yao et al., Science, 267:2003-05 (1995)). Though the downstream targets of phosphorylated lipids generated following PI 3kinase activation have not been well characterized, emerging evidence suggests that pleckstrin-homology domain- and FYVE-finger domain-containing proteins are activated when binding to various phosphatidylinositol lipids (Sternmark et al., J Cell Sci, 112:4175-83 (1999); Lemmon et al., Trends Cell Biol, 7:237-42 (1997)). In vitro, some isoforms of protein kinase C (PKC) are directly activated by PIP3, and the PKC-related protein kinase, PKB, has been shown to be activated by PI 3-kinase (Burgering et al., Nature, 376:599-602 (1995)).

Presently, the PI 3-kinase enzyme family has been divided into three classes based on their substrate specificities. Class I PI3Ks can phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-biphosphate (PIP2) to produce phosphatidylinositol-3-phosphate (PIP), phosphatidylinositol-3,4-biphosphate, and phosphatidylinositol-3,4,5-triphosphate, respectively. Class II PI3Ks phosphorylate PI and

phosphatidylinositol-4-phosphate, whereas Class III PI3Ks can only phosphorylate PI.

The initial purification and molecular cloning of PI 3-kinase revealed that it was a heterodimer consisting of p85 and p110 subunits (Otsu et al., Cell, 65:91-104 (1991); Hiles et al., Cell, 70:419-29 (1992)). Since then, four distinct Class I PI3Ks have been identified, designated PI3K α , β , δ , and γ , each consisting of a distinct 110 kDa catalytic subunit and a regulatory subunit. More specifically, three of the catalytic subunits, i.e., pl10 α , pl10 β and pl10 δ , each interact with the same regulatory subunit, p85; whereas p110y interacts with a distinct regulatory subunit, plo1. As described below, the patterns of expression of each of these PI3Ks in human cells and tissues are also Though a wealth of information has been accumulated in recent past on the cellular functions of PI 3-kinases in general, the roles played by the individual isoforms are largely unknown.

Cloning of bovine p110 α has been described. This protein was identified as related to the Saccharomyces cerevisiae protein: Vps34p, a protein involved in vacuolar protein processing. The recombinant p110 α product was also shown to associate with p85 α , to yield a PI3K activity in transfected COS-1 cells. See Hiles et al., Cell, 70, 419-29 (1992).

The cloning of a second human p110 isoform, designated p110 β , is described in Hu et al., Mol Cell Biol, 13:7677-88 (1993). This isoform is said to associate with p85 in cells, and to be ubiquitously expressed, as p110 β mRNA has been found

in numerous human and mouse tissues as well as in human umbilical vein endothelial cells, Jurkat human leukemic T cells, 293 human embryonic kidney cells, mouse 3T3 fibroblasts, HeLa cells, and NBT2 rat bladder carcinoma cells. Such wide expression suggests that this isoform is broadly important in signaling pathways.

Identification of the p110 δ isoform of PI 3-kinase is described in Chantry et al., *J Biol Chem*, 272:19236-41 (1997). It was observed that the human p110 δ isoform is expressed in a tissue-restricted fashion. It is expressed at high levels in lymphocytes and lymphoid tissues, suggesting that the protein might play a role in PI 3-kinase-mediated signaling in the immune system. Details concerning the P110 δ isoform also can be found in U.S. Patent Nos. 5,858,753; 5,822,910; and 5,985,589. See also, Vanhaesebroeck et al., *Proc Natl Acad Sci USA*, 94:4330-5 (1997), and international publication WO 97/46688.

In each of the PI3K α , β , and δ subtypes, the p85 subunit acts to localize PÍ 3-kinase to the plasma membrane by the interaction of its SH2 domain with phosphorylated tyrosine residues (present in an appropriate sequence context) in target proteins (Rameh et al., Cell, 83:821-30 (1995)). Two isoforms of p85 have been identified, p85 α , which is ubiquitously expressed, and p85 β , which is primarily found in the brain and lymphoid tissues (Volinia et al., Oncogene, 7:789-93 (1992)). Association of the p85 subunit to the PI 3-kinase p110 α , β , or δ catalytic subunits appears to be required for the catalytic activity and stability of these enzymes. In

addition, the binding of Ras proteins also upregulates PI 3-kinase activity.

The cloning of p110 γ revealed still further complexity within the PI3K family of enzymes (Stoyanov et al., Science, 269:690-93 (1995)). The p110 γ isoform is closely related to p110 α and p110 β (45-48% identity in the catalytic domain), but as noted does not make use of p85 as a targeting subunit. Instead, p110 γ contains an additional domain termed a "pleckstrin homology domain" near its amino terminus. This domain allows interaction of p110 γ with the $\beta\gamma$ subunits of heterotrimeric G proteins and this interaction appears to regulate its activity.

The pl01 regulatory subunit for PI3Kgamma was originally cloned in swine, and the human ortholog identified subsequently (Krugmann et al., J Biol Chem, 274:17152-8 (1999)). Interaction between the N-terminal region of pl01 with the N-terminal region of pl10 γ appears to be critical for the PI3K γ activation through G $\beta\gamma$ mentioned above.

A constitutively active PI3K polypeptide is described in international publication WO 96/25488. This publication discloses preparation of a chimeric fusion protein in which a 102-residue fragment of p85 known as the inter-SH2 (iSH2) region is fused through a linker region to the N-terminus of murine p110. The p85 iSH2 domain apparently is able to activate PI3K activity in a manner comparable to intact p85 (Klippel et al., Mol Cell Biol, 14:2675-85 (1994)).

Thus, PI 3-kinases can be defined by their amino acid identity or by their activity. Addi-

tional members of this growing gene family include more distantly related lipid and protein kinases including Vps34 TOR1, and TOR2 of Saccharomyces cerevisiae (and their mammalian homologs such as FRAP and mTOR), the ataxia telangiectasia gene product (ATR) and the catalytic subunit of DNA-dependent protein kinase (DNA-PK). See generally, Hunter, Cell, 83:1-4 (1995).

PI 3-kinase also appears to be involved in a number of aspects of leukocyte activation. associated PI 3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important costimulatory molecule for the activation of T-cells in response to antigen (Pages et al., Nature, 369:327-29 (1994); Rudd, Immunity, 4:527-34 (1996)). Activation of T cells through CD28 lowers the threshold for activation by antigen and increases the magnitude and duration of the proliferative response. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL2), an important T cell growth factor (Fraser et al., Science, 251:313-16 (1991)). Mutation of CD28 such that it can no longer interact with PI 3-kinase leads to a failure to initiate IL2 production, suggesting a critical role for PI 3-kinase in T cell activation.

Specific inhibitors against individual members of a family of enzymes provide invaluable tools for deciphering functions of each enzyme. Two compounds, LY294002 and wortmannin, have been widely used as PI 3-kinase inhibitors. These compounds, however, are nonspecific PI3K inhibitors, as they do not distinguish among the four members of Class I PI

3-kinases. For example, the IC₅₀ values of wortmannin against each of the various Class I PI 3-kinases are in the range of 1-10 nM. Similarly, the IC₅₀ values for LY294002 against each of these PI 3-kinases is about 1 µM (Fruman et al., Ann Rev Biochem, 67:481-507 (1998)). Hence, the utility of these compounds in studying the roles of individual Class I PI 3-kinases is limited.

Based on studies using wortmannin, there is evidence that PI 3-kinase function also is required for some aspects of leukocyte signaling through G-protein coupled receptors (Thelen et al., Proc Natl Acad Sci USA, 91:4960-64 (1994)). Moreover, it has been shown that wortmannin and LY294002 block neutrophil migration and superoxide release. However, inasmuch as these compounds do not distinguish among the various isoforms of PI3K, it remains unclear which particular PI3K isoform or isoforms are involved in these phenomena.

LY294002

wortmannin

In view of the above considerations, it is clear that existing knowledge is lacking with respect to structural and functional features of the PI 3-kinase enzymes, including subcellular localization, activation states, substrate affinities, and the like. Moreover, the functions that these enzymes perform in both normal and diseased tissues remains to be elucidated. In particular, the function of PI3Ko in leukocytes has not previously been characterized, and knowledge concerning its function in human physiology remains limited. The coexpression in these tissues of other PI3K isoforms has heretofore confounded efforts to segregate the activities of each enzyme. Furthermore, separation of the activities of the various PI3K isozymes may not be possible without identification of inhibitors that demonstrate selective inhibition character-Indeed, Applicants are not presently aware that such selective, or better, specific, inhibitors of PI3K isozymes have been demonstrated.

Thus, there exists a need in the art for further structural characterization of the PI3K δ polypeptide. There also exists a need for func-

WO 01/81346 PCT/US01/13315

- 9 -

tional characterization of PI3Kō. Furthermore, our understanding of PI3Kō requires further elaboration of the structural interactions of p110ō, both with its regulatory subunit and with other proteins in the cell. There also remains a need for selective or specific inhibitors of PI3K isozymes, in order that the functions of each isozyme can be better characterized. In particular, selective or specific inhibitors of PI3Kō are desirable for exploring the role of this isozyme and for development of pharmaceuticals to modulate the activity of the isozyme.

One aspect of the present invention is to provide compounds that can inhibit the biological activity of human PI3Kō. Another aspect of the invention is to provide compounds that inhibit PI3Kō selectively while having relatively low inhibitory potency against the other PI3K isoforms. Another aspect of the invention is to provide methods of characterizing the function of human PI3Kō. Another aspect of the invention is to provide methods of selectively modulating human PI3Kō activity, and thereby promoting medical treatment of diseases mediated by PI3Kō dysfunction. Other aspects and advantages of the invention will be readily apparent to the artisan having ordinary skill in the art.

SUMMARY OF THE INVENTION

It has now been discovered that these and other aspects can be achieved by the present invention, which, in one aspect, is a method for disrupting leukocyte function, comprising contacting leukocytes with a compound that selectively inhibits

WO 01/81346 PCT/US01/13315

- 10 -

phosphatidylinositol 3-kinase delta (PI3Kδ) activity in the leukocytes. According to the method, the leukocytes can comprise cells selected from the group consisting of neutrophils, B lymphocytes, T lymphocytes, and basophils.

For example, in cases in which the leukocytes comprise neutrophils, the method can comprise disrupting at least one neutrophil function selected from the group consisting of stimulated superoxide release, stimulated exocytosis, and chemotactic migration. Preferably, the method does not substantially disrupt bacterial phagocytosis or bacterial killing by the neutrophils. In cases wherein the leukocytes comprise B lymphocytes, the method can comprise disrupting proliferation of the B lymphocytes or antibody production by the B lymphocytes. In cases wherein the leukocytes comprise T lymphocytes, the method can comprise disrupting proliferation of the T lymphocytes. In cases wherein the leukocytes comprise basophils, the method can comprise disrupting histamine release by the basophils.

In the methods of the invention wherein a selective PI3Kō inhibitor is employed, it is preferred that the compound be at least about 10-fold selective for inhibition of PI3Kō relative to other Type I PI3K isoforms in a cell-based assay. More preferably, the compound is at least about 20-fold selective for inhibition of PI3Kō relative to other Type I PI3K isoforms in a cell-based assay. Still more preferably, the compound is at least about 50-fold selective for inhibition of PI3Kō relative to other Type I PI3K isoforms in a biochemical assay.

Preferred selective compounds useful according to the methods include compounds having the structure (I):

$$R^{1}$$
 R^{2}
 N
 $X-Y A$
 (I)

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHR^b , CH_2CHR^b , and $CH=C\left(R^b\right)$;

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=O), OC(=O), C(=O)O, and NHC(=O)CH₂S;

 R^1 and R^2 , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, NHC(=0) C_{1-3} alkyleneN(R^a)₂, NO₂, OR^a, OCF₃, N(R^a)₂, CN, OC(=0) R^a , C(=0) R^a , C(=0)OR^a, aryloR^b, Het, NR^aC(=0) C_{1-3} alkyleneC(=0)OR^a, arylOC₁₋₃alkylene-N(R^a)₂, arylOC(=0)R^a, C_{1-4} alkyleneC(=0)OR^a, OC₁₋₄alkyleneC(=0)OR^a, C(=0)-NR^aSO₂R^a, C_{1-4} alkyleneOC₁₋₄alkyleneC(=0)OR^a, C(=0)-NR^aSO₂R^a, C_{1-4} alkyleneN(R^a)₂, C_{2-6} alkenyleneN(R^a)₂, C(=0)NR^aC₁₋₄alkyleneOR^a, C(=0)NR^aC₁₋₄alkyleneHet, OC₂₋₄-alkyleneN(R^a)₂, OC₁₋₄alkyleneCH(OR^b)CH₂N(R^a)₂, OC₁₋₄al-kyleneHet, OC₂₋₄-alkyleneHet, OC₂₋₄-alkyleneHet, OC₂₋₄-alkyleneOR^a, OC₂₋₄alkyleneNR^aC(=0)OR^a,

 $\label{eq:NRaccondition} NR^aC_{1-4}alkyleneN\left(R^a\right)_2, \ NR^aC\left(=0\right)R^a, \ NR^aC\left(=0\right)N\left(R^a\right)_2, \\ N\left(SO_2C_{1-4}alkyl\right)_2, \ NR^a\left(SO_2C_{1-4}alkyl\right), \ SO_2N\left(R^a\right)_2, \ OSO_2CF_3, \\ C_{1-3}alkylenearyl, \ C_{1-4}alkyleneHet, \ C_{1-6}alkyleneOR^b, \\ C_{1-3}alkyleneN\left(R^a\right)_2, \ C\left(=0\right)N\left(R^a\right)_2, \ NHC\left(=0\right)C_1-C_3alkylene-aryl, \ C_{3-6}cycloalkyl, \ C_{3-8}heterocycloalkyl, \ aryl-OC_{1-3}alkyleneN\left(R^a\right)_2, \ arylOC\left(=0\right)R^b, \ NHC\left(=0\right)C_{1-3}alkylene-C_{3-8}heterocycloalkyl, \ NHC\left(=0\right)C_{1-3}alkyleneHet, \ OC_{1-4}al-kyleneOC_{1-4}alkyleneC\left(=0\right)OR^b, \ C\left(=0\right)C_{1-4}alkyleneHet, \ and \\ NHC\left(=0\right)haloC_{1-6}alkyl;$

or R^1 and R^2 are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R³ is selected from the group consisting of optionally substituted hydrogen, C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C1-4alkylenecycloalkyl, C_{2-6} alkenyl, C_{1-3} alkylenearyl, aryl C_{1-3} alkyl, C(=0) R^a , aryl, heteroaryl, $C(=0)OR^a$, $C(=0)N(R^a)_2$, $C(=S)N(R^a)_2$, SO_2R^a , $SO_2N(R^a)_2$, $S(=0)R^a$, $S(=0)N(R^a)_2$, $C(=0)NR^aC_{1-4}$ alkyleneOR^a, $C(=0)NR^aC_{1-4}alkyleneHet$, $C(=0)C_{1-4}alkyl$ enearyl, $C(=0)C_{1-4}alkyleneheteroaryl, C_{1-4}alkylenearyl$ optionally substituted with one or more of halo, $SO_2N(R^a)_2$, $N(R^a)_2$, $C(=O)OR^a$, $NR^aSO_2CF_3$, CN, NO_2 , $C(=O)R^a$, OR^a , C_{1-4} alkyleneN(R^a)₂, and OC_{1-4} alkyleneN(R^a)₂, C_{1-4} alkyleneheteroaryl, C1-4alkyleneHet, C1-4alkyleneC(=0)-C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=0)C₁₋₄alkyleneheteroaryl, C_{1-4} alkyleneC(=0)Het, C_{1-4} alkyleneC(=0)N(R^a)₂, C_{1-4} alkylene OR^a , C_{1-4} alkylene NR^aC (=0) R^a , C_{1-4} alkyleneO- C_{1-4} alkylene OR^a , C_{1-4} alkylene $N(R^a)_2$, C_{1-4} alkylene $C(\approx 0)$ -ORa, and C₁₋₄alkyleneOC₁₋₄alkyleneC(=O)ORa;

 R^a is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneN(R^a)₂, aryl, aryl C_{1-3} alkyl, C_{1-3} -

WO 01/81346 PCT/US01/13315

- 13 -

alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

 R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and C_{1-3} alkylenearyl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0)OR^a;

and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof,

wherein the compound has at least about a 10-fold selective inhibition for PI3Kδ relative other Type-I PI3K isoforms in a cell-based assay.

In another embodiment, the invention is a method for treating a medical condition mediated by neutrophils, comprising administering to an animal in need thereof an effective amount of a compound that selectively inhibits phosphatidylinositol 3-kinase delta (PI3Kō) activity in the neutrophils. Exemplary medical conditions that can be treated according to the method include those conditions characterized by an undesirable neutrophil function selected from the group consisting of stimulated superoxide release, stimulated exocytosis, and chemotactic migration. Preferably, according to the method, phagocytic activity or bacterial killing by the neutrophils is substantially uninhibited.

WO 01/81346 PCT/US01/13315

In another embodiment, the invention is a method for disrupting a function of osteoclasts comprising contacting osteoclasts with a compound that selectively inhibits phosphatidylinositol 3-kinase delta (PI $3K\delta$) activity in the osteoclasts. According to the method, the compound can comprise a moiety that preferentially binds to bone.

In another embodiment, the invention is a method of ameliorating a bone-resorption disorder in an animal in need thereof comprising administering to the animal an effective amount of a compound that inhibits phosphatidylinositol 3-kinase delta (PI3K δ) activity in osteoclasts of the animal. A preferred bone-resorption disorder amenable to treatment according to the method is osteoporosis.

In another embodiment, the invention is a method for inhibiting the growth or proliferation of cancer cells of hematopoietic origin, comprising contacting the cancer cells with a compound that selectively inhibits phosphatidylinositol 3-kinase delta (PI3K δ) activity in the cancer cells. The method can be advantageous in inhibiting the growth or proliferation of cancers selected from the group consisting of lymphomas, multiple myelomas, and leukemias.

In another embodiment, the invention is a method of inhibiting kinase activity of a phosphatidylinositol 3-kinase delta (PI3Kδ) polypeptide, comprising contacting the PI3Kδ polypeptide with a compound having the generic structure (I).

Preferred compounds useful according to the method include compounds selected from the group consisting of:

wherein Y is selected from the group consisting of null, S, and NH;

 R^4 is selected from the group consisting of H, halogen, NO_2 , OH, OCH₃, CH₃, and CF₃;

 $$\rm R^{5}$$ is selected from the group consisting of H, OCH3, and halo;

or R⁴ and R⁵ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6-membered aromatic ring optionally containing one or more O, N, or S atoms;

 $$\rm R^6$$ is selected from the group consisting of $\rm C_1\text{-}C_6alkyl,$ phenyl, halophenyl, alkoxyphenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0)OC_2H_5, and morpholinyl;

 R^d , independently, is selected from the group consisting of NH_2 , halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, $NH(C_{1-3}$ alkyl), $N(C_{1-3}$ alkyl), $NH(C_{1-3}$ alkyl), $NH(C_{1-3}$ alkyl), and

; and

q is 1 or 2,

provided that at least one of R^4 and R^5 is other than H when R^6 is phenyl or 2-chlorophenyl.

More preferably, the compound is selected from the group consisting of:

wherein Y is selected from the group consisting of null, S, and NH;

 $$\rm R^7$ is selected from the group consisting of H, halo, OH, OCH3, CH3, and CF3;

 ${\tt R}^{\tt B}$ is selected from the group consisting of is H, OCH3, and halogen;

or R⁷ and R⁸ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6membered aromatic ring optionally containing one or more O, N, or S atoms;

 R^9 is selected from the group consisting of C_1 - C_6 alkyl, phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0)- OC_2H_5 , and morpholinyl;

 R^d , independently, is selected from the group consisting of NH_2 , halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, $NH(C_{1-3}$ alkyl), $N(C_{1-3}$ alkyl), $NH(C_{1-3}$ alkyl), and

q is 1 or 2,

provided that at least one of R^7 and R^8 is different from 6-halo or 6,7-dimethoxy groups, and that R^9 is different from 4-chlorophenyl.

In another embodiment, the invention is a method for disrupting leukocyte function, comprising contacting leukocytes with a compound having a general structure (I).

In another embodiment, the invention is a class of compounds that have been observed to inhibit PI3K δ activity in biochemical and cell-based assays, and are expected to exhibit therapeutic benefit in medical conditions in which PI3K δ activity is excessive or undesirable. Thus, the invention provides a class of compounds having the structure (II).

Preferably, the compounds have a general structure (IV)

wherein Y is selected from the group consisting of null, S, and NH;

 R^{10} is selected from the group consisting of H, halo, OH, OCH3, CH3, and CF3;

 ${\bf R}^{11}$ is selected from the group consisting of H, OCH3, and halo;

or R¹⁰ and R¹¹ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6membered aromatic ring optionally containing one or more O, N, or S atoms;

 $$R^{12}$$ is selected from the group consisting of $C_1\text{-}C_6alkyl,$ phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, $C(=O)\,C_2H_5,$ and morpholinyl;

 R^d , independently, is selected from the group consisting of NH_2 , halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, $NH(C_{1-3}$ alkyl), $N(C_{1-3}$ alkyl), $NH(C_{1-3}$ alkyl), $NH(C_{1-3}$ alkyl), and

q is 1 or 2, provided that:

- (a) at least one of R¹⁰ and R¹¹ is different from 6-halo or 6,7-dimethoxy groups;
- (b) R^{12} is different from 4-chlorophenyl; and
- (c) at least one of R^{10} and R^{11} is different from H when R^{12} is phenyl or 2-chlorophenyl and X is S.

These and other features and advantages of the present invention will be appreciated from the detailed description and examples that are set forth herein. The detailed description and examples are provided to enhance the understanding of the invention, but are not intended to limit the scope of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the effect of a selective PI3K δ inhibitor of the invention on the activity of three PI3K isoforms.

Figure 2 shows the effect of a selective PI3K δ inhibitor on superoxide generation by human neutrophils in the presence of TNF or IgG.

Figure 3 shows the effect of a selective PI3K δ inhibitor on superoxide generation by human neutrophils in the presence of TNF or fMLP.

Figure 4 shows the effect of a selective PI3K δ inhibitor on elastase exocytosis in the presence of fMLP by human neutrophils.

Figure 5 shows the effect of a selective PI3K δ inhibitor on fMLP-induced chemotaxis by human neutrophils.

Figure 6 shows that a selective PI3Kδ inhibitor does not affect phagocytosis and killing of S. aureus by neutrophils.

Figure 7 shows the effect of a selective PI3K δ inhibitor on proliferation and antibody production by human B lymphocytes.

Figure 8 shows the effect of a selective PI3K δ inhibitor on anti-IgM stimulated mouse splenic B lymphocyte proliferation.

Figure 9 shows the effect of a selective PI3K δ inhibitor on elastase exocytosis in an animal model.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention provides compounds that selectively inhibit the activity of PI3Kδ. The invention further provides methods of inhibiting PI3Kδ activity, including methods of selectively modulating the activity of the PI3Kδ isozyme in cells, especially leukocytes, osteoclasts, and cancer cells. The methods include in vitro, in vivo, and ex vivo applications.

Of particular benefit are methods of selectively modulating PI3K δ activity in the clinical setting in order to ameliorate disease or discorders mediated by PI3K δ activity. Thus, treatment of diseases or disorders characterized by excessive or inappropriate PI3K δ activity can be treated through use of selective modulators of PI3K δ according to the invention.

Other methods of the invention include enabling the further characterization of the physio-

logical role of the isozyme. Moreover; the invention provides pharmaceutical compositions comprising selective PI3Kō inhibitors. Also provided are articles of manufacture comprising a selective PI3Kō inhibitor compound (or a pharmaceutical composition comprising the compound) and instructions for using the compound. Details of these and other useful embodiments of the invention are now described.

The methods described herein benefit from the use of compounds that selectively inhibit, and preferably specifically inhibit, the activity of PI3Ko in cells, including cells in vitro, in vivo, or ex vivo. Cells useful in the methods include those that express endogenous PI3Ko, wherein endogenous indicates that the cells express PI3Ko absent recombinant introduction into the cells of one or more polynucleotides encoding a PI3Ko polypeptide or a biologically active fragment thereof. Methods also encompass use of cells that express exogenous PI3Ko, wherein one or more polynucleotides encoding PI3Ko or a biologically active fragment thereof have been introduced into the cell using recombinant procedures.

Of particular advantage, the cells can be in vivo, i.e., in a living subject, e.g., an animal or human, wherein a PI3Kō inhibitor can be used as a therapeutic to inhibit PI3Kō activity in the subject. Alternatively, the cells can be isolated as discrete cells or in a tissue, for ex vivo or in vitro methods. In vitro methods also encompassed by the invention can comprise the step of contacting a PI3Kō enzyme or a biologically active fragment thereof with an inhibitor compound of the invention.

The PI3K δ enzyme can include a purified and isolated enzyme, wherein the enzyme is isolated from a natural source (e.g., cells or tissues that normally express a PI3K δ polypeptide absent modification by recombinant technology) or isolated from cells modified by recombinant techniques to express exogenous enzyme.

The term "selective PI3Kδ inhibitor" as used herein refers to a compound that inhibits the PI3K δ isozyme more effectively than other isozymes of the PI3K family. A "selective PI3Ko inhibitor" compound is understood to be more selective for PI3Kδ than compounds conventionally and generically designated PI3K inhibitors, e.g., wortmannin or LY294002. Concomitantly, wortmannin and LY294002 are deemed "nonselective PI3K inhibitors." Compounds of any type that selectively negatively regulate PI3Kδ expression or activity can be used as selective PI3K δ inhibitors in the methods of the Moreover, compounds of any type that invention. selectively negatively regulate PI3Kδ expression or activity and that possess acceptable pharmacological properties can be used as selective PI3Kδ inhibitors in the therapeutic methods of the invention.

The relative efficacies of compounds as inhibitors of an enzyme activity (or other biological activity) can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results. Typically, the preferred determination is the concentration that inhibits 50% of the activity in a biochemical assay, i.e., the 50% inhibitory concentration or "IC₅₀." IC₅₀ determinations can be

accomplished using conventional techniques known in the art. In general, an IC_{50} can be determined by measuring the activity of a given enzyme in the presence of a range of concentrations of the inhibitor under study. The experimentally obtained values of enzyme activity then are plotted against the inhibitor concentrations used. The concentration of the inhibitor that shows 50% enzyme activity (as compared to the activity in the absence of any. inhibitor) is taken as the IC₅₀ value. Analogously, other inhibitory concentrations can be defined through appropriate determinations of activity. For example, in some settings it can be desirable to establish a 90% inhibitory concentration, i.e., IC, etc.

Accordingly, a "selective PI3K δ inhibitor" alternatively can be understood to refer to a compound that exhibits a 50% inhibitory concentration (IC $_{50}$) with respect to PI3K δ that is at least at least 10-fold, preferably at least 20-fold, and more preferably at least 30-fold, lower than the IC $_{50}$ value with respect to any or all of the other Class I PI3K family members. The term "specific PI3K δ inhibitor" can be understood to refer to a selective PI3K δ inhibitor compound that exhibits an IC $_{50}$ with respect to PI3K δ that is at least 50-fold, preferably at least 200-fold, and still more preferably at least 200-fold, lower than the IC $_{50}$ with respect to any or all of the other PI3K Class I family members.

Among other things, the invention provides methods of inhibiting leukocyte function. More particularly, the invention provides methods of inhib-

iting or suppressing functions of neutrophils and T and B lymphocytes. With respect to neutrophils, it has unexpectedly been found that inhibition of PI3Ko activity inhibits functions of neutrophils. example, it has been observed that the compounds of the invention elicit inhibition of classical neutrophil functions such as stimulated superoxide release, stimulated exocytosis, and chemotactic migra-However, it has been further observed that tion. the method of the invention permits suppression of certain functions of neutrophils, while not substantially affecting other functions of these cells. For example, it has been observed that phagocytosis of bacteria by neutrophils is not substantially inhibited by the selective PI3Kδ inhibitor compounds of the invention.

Thus, the invention includes methods for inhibiting neutrophil functions, without substantially inhibiting phagocytosis of bacteria. phil functions suitable for inhibition according to the method include any function that is mediated by PI3Kδ activity or expression. Such functions include, without limitation, stimulated superoxide release, stimulated exocytosis or degranulation, chemotactic migration, adhesion to vascular endothelium (e.g., tethering/rolling of neutrophils, triggering of neutrophil activity, and/or latching of neutrophils to endothelium), transmural diapedesis or emigration through the endothelium to peripheral tissues. In general, these functions can be collectively termed "inflammatory functions," as they are typically related to neutrophil response to inflammation. The inflammatory functions of neutroWO 01/81346 PCT/US01/13315

phils can be distinguished from the bacterial killing functions exhibited by these cells, e.g., phagocytosis and killing of bacteria. Accordingly, the
invention further includes methods of treating disease states in which one or more of the inflammatory functions of neutrophils are abnormal or undesirable.

It has further been established through the invention that PI3Kō plays a role in the stimulated proliferation of lymphocytes, including B cells and T cells. Moreover, PI3Kō appears to play a role in stimulated secretion of antibodies by B cells. Selective PI3Kō inhibitor compounds of the invention have been employed to establish that these phenomena can be abrogated by inhibition of PI3Kō. Thus, the invention includes methods of inhibiting lymphocyte proliferation, and methods of inhibiting antibody production by B lymphocytes. Other methods enabled by the invention include methods of treating disease states in which one or more of these lymphocyte functions are abnormal or undesirable.

It has now been determined that PI3K δ activity can be inhibited selectively or specifically to facilitate treatment of a PI3K δ -mediated disease while reducing or eliminating complications that are typically associated with concomitant inhibition of the activity of other Class I PI 3-kinases. To illustrate this embodiment, methods of the invention can be practiced using members of a class of compounds that have been found to exhibit selective inhibition of PI3K δ relative to other PI3K isoforms.

The methods of this embodiment can be practiced using compounds having the general structure (III). Preferred methods employ compounds that have been empirically determined to exhibit at least 10-fold selective inhibition of PI3Kδ relative to other PI3K isoforms. For example, the methods can be practiced using the following compounds: 3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one; 5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-y-ylsulfanylmethyl-3H-quinazolin-4-one; 3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-6-fluoro-2-(9h-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-.ylmethyl)-3H-quinazolin-4-one; 3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 3-(3-methoxyphenyl-2-(9H-purin-6-ylsulfanylmethyl-3H-quinazolin-4-one; 3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl) - 3H-quinazolin-4-one; 3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one; 3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one;

```
3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
 quinazolin-4-one, acetate salt;
8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 3-(2-methoxyphenyl-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
 3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
 quinazolin-4-one;
 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
trifluoromethyl-3H-quinazolin-4-one;
 3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
 3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one, acetate salt;
 3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
 [5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
 quinazolin-3-yl]acetic acid ethyl ester;
 3-(2,4-dimethoxyphenyl)-2-(9H-purin-6-ylsulfanyl-
 methyl) -3H-quinazolin-4-one;
 3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-
 ylsulfanylmethyl)-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
 methyl-3H-quinazolin-4-one;
```

```
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
chloro-3H-quinazolin-4-one;
5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsul-
fanylmethyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
fluoro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-
fluoro-3H-quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-phenyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-isopropyl-
phenyl)-3H-quinazolin-4-one; and
```

2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazolin-4-one.

It has further been determined that the methods of the invention can be advantageously practiced using members of a class of compounds that exhibit PI3Kδ inhibitory activity, thereby facilitating inhibitions of PI3Kδ activity in diseases mediated thereby. For example, in this embodiment, the methods of the invention can be practiced using compounds having the general structure (I).

$$R^{1}$$
 R^{2}
 N
 $X-Y A$

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHR^b , CH_2CHR^b , and $CH=C\left(R^b\right)$;

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=O), OC(=O), C(=O)O, and NHC(=O)CH₂S;

 R^1 and R^2 , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, NHC(=0) C_{1-3} alkyleneN(R^a)₂, NO₂, OR^a, OCF₃, N(R^a)₂, CN, OC(=0) R^a , C(=0) R^a , C(=0)OR^a, aryloR^b, Het, NR^aC(=0) C_{1-3} alkyleneC(=0)OR^a, aryloC₁₋₃alkylene-

N(R^a)₂, arylOC(=0)R^a, C₁₋₄alkyleneC(=0)OR^a, OC₁₋₄alkyleneC(=0)OR^a, C₁₋₄alkyleneC(=0)OR^a, C(=0)
NR^aSO₂R^a, C₁₋₄alkyleneN(R^a)₂, C₂₋₆alkenyleneN(R^a)₂,

C(=0)NR^aC₁₋₄alkyleneOR^a, C(=0)NR^aC₁₋₄alkyleneHet,

OC₂₋₄alkyleneN(R^a)₂, OC₁₋₄alkyleneCH(OR^b)CH₂N(R^a)₂,

OC₁₋₄alkyleneHet, OC₂₋₄alkyleneOR^a, OC₂₋₄alkylene
NR^aC(=0)OR^a, NR^aC₁₋₄alkyleneN(R^a)₂, NR^aC(=0)R^a,

NR^aC(=0)N(R^a)₂, N(SO₂C₁₋₄alkyl)₂, NR^aC(=0)R^a,

SO₂N(R^a)₂, OSO₂CF₃, C₁₋₃alkylenearyl, C₁₋₄alkyleneHet,

C₁₋₆alkyleneOR^b, C₁₋₃alkyleneN(R^a)₂, C(=0)N(R^a)₂,

NHC(=0)C₁-C₃alkylenearyl, C₃₋₈cycloalkyl, C₃₋₈hetero
cycloalkyl, arylOC₁₋₃alkyleneN(R^a)₂, arylOC(=0)R^b,

NHC(=0)C₁₋₃alkyleneC₃₋₈heterocycloalkyl, NHC(=0)C₁₋₃
alkyleneHet, OC₁₋₄alkyleneOC₁₋₄alkyleneC(=0)OR^b,

C(=0)C₁₋₄alkyleneHet, and NHC(=0)haloC₁₋₆alkyl;

or R¹ and R² are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R³ is selected from the group consisting of optionally substituted hydrogen, C₁₋₆alkyl, C₃₋₈cyclo-alkyl, C₃₋₈heterocycloalkyl, C₁₋₄alkylenecycloalkyl, C₂₋₆alkenyl, C₁₋₃alkylenearyl, arylC₁₋₃alkyl, C(=0)R^a, aryl, heteroaryl, C(=0)OR^a, C(=0)N(R^a)₂, C(=S)N(R^a)₂, SO₂R^a, SO₂N(R^a)₂, S(=O)R^a, S(=O)N(R^a)₂, C(=O)NR^aC₁₋₄-alkyleneOR^a, C(=O)NR^aC₁₋₄alkyleneHet, C(=O)C₁₋₄alkyl-enearyl, C(=O)C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl optionally substituted with one or more of halo SO₂N(R^a)₂, N(R^a)₂, C(=O)OR^a, NR^aSO₂CF₃, CN, NO₂, C(=O)R^a, OR^a, C₁₋₄alkyleneN(R^a)₂, and OC₁₋₄alkyleneN(R^a)₂, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkylene-C(=O)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneC(=O)-

 $N(R^a)_2$, C_{1-4} alkylene OR^a , C_{1-4} alkylene NR^aC (=0) R^a , C_{1-4} alkylene OC_{1-4} alkylene OR^a , C_{1-4} alkylene OC_{1-4} alkylene

 R^a is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneN(R^a)₂, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

 R^b is selected from the group consisting of hydrogen, C_{1-5} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, C_{1-3} alkyl, and C_{1-3} alkyl-eneheteroaryl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0) OR^a ;

and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.

For example, methods of the invention can employ compounds that possess PI3K δ inhibitory activity, as follows:

3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one;

5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one;

5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-ylmethyl)-3H-quinazolin-4-one;

```
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
 3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6-fluoro-2-(9h-purin-6-ylsulfan-
 ylmethyl)-3h-quinazolin-4-one;
 5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
:3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
 quinazolin-4-one, acetate salt;
 8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 3-(3-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
```

```
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
 quinazolin-4-one;
 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 trifluoromethyl-3H-quinazolin-4-one;
 3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one, acetate salt;
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 [5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
 quinazolin-3-yl]acetic acid ethyl ester;
3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
 methyl) -3H-quinazolin-4-one;
 5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-t-
chloro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
```

```
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
 fluoro-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
 quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
 one;
· 2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H- ·
 quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-
 fluoro-3H-quinazolin-4-one;
 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
3-phenyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
 phenyl) -3H-quinazolin-4-one;
 3-(4-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-
 ylsulfanylmethyl) - 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-7-nitro-2-(9H-purin-6-ylsulfanyl-
 methyl)-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-6-bromo-3-(2-chloro-
 phenyl) -3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-
 dimethoxy-3H-quinazolin-4-one;
 6-bromo-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanyl-
 methyl) -3H-quinazolin-4-one;
 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-benzo[g]quinazolin-4-one;
```

2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazolin-4-one; and

2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-phenyl)-3H-quinazolin-4-one.

The invention further provides compounds that are selective inhibitors of PI3Kō activity. The compounds exhibit inhibition of PI3Kō in biochemical assays, and selectively disrupt function of PI3Kō-expressing cells in cell-based assays. As described elsewhere herein, the compounds of the invention have been demonstrated to inhibit certain functions in neutrophils and other leukocytes, as well as functions of osteoclasts.

In general, compounds provided by the invention have the general structure (I), a pharmaceutically acceptable salt thereof, or a prodrug thereof:

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHR^b , CH_2CHR^b , and $CH=C\left(R^b\right)$;

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=0), OC(=0), C(=0)O, and NHC(=0)CH₂S;

R¹ and R², independently, are selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, halo, NHC(=0)C1.3alkyleneN(Ra), NO, ORa, OCF_3 , $N(R^a)_2$, CN, $OC(=O)R^a$, $C(=O)R^a$, $C(=O)OR^a$, $arylor^b$, Het, NRaC(=0)C1.3alkyleneC(=0)ORa, arylOC1-3alkylene- $N(R^a)_2$, aryloc(=0) R^a , C_{1-4} alkylenec(=0) OR^a , OC_{1-4} alkyleneC(=0)ORa, C1-4alkyleneOC1-4alkyleneC(=0)ORa, C(=0)-·NRaSO₂Ra, C₁₋₄alkyleneN(Ra)₂, C₂₋₆alkenyleneN(Ra)₂, C(=0)NRaC₁₋₄alkyleneORa, C(=0)NRaC₁₋₄alkyleneHet, OC₂₋₄alkyleneN(R^a)₂, OC₁₋₄alkyleneCH(OR^b)CH₂N(R^a)₂, OC₁₋₄alkyleneHet, OC₂₋₄alkyleneOR^a, OC₂₋₄alkylene- $NR^{a}C(=0)OR^{a}$, $NR^{a}C_{1..4}alkyleneN(R^{a})_{2}$, $NR^{a}C(=0)R^{a}$, $NR^{a}C(=0)N(R^{a})_{2}$, $N(SO_{2}C_{1-4}alkyl)_{2}$, $NR^{a}(SO_{2}C_{1-4}alkyl)_{2}$, SO₂N(R^a)₂, OSO₂CF₃, C₁₋₃alkylenearyl, C₁₋₄alkyleneHet, C_{1-6} alkyleneOR^b, C_{1-3} alkyleneN(R^a)₂, C(=0)N(R^a)₂, NHC(=0)C₁-C₃alkylenearyl, C₂₋₈cycloalkyl, C₄₋₈heterocycloalkyl, arylOC₁₋₃alkyleneN(R^a)₂, arylOC(=0)R^b, NHC(=0)C₁₋₃alkyleneC₃₋₈heterocycloalkyl, NHC(=0)C₁₋₃alkyleneHet, OC₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^b, C(=0)C₁₋₄alkyleneHet, and NHC(=0)haloC₁₋₆alkyl;

or R¹ and R² are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

 $\rm R^3$ is selected from the group consisting of optionally substituted hydrogen, $\rm C_{1-6}alkyl$, $\rm C_{3-8}cyclo-alkyl$, $\rm C_{3-8}heterocycloalkyl$, $\rm C_{1-4}alkylenecycloalkyl$, $\rm C_{2-6}alkenyl$, $\rm C_{1-3}alkylenearyl$, $\rm arylC_{1-3}alkyl$, $\rm C(=0)\,R^a$, aryl, heteroaryl, $\rm C(=0)\,OR^a$, $\rm C(=0)\,N(R^a)_2$, $\rm C(=S)\,N(R^a)_2$, $\rm SO_2R^a$, $\rm SO_2N\,(R^a)_2$, $\rm S(=0)\,R^a$, $\rm S(=0)\,N(R^a)_2$, $\rm C(=0)\,NR^aC_{1-4}-$

alkyleneOR^a, $C(=0)NR^{3}C_{1.4}$ alkyleneHet, $C(=0)C_{1.4}$ alkylenearyl enearyl, $C(=0)C_{1.4}$ alkyleneheteroaryl, $C_{1.4}$ alkylenearyl optionally substituted with one or more of halo $SO_{2}N(R^{a})_{2}$, $N(R^{a})_{2}$, $C(=0)OR^{a}$, $NR^{a}SO_{2}CF_{3}$, CN, NO_{2} , $C(=0)R^{a}$, OR^{a} , $C_{1.4}$ alkyleneN(R^{a}), and $OC_{1.4}$ alkyleneN(R^{a}), $C_{1.4}$ -alkyleneheteroaryl, $C_{1.4}$ alkyleneHet, $C_{1.4}$ alkyleneC(=0)- $C_{1.4}$ alkylenearyl, $C_{1.4}$ alkyleneC(=0) $C_{1.4}$ alkyleneC(=0)N($C_{1.4}$ alkyleneC(=0)N($C_{1.4}$ alkyleneO(=0)N($C_{1.4}$ alkyleneO(=0)N($C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneNRaC(=0)Ra, $C_{1.4}$ alkyleneO- $C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneN($C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneORa, $C_{1.4}$ alkyleneO(=0)- $C_{1.4}$ alkyleneO(=0)

 R^a is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneN(R^a)₂, aryl, aryl C_{1-3} alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

 R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and C_{2-3} alkylenearyl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0) OR^a ;

and pharmaceutically acceptable salts and solvates (e.g., hydrates) thereof.

As used herein, the term "alkyl" includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms,

typically methyl, ethyl, and straight chain and branched propyl and butyl groups. The hydrocarbon group can contain up to 16 carbon atoms, preferably one to eight carbon atoms. The term "alkyl" includes "bridged alkyl," i.e., a C₅-C₁₆ bicyclic or polycyclic hydrocarbon group, for example, norbornyl, adamantyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]-heptyl, bicyclo[3.2.1]octyl, or decahydronaphthyl. The term "cycloalkyl" is defined as a cyclic C₃-C₈ hydrocarbon group, e.g., cyclopropyl, cyclobutyl, cyclohexyl, and cyclopentyl.

The term "alkenyl" is defined identically as "alkyl," except for containing a carbon-carbon double bond. "Cycloalkenyl" is defined similarly to cycloalkyl, except a carbon-carbon double bond is present in the ring.

The term "alkylene" refers to an alkyl group having a substituent. For example, the term "C₁₋₃alkylenearyl" refers to an alkyl group containing one to three carbon atoms, and substituted with an aryl group.

The term "halo" or "halogen" is defined herein to include fluorine, bromine, chlorine, and iodine.

The term "haloalkyl" is defined herein as an alkyl group substituted with one or more halo substituents, either fluoro, chloro, bromo, iodo, or combinations thereof. Similarly, "halocycloalkyl" is defined as a cycloalkyl group having one or more halo substituents.

The term "aryl," alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic

aromatic group, e.g., phenyl or naphthyl. Unless otherwise indicated, an "aryl" group can be unsubstituted or substituted, for example, with one or more, and in particular one to three, halo, alkyl, phenyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Exemplary aryl groups include phenyl, naphthyl, biphenyl, tetrahydronaphthyl, chlorophenyl, fluorophenyl, aminophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, nitrophenyl, carboxyphenyl, and the like. The terms "arylC₁₋₃alkyl" and "heteroaryl-C₁₋₃alkyl" are defined as an aryl or heteroaryl group having a C₁₋₃alkyl substituent.

The term "heteroaryl" is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Examples of heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidizolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.

The term "Het" is defined as monocyclic, bicyclic, and tricyclic groups containing one or more heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. A "Het" group also can contain an oxo group (=0) attached to the ring.

Nonlimiting examples of Het groups include 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, a pyrroline, 2H-pyran, 4H-pyran, morpholine, thiopholine, piperidine, 1,4-dithiane, and 1,4-dioxane.

The term "hydroxy" is defined as -OH.

The term "alkoxy" is defined as -OR,

wherein R is alkyl.

The term "alkoxyalkyl" is defined as an alkyl group wherein a hydrogen has been replaced by an alkoxy group. The term "(alkylthio)alkyl" is defined similarly as alkoxyalkyl, except a sulfur atom, rather than an oxygen atom, is present.

The term "hydroxyalkyl" is defined as a hydroxy group appended to an alkyl group.

The term "amino" is defined as $-NH_2$, and the term "alkylamino" is defined as $-NR_2$, wherein at least one R is alkyl and the second R is alkyl or hydrogen.

The term "acylamino" is defined as RC(=0)N, wherein R is alkyl or aryl.

The term "alkylthio" is defined as -SR, wherein R is alkyl.

The term "alkylsulfinyl" is defined as $R-SO_2$, wherein R is alkyl.

The term "amino" is defined as $-NH_2$, and the term "alkylamino" is defined as $-NR_2$, wherein at least one R is alkyl and the second R is alkyl or hydrogen.

The term "acylamino" is defined as RC(=0)N, wherein R is alkyl or aryl.

The term "alkylthio" is defined as -SR, wherein R is alkyl.

The term "alkylsulfinyl" is defined as $R\text{-}SO_2$, wherein R is alkyl.

The term "alkylsulfonyl" is defined as $R\text{-}SO_3$, wherein R is alkyl.

The term "nitro" is defined as $-NO_2$. The term "trifluoromethyl" is defined as $-CF_3$.

The term "trifluoromethoxy" is defined as -OCF₃.

The term "cyano" is defined as -CN.

In preferred embodiments, X is selected from the group consisting of CH₂, CH₂CH₂, CH=CH, CH(CH₃), CH₂CH(CH₃), and C(CH₃)₂. In further preferred embodiments, Y is selected from the group consisting of null, S, and NH.

The A ring can be monocyclic or bicyclic. Monocyclic A ring systems are aromatic. Bicyclic A ring systems contain at least one aromatic ring, but both rings can be aromatic. Examples of A ring systems include, but are not limited to, imidazolyl, pyrazolyl, 1,2,3-triazolyl, pyridizinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, 1H-indazolyl, and benzimidazolyl.

In a preferred group of compounds of formula (I), A is represented by an optionally substituted ring system selected from the group consisting of



, and

The A ring system optionally can be substituted with one to three, and preferably one to two, substituents selected from the group consisting of $N(R^a)_2$, halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OR^a , and

Specific substituents include, but are not limited to, NH_2 , $NH(CH_3)$, $N(CH_3)_2$, $NHCH_2C_6H_5$, $NH(C_2H_5)$, Cl, F, CH_3 , SCH_3 , OH, and

In another preferred group of compounds of formula (I), R^1 and R^2 , independently, are represented by hydrogen, OR^a , halo, C_{1-6} alkyl, CF_3 , NO_2 , $N(R^a)_2$, NR^aC_{1-3} alkyleneN($R^a)_2$, and OC_{1-3} alkyleneOR^a. Specific substituents include, but are not limited to, H, OCH_3 , Cl, Br, F, CH_3 , CF_3 , NO_2 , OH, $N(CH_3)_2$,

and $O(CH_2)_2OCH_2C_6H_5$. R^1 and R^2 also can be taken together to form a ring, for example, a phenyl ring.

In a preferred embodiment, R^3 is selected from the group consisting of optionally substituted C_{1-6} alkyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, $C(=0)OR^a$, C_{1-4} alkyleneHet, C_{1-4} alkylenecycloalkyl, C_{1-4} alkylenearyl, C_{1-4} alkyleneC(=0) C_{1-4} -alkylenearyl, C_{1-4} alkyleneC(=0) OR^a , C_{1-4} alkylene- $O(=0)N(R^a)_2$, $OO(R^a)_2$, $OO(R^a)_2$, $OO(R^a)_2$, $OO(R^a)_3$, $OO(R^a)_4$ Specific $OO(R^a)_4$ alkyleneNRaC(=0) $OO(R^a)_4$ Specific $OO(R^a)_4$ groups include, but are not limited to









, and



The R³ group can be substituted with one to three substituents, for example, halo, OR^a , $C_{1-6}alkyl$, aryl, heteroaryl, NO_2 , $N(R^a)_2$, $iR^aSO_2CF_3$, $NR^aC(=O)R^a$, $C(=O)OR^a$, $N(R^a)C_{1-4}alkylene(R^a)_2$, $SO_2N(R^a)_2$, CN, $C(=O)R^a$, $C_{1-4}alkyleneN(R^a)_2$, and $OC_{1-4}alkyleneN(R^a)_2$. Specific substituents for the R³ group include, but are not limited to, Cl, F, CH_3 , $CH(CH_3)_2$, OCH_3 , C_6H_5 , NO_2 , NH_2 , $NHC(=O)CH_3$, CO_2H , and $N(CH_3)CH_2CH_2N(CH_3)_2$.

As used herein, the quinazoline ring structure, and numbering of the ring structure, is

The purine ring structure, and numbering of the ring structure, is

The compounds provided by the invention are exemplified as follows:

3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one;

5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one;

5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-ylmethyl)-3H-quinazolin-4-one;

3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-ylmethyl)-3H-quinazolin-4-one;

3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-6-ylsulfan-ylmethyl)-3H-quinazolin-4-one;

3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one;

```
3-(2-chlorophenyl)-6-fluoro-2-(9h·purin-6-ylsulfan-
 ylmethyl)-3h-quinazolin-4-one;
 5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
 3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one:
 3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
 quinazolin-4-one, acetate salt;
 8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 3-(3-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
 quinazolin-4-one;
 3-(2-chlorophenyl)-8-trifluoromethyl-2-(9H-purin-6-
ylsulfanylmethyl)-3H-quinazolin-4-one;
```

```
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
  3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
 ylmethyl) -3H-quinazolin-4-one, acetate salt;
 3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
  [5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
  quinazolin-3-yl]acetic acid ethyl ester;
  3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
  3H-quinazolin-4-one;
· 3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
 methyl)-3H-quinazolin-4-one;
  5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
 methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
 quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
  chloro-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
 methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
 phenyl) - 3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
 phenyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
 phenyl)-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
 methyl-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
 fluoro-3H-quinazolin-4-one;
```

```
2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
 quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-
 quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-
 fluoro-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-6-chloro-3-(2-chloro-
 phenyl)-3H-quinazolin-4-one;
3-(4-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-
 ylsulfanylmethyl)-3H-quinazoline-4-one;
3-(2-chlorophenyl)-7-nitro-2-(9H-purin-6-ylsulfan-
 ylmethyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-6-bromo-3-(2-chlorophen-
 yl)-3H-quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-
 dimethoxy-3H-quinazolin-4-one;
 6-bromo-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl) -3H-quinazolin-4-one;
 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
 3H-benzo[g] quinazolin-4-one;
 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-
 quinazolin-4-one; and
 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-
 phenyl)-3H-quinazolin-4-one.
```

The preferred compounds provided by the invention have the structure (IV), exemplified as follows:

WO 01/81346 PCT/US01/13315

- 51 -

```
3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl
 3H-quinazolin-4-one;
 5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-
 fanylmethyl) - 3H-quinazolin - 4-one;
3-(2-chlorophenyl)-6-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3h-quinazolin-4-one;
 5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl) - 3H-quinazolin-4-one;
3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
 azolin-4-one;
 3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
 3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
 quinazolin-4-one, acetate salt;
 8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl) -3H-quinazolin-4-one;
 3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
 fanylmethyl)-3H-quinazolin-4-one;
 6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
 ylmethyl)-3H-quinazolin-4-one;
```

```
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
trifluoromethyl-3H-quinazolin-4-one;
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl) -
3H-quinazolin-4-one;
3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one, acetate salt;
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
[5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
quinazolin-3-yl]acetic acid ethyl ester;
3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
methyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
chloro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
methyl-3H-quinazolin-4-one;
```

- 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4one;
- 2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-(2-chlcrophenyl)-7-fluoro-3H-quinazolin-4-one; and
- 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazoline-4-one.

The term "prodrug" as used herein refers to compounds that are rapidly transformed in vivo to a compound having structural formula (I) hereinabove, for example, by hydrolysis. Prodrug design is discussed generally in Hardma et al. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A thorough discussion is provided in Higuchi et al., Prodrugs as Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in Roche (ed.), Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987). Briefly, administration of a drug is followed by elimination from the body or some biotransformation whereby biological activity of the drug is reduced or eliminated. Alternatively, a biotransformation process can lead to a metabolic by-product, which is itself more active or equally active as compared to the drug initially administered. Increased understanding of these biotransformation processes permits the design WO 01/81346 PCT/US01/13315

of so-called "prodrugs," which, following a biotransformation, become more physiologically active in their altered state. Prodrugs, therefore, encompass pharmacologically inactive compounds that are converted to biologically active metabolites.

To illustrate, prodrugs can be converted into a pharmacologically active form through hydrolysis of, for example, an ester or amide linkage, thereby introducing or exposing a functional group The prodrugs can be deon the resultant product. signed to react with an endogenous compound to form a water-soluble conjugate that further enhances the pharmacological properties of the compound, for example, increased circulatory half-life. Alternatively, prodrugs can be designed to undergo covalent modification on a functional group with, for example, glucuronic acid, sulfate, glutathione, amino acids, or acetate. The resulting conjugate can be inactivated and excreted in the urine, or rendered more potent than the parent compound. High molecular weight conjugates also can be excreted into the bile, subjected to enzymatic cleavage, and released back into the circulation, thereby effectively increasing the biological half-life of the originally administered compound.

Methods for Identifying Negative Regulators of PI3Kδ Activity

The PI3Kδ protein, as well as fragments thereof possessing biological activity, can be used for screening putative negative regulator compounds in any of a variety of drug screening techniques. A negative regulator of PI3Ko is a compound that diminishes or abolishes the ability of PI3Kδ to carry out any of its biological functions. example of such compounds is an agent that decreases the ability of a PI3Ko polypeptide to phosphorylate phosphatidylinositol or to target appropriate structures within a cell. The selectivity of a compound that negatively regulates PI3Ko activity can be evaluated by comparing its activity on the PI3Kδ to its activity on other proteins. Selective negative regulators include, for example, antibodies and other proteins or peptides that specifically bind to a PI3Ko polypeptide, oligonucleotides that specifically bind to PI3Kδ polypeptides, and other nonpeptide compounds (e.g., isolated or synthetic organic molecules) that specifically interact with PI3Kö polypeptides. Negative regulators also include compounds as described above, but which interact with a specific binding partner of PI3Kδ polypeptides.

Presently preferred targets for the development of selective negative regulators of PI3K $\!\delta$ include, for example:

 cytoplasmic regions of PI3Kδ polypeptides that contact other proteins and/or localize
 PI3Kδ within a cell;

- (2) regions of PI3Kδ polypeptides that bind specific binding partners;
- (3) regions of the PI3K δ polypeptides that bind substrate;
- (4) allosteric regulatory sites of the PI3Kδ polypeptides that can or cannot interact directly with the active site upon regulatory signal;
- (5) regions of the PI3Ko polypertides that mediate multimerization.

For example, one target for development of modulators is the identified regulatory interaction of p85 with p1100, which can be involved in activation and/or subcellular localization of the p1100 moiety. Still other selective modulators include those that recognize specific regulatory or PI3KO-encoding nucleotide sequences. Modulators of PI3KO activity can be therapeutically useful in treatment of a wide range of diseases and physiological conditions in which aberrant PI3KO activity is involved.

Accordingly, the invention provides methods of characterizing the potency of a test compound as an inhibitor of PI3Kδ polypeptide, said method comprising the steps of (a) measuring activity of a PI3Kδ polypeptide in the presence of a test compound; (b) comparing the activity of the PI3Kδ polypeptide in the presence of the test compound to the activity of the PI3Kδ polypeptide in the presence of an equivalent amount of a reference compound (e.g., a PI3Kδ inhibitor compound of the invention as described herein), wherein a lower activity of the PI3Kδ polypeptide in the presence of the test compound than in the presence of the refer-

ence indicates that the test compound is a more potent inhibitor than the reference compound, and a higher activity of the PI3Ko polypeptide in the presence of the test compound than in the presence of the reference indicates that the test compound is a less potent inhibitor than the reference compound.

The invention further provides methods of characterizing the potency of a test compound as an inhibitor of PI3Kδ polypeptide, comprising the steps of (a) determining an amount of a control compound (e.g., a PI3Kδ inhibitor compound of the invention as described herein): that inhibits an activity of a PI3Kδ polypeptide by a reference percentage of inhibition, thereby defining a reference inhibitory amount for the control compound; (b) determining an amount of a test compound that inhibits an activity of a PI3Kδ polypeptide by a reference percentage of inhibition, thereby defining a reference inhibitory amount for the test compound; (c) comparing the reference inhibitory amount for the test compound to the reference inhibitory amount for the control compound, wherein a lower reference inhibitory amount for the test compound than for the control compound indicates that the test compound is a more potent inhibitor than the control compound, and a higher reference inhibitory amount for the test. compound than for the control compound indicates that the test compound is a less potent inhibitor than the control compound. In one aspect, the method uses a reference inhibitory amount which is the amount of the compound than inhibits the activity of the PI3Kö polypeptide by 50%, 60%, 70%, or 80%. In another aspect the method employs a

reference inhibitory amount that is the amount of the compound that inhibits the activity of the PI3Ko polypeptide by 90%, 95%, or 99%. These methods comprise determining the reference inhibitory amount of the compounds in an *in vitro* biochemical assay, in an *in vitro* cell-based assay, or in an *in vivo* assay.

The invention further provides methods of identifying a negative regulator of PI3K& activity, comprising the steps of (i) measuring activity of a PI3K δ polypeptide in the presence and absence of a test compound, and (ii) identifying as a negative regulator a test compound that decreases PI3Kδ activity and that competes with a compound of the invention for binding to PI3K δ . Furthermore, the invention provides methods for identifying compounds , that inhibit PI3Kδ activity, comprising the steps of (i) contacting a PI3Ko polypeptide with a compound of the invention in the presence and absence of a test compound, and (ii) identifying a test compound as a negative regulator of PI3Kδ activity wherein the compound competes with a compound of the invention for binding to PI3K δ . The invention therefore provides a method for screening for candidate nega-. tive regulators of PI3Ko activity and/or to confirm the mode of action of candidate such negative regulators. Such methods can be employed against other PI3K isoforms in parallel to establish comparative activity of the test compound across the isoforms and/or relative to a compound of the invention.

In these methods, the PI3Ko polypeptide can be a fragment of p110o that exhibits kinase activity, i.e., a fragment comprising the catalytic

site of p110δ. Alternatively, the PI3Kδ polypeptide can be a fragment from the p110δ-binding domain of p85 and provides a method to identify allosteric modulators of PI3Kδ. The methods can be employed in cells expressing cells expressing PI3Kδ or its subunits, either endogenously or exogenously. Accordingly, the polypeptide employed in such methods can be free in solution, affixed to a solid support, modified to be displayed on a cell surface, cr located intracellularly. The modulation of activity or the formation of binding complexes between the PI3Kδ polypeptide and the agent being tested then can be measured.

Human PI3K polypeptides are amenable to biochemical or cell-based high throughput screening (HTS) assays according to methods known and practiced in the art, including melanophore assay systems to investigate receptor-ligand interactions, yeast-based assay systems, and mammalian cell expression systems. For a review, see Jayawickreme and Kost, Curr Opin Biotechnol, 8:629-34 (1997). Automated and miniaturized HTS assays also are comprehended as described, for example, in Houston and Banks, Curr Opin Biotechnol, 8:734-40 (1997).

Such HTS assays are used to screen libraries of compounds to identify particular compounds that exhibit a desired property. Any library of compounds can be used, including chemical libraries, natural product libraries, and combinatorial libraries comprising random or designed oligopeptides, oligonucleotides, or other organic compounds.

Chemical libraries can contain known compounds, proprietary structural analogs of known

compounds, or compounds that are identified from natural product screening.

Natural product libraries are collections of materials isolated from naturals sources, typically, microorganisms, animals, plants, or marine organisms. Natural products are isolated from their sources by fermentation of microorganisms followed by isolation and extraction of the fermentation broths or by direct extraction from the microorganisms or tissues (plants or animal) themselves. Natural product libraries include polyketides, nonribosomal peptides, and variants (including nonnaturally occurring variants) thereof. For a review, see Cane et al., Science, 282:63-68 (1998).

Combinatorial libraries are composed of large numbers of related compounds, such as peptides, oligonucleotides, or other organic compounds as a mixture. Such compounds are relatively straightforward to design and prepare by traditional automated synthesis protocols, PCR, cloning, or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries.

Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created thereby, see Myers, Curr Opin Biotechnol, 8:701-07 (1997).

Once compounds have been identified that show activity as negative regulators of PI3K δ function, a program of optimization can be undertaken in an effort to improve the potency and or

selectivity of the activity. This analysis of structure-activity relationships (SAR) typically involves of iterative series of selective modifications of compound structures and their correlation to biochemical or biological activity. Families of related compounds can be designed that all exhibit the desired activity, with certain members of the family, namely those possessing suitable pharmacological profiles, potentially qualifying as therapeutic candidates.

Therapeutic Uses of Inhibitors of PI3Ko Activity

The invention provides a method for selectively or specifically inhibiting PI3K δ activity therapeutically or prophylactically. The method comprises administering a selective or specific inhibitor of PI3K δ activity in an amount effective therefor. This method can be employed in treating humans or animals who are or can be subject to any condition whose symptoms or pathology is mediated by PI3K δ expression or activity.

"Treating" as used herein refers to preventing a disorder from occurring in an animal that can be predisposed to the disorder, but has not yet been diagnosed as having it; inhibiting the disorder, i.e., arresting its development; relieving the disorder, i.e., causing its regression; or ameliorating the disorder, i.e., reducing the severity of symptoms associated with the disorder. "Disorder" is intended to encompass medical dis-

orders, diseases, conditions, syndromes, and the like, without limitation.

The methods of the invention embrace various modes of treating an animal subject, preferably a mammal, more preferably a primate, and still more preferably a human. Among the mammalian animals that can be treated are, for example, companion animals (pets), including dogs and cats; farm animals, including cattle, horses, sheep, pigs, and goats; laboratory animals, including rats, mice, rabbits, guinea pigs, and nonhuman primates, and zoo specimens. Nonmammalian animals include, for example, birds, fish, reptiles, and amphibians.

In one aspect, the method of the invention can be employed to treat subjects therapeutically or prophylactically who have or can be subject to an inflammatory disorder. One aspect of the present invention derives from the involvement of PI3Kô in mediating aspects of the inflammatory process. Without intending to be bound by any theory, it is theorized that, because inflammation involves processes are typically mediated by leukocyte (e.g., neutrophil, lymphocyte, etc.) activation and chemotactic transmigration, and because PI3Kô can mediate such phenomena, antagonists of PI3Kô can be used to suppress injury associated with inflammation.

"Inflammatory disorder" as used herein can refer to any disease, disorder, or syndrome in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue damage, or loss of tissue function. "Inflammatory disorder" also refers to a pathological state

WO 01/81346 PCT/US01/13315

- 63

mediated by influx of leukocytes and/or neutrophil chemotaxis.

"Inflammation" as used herein refers to a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off (sequester) both the injurious agent and the injured tissue. Inflammation is notably associated with influx of leukocytes and/or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses and from noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune response to foreign antigen, and autoimmune responses. Accordingly, inflammatory disorders . amenable to the invention encompass disorders associated with reactions of the specific defense system as well as with reactions of the nonspecific defense system.

As used herein, the term "specific defense system" refers to the component of the immune system that reacts to the presence of specific antigens. Examples of inflammation resulting from a response of the specific defense system include the classical response to foreign antigens, autoimmune diseases, and delayed type hypersensitivity response mediated by T-cells. Chronic inflammatory diseases, the rejection of solid transplanted tissue and organs, e.g., kidney and bone marrow transplants, and graft versus host disease (GVHD), are further examples of inflammatory reactions of the specific defense system.

The term "nonspecific defense system" as used herein refers to inflammatory disorders that are mediated by leukocytes that are incapable of

immunological memory (e.g., granulocytes, and macrophages). Examples of inflammation that result, at least in part, from a reaction of the nonspecific defense system include inflammation associated with conditions such as adult (acute) respiratory distress syndrome (ARDS) or multiple organ injury syndromes; reperfusion injury; acute glomerulonephritis; reactive arthritis; dermatoses with acute inflammatory components; acute purulent meningitis or other central nervous system inflammatory disorders such as stroke; thermal injury; inflammatory bowel disease; granulocyte transfusion associated syndromes; and cytokine-induced toxicity.

"Autoimmune disease" as used herein refers to any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents. "Allergic disease" as used herein refers to any symptoms, tissue damage, or loss of tissue function resulting from allergy. "Arthritic disease" as used herein refers to any disease that is characterized by inflammatory lesions of the joints attributable to a variety of etiologies. "Dermatitis" as used herein refers to any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies. "Transplant rejection" as used herein refers to any immune reaction directed against grafted tissue, such as organs or cells (e.g., bone marrow), characterized by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and thrombocytopenia.

The therapeutic methods of the present. invention include methods for the treatment of disorders associated with inflammatory cell activation. "Inflammatory cell activation" refers to the induction by a stimulus (including, but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or cell surface expression of new or increased numbers of mediators (including, but not limited to, major histocompatability antigens or cell adhesion molecules) in inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclear leukocytes such as neutrophils, basophils, and eosinophils), mast cells, dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons skilled in the art that the activation of one or a combination of these phenotypes in these cells can contribute to the initiation, perpetuation, or exacerbation of an inflammatory disorder.

The compounds of the invention have been found to inhibit superoxide release by neutrophils. Superoxide is released by neutrophils in response to any of a variety of stimuli, including signals of infection, as a mechanism of cell killing. For example, superoxide release is known to be induced by tumor necrosis factor alpha (TNFa), which is released by macrophages, mast cells, and lymphocytes upon contact with bacterial cell wall components such as lipopolysaccharide (LPS). TNFa is an extra-

ordinarily potent and promiscuous activator of inflammatory processes, being involved in activation of neutrophils and various other cell types, induction of leukocyte/endothelial cell adhesion, pyrexia, enhanced MHC class I production, and stimulation of angiogenesis. Alternatively, superoxide release can be stimulated by formyl-Met-Leu-Phe (fMLP) or other peptides blocked at the N-terminus by formylated methionine. Such peptides are not normally found in eukaryotes, but are fundamentally characteristic of bacteria, and signal the presence of bacteria to the immune system. Leukocytes expressing the fMLP receptor, e.g., neutrophils and macrophages, are stimulated to migrate up gradients of these peptides (i.e., chemotaxis) toward loci of infection. As demonstrated herein, the compounds of the invention inhibit stimulated superoxide release by neutrophils in response to either $TNF\alpha$ or fMLP. Other functions of neutrophils, including stimulated exocytosis and directed chemotactic migration, also have been shown to be inhibited by the PI3Kδ inhibitors of the invention. Accordingly, the compounds of the invention can be expected to be useful in treating disorders, such as inflammatory disorders, that are mediated by any or all of these neutrophil functions.

The present invention enables methods of treating such diseases as arthritic diseases, such as rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis; Behcet disease; sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome; multiple organ injury syndrome

secondary to septicemia, trauma, or hemorrhage; ophthalmic disorders such as allergic conjunctivitis, vernal conjunctivitis, uveitis, and thyroidassociated ophthalmopathy; ecsinophilic granuloma; pulmonary or respiratory disorders such as asthma, chronic bronchitis, allergic rhinitis, ARDS, chronic pulmonary inflammatory disease (e.g., chronic obstructive pulmonary disease), silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, and pulmonary oxygen toxicity; reperfusion injury of the myocardium, brain, or extremities; fibrosis such as cystic fibrosis; keloid formation or scar tissue formation; atherosclerosis; autoimmune diseases, such as systemic lupus erythematosus (SLE), autoimmune thyroiditis, multiple sclerosis, some forms of diabetes, and Reynaud's syndrome; and transplant rejection disorders such as GVHD and allograft rejection; chronic glomerulonephritis; inflammatory bowel diseases such as chronic inflammatory bowel disease (CIBD), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis; inflammatory dermatoses such as contact dermatitis, atopic dermatitis, psoriasis, or urticaria; fever and myalgias due to infection; central or peripheral nervous system inflammatory disorders such as meningitis, encephalitis, and brain or spinal cord injury due to minor trauma; Sjögren's syndrome; diseases involving. leukocyte diapedesis; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex mediated diseases; hypovolemic shock; Type I diabetes mellitus; acute and delayed hypersensitivity; disease states due to leukocyte dyscrasia and metastasis; thermal

injury; granulocyte transfusion-associated syndromes; and cytokine-induced toxicity.

The method can have utility in treating subjects who are or can be subject to reperfusion injury, i.e., injury resulting from situations in which a tissue or organ experiences a period of ischemia followed by reperfusion. The term "ischemia" refers to localized tissue anemia due to obstruction of the inflow of arterial blood. sient ischemia followed by reperfusion characteristically results in neutrophil activation and transmigration through the endothelium of the blood vessels in the affected area. Accumulation of activated neutrophils in turn results in generation of reactive oxygen metabolites, which damage components of the involved tissue or organ. This phenomenon of "reperfusion injury" is commonly associated with conditions such as vascular stroke (including global and focal ischemia), hemorrhagic shock, myocardial ischemia or infarction, organ transplantation, and cerebral vasospasm. To illustrate, reperfusion injury occurs at the termination of cardiac bypass procedures or during cardiac arrest when the heart, once prevented from receiving blood, begins to reperfuse. It is expected that inhibition of PI3Kδ activity will result in reduced amounts of reperfusion injury in such situations.

With respect to the nervous system, global ischemia occurs when blood flow to the entire brain ceases for a period. Global ischemia can result from cardiac arrest. Focal ischemia occurs when a portion of the brain is deprived of its normal blood supply. Focal ischemia can result from thromboembo-

lytic occlusion of a cerebral vessel, traumatic head injury, edema, or brain tumor. Even if transient, both global and focal ischemia can cause widespread neuronal damage. Although nerve tissue damage occurs over hours or even days following the onset of ischemia, some permanent nerve tissue damage can develop in the initial minutes following the cessation of blood flow to the brain.

Ischemia also can occur in the heart in myocardial infarction and other cardiovascular disorders in which the coronary arteries have been obstructed as a result of atherosclerosis, thrombus, or spasm. Accordingly, the invention is believed to be useful for treating cardiac tissue damage, particularly damage resulting from cardiac ischemia or caused by reperfusion injury in mammals.

In another aspect, selective inhibitors of PI3Kō activity, such as the compounds of the invention, can be employed in methods of treating diseases of bone, especially diseases in which osteoclast function is abnormal or undesirable. As shown in Example 6, below, compounds of the invention inhibit osteoclast function in vitro. Accordingly, the use of such compounds and other PI3Kō selective inhibitors can be of value in treating osteoporosis, Paget's disease, and related bone resorption disorders.

In a further aspect, the invention includes methods of using PI3Kō inhibitory compounds to inhibit the growth or proliferation of cancer cells of hematopoietic origin, preferably cancer cells of lymphoid origin, and more preferably cancer cells related to or derived from B lymphocytes or B

lymphocyte progenitors. Cancers amenable to treatment using the method of the invention include, without limitation, lymphomas, e.g., malignant neoplasms of lymphoid and reticuloendothelial tissues, such as Burkitt's lymphoma, Hodgkins' lymphoma, non-Hodgkins lymphomas, lymphocytic lymphomas and the like; multiple myelomas; as well as leukemias such as lymphocytic leukemias, chronic myeloid (myelogenous) leukemias, and the like. In a preferred embodiment, PI3Kō inhibitory compounds can be used to inhibit or control the growth or proliferation of chronic myeloid (myelogenous) leukemia cells.

In another aspect, the invention includes a method for suppressing a function of basophils and/or mast cells, and thereby enabling treatment of diseases or disorders characterized by excessive or undesirable basophil and/or mast cell activity. According to the method, a compound of the invention can be used that selectively inhibits the expression or activity of phosphatidylinositol 3-kinase delta (PI3K δ) in the basophils and/or mast cells. ably, the method employs a PI3Kδ inhibitor in an amount sufficient to inhibit stimulated histamine release by the basophils and/or mast cells. ingly, the use of such compounds and other PI3Ko selective inhibitors can be of value in treating diseases characterized by histamine release, i.e., allergic disorders, including disorders such as chronic obstructive pulmonary disease (COPD), asthma, ARDS, emphysema, and related disorders.

Pharmaceutical Compositions of Inhibitors of PI3Ko Activity

A compound of the present invention can be administered as the neat chemical, but it is typically preferable to administer the compound in the form of a pharmaceutical composition or formulation. Accordingly, the present invention also provides pharmaceutical compositions that comprise a chemical or biological compound ("agent") that is active as a modulator of PI3K δ activity and a biocompatible pharmaceutical carrier, adjuvant, or vehicle. The composition can include the agent as the only active moiety or in combination with other agents, such as oligo- or polynucleotides, oligo- or polypeptides, drugs, or hormones mixed with excipient(s) or other pharmaceutically acceptable carriers. Carriers and other ingredients can be deemed pharmaceutically acceptable insofar as they are compatible with other ingredients of the formulation and not deleterious to the recipient thereof.

Techniques for formulation and administration of pharmaceutical compositions can be found in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co, Easton, PA, 1990. The pharmaceutical compositions of the present invention can be manufactured using any conventional method, e.g., mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, melt-spinning, spray-drying, or lyophilizing processes. However, the optimal pharmaceutical formulation will be determined by one of skill in the art depending on the route of administration and the

desired dosage. Such formulations can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agent. Depending on the condition being treated, these pharmaceutical compositions can be formulated and administered systemically or locally.

The pharmaceutical compositions are formulated to contain suitable pharmaceutically acceptable carriers, and can optionally comprise excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. The administration modality will generally determine the nature of the carrier. For example, formulations for parenteral administration can comprise aqueous solutions of the active compounds in water-soluble form. Carriers suitable for parenteral administration can be selected from among saline, buffered saline, dextrose, water, and other physiologically compatible solutions. ferred carriers for parenteral administration are physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline. For tissue or cellular administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For preparations comprising proteins, the formulation can include stabilizing materials, such as polyols (e.g., sucrose) and/or surfactants (e.g., nonionic surfactants), and the like.

Alternatively, formulations for parenteral use can comprise dispersions or suspensions of the active compounds prepared as appropriate oily injec-

tion suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, and synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Aqueous polymers that provide pH-sensitive solubilization and/or sustained release of the active agent also can be used as coatings or matrix structures, e.g., methacrylic polymers, such as the $\mathtt{EUDRAGIT}^{ exttt{@}}$ series available from $\mathtt{R\"{o}hm}$ America . Inc. (Piscataway, NJ). Emulsions, e.g., oil-inwater and water-in-oil dispersions, also can be used, optionally stabilized by an emulsifying agent or dispersant (surface active materials; surfactants). Suspensions can contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethlyene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, gum tragacanth, and mixtures thereof.

Liposomes containing the active agent also can be employed for parenteral administration.

Liposomes generally are derived from phospholipids or other lipid substances. The compositions in liposome form also can contain other ingredients, such as stabilizers, preservatives, excipients, and the like. Preferred lipids include phospholipids and phosphatidyl cholines (lecithins), both natural

and synthetic. Methods of forming liposomes are known in the art. See, e.g., Prescott (Ed.), Methods in Cell Biology, Vol. XIV, p. 33, Academic Press, New York (1976).

The pharmaceutical compositions comprising the agent in dosages suitable for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art. The preparations formulated for oral administration can be in the form of tablets, pills, capsules, cachets, dragees, lozenges, liquids, gels, syrups; slurries, elixirs, suspensions, or powders. To illustrate, pharmaceutical preparations for oral use can be obtained by combining the active compounds with a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Oral formulations can employ liquid carriers similar in type to those described for parenteral use, e.g., buffered aqueous solutions, suspensions, and the like.

Preferred oral formulations include tablets, dragees, and gelatin capsules. These preparations can contain one or excipients, which include, without limitation:

- a) diluents, such as sugars, including lactose, dextrose, sucrose, mannitol, or sorbitol;
- b) binders, such as magnesium aluminum silicate, starch from corn, wheat, rice, potato, etc.;
- c) cellulose materials, such as methylcellulose, hydroxypropylmethyl cellulose, and sodium carboxymethylcellulose, polyvinylpyrrolidone, gums,

such as gum arabic and gum tragacanth, and proteins, such as gelatin and collagen;

- d) disintegrating or solubilizing agents such as cross-linked polyvinyl pyrrolidone, starches, agar, alginic acid or a salt thereof, such as sodium alginate, or effervescent compositions;
- e) lubricants, such as silica, talc, stearic acid or its magnesium or calcium salt, and polyethylene glycol;
 - f) flavorants and sweeteners;
- g) colorants or pigments, e.g., to identify the product or to characterize the quantity (dosage) of active compound; and
- h) other ingredients, such as preservatives, stabilizers, swelling agents, emulsifying agents, solution promoters, salts for regulating osmotic pressure, and buffers.

Gelatin capsules include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain the active ingredient(s) mixed with fillers, binders, lubricants, and/or stabilizers, etc. In soft capsules, the active compounds can be dissolved or suspended in suitable fluids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Dragee cores can be provided with suitable coatings such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

The pharmaceutical composition can be provided as a salt of the active agent. Salts tend to be more soluble in aqueous or other protonic solvents than the corresponding free acid or base forms. Pharmaceutically acceptable salts are well known in the art. Compounds that contain acidic moieties can form pharmaceutically acceptable salts with suitable cations. Suitable pharmaceutically acceptable cations include, for example, alkali metal (e.g., sodium or potassium) and alkaline earth (e.g., calcium or magnesium) cations.

Compounds of structural formula (I) that contain basic moieties can form pharmaceutically acceptable acid addition salts with suitable acids. For example, Berge et al. describe pharmaceutically acceptable salts in detail in *J Pharm Sci*, 66:1 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid.

Representative acid addition salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorolsulfonate, digluconate, glycerophosphate, hemisulfate; heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isothionate), lactate, maleate, methanesulfonate or sulfate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate or hydrogen phosphate, glutamate, bicarbonate, p-

toluenesulfonate, and undecanoate. Examples of acids that can be employed to form pharmaceutically acceptable acid addition salts include, without limitation, such inorganic acids as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and such organic acids as oxalic acid, maleic acid, succinic acid, and citric acid.

In light of the foregoing, any reference to compounds of the present invention appearing herein is intended to include compounds of structural formula (I)-(V), as well as pharmaceutically acceptable salts and solvates, as well as prodrugs, thereof.

Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, or with ammonia or organic primary, secondary, or tertiary amine. Pharmaceutically acceptable basic addition salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like, and nontoxic quaternary ammonium and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, diethylammonium, triethylammonium, and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanol-

- 78 -

amine, diethanolamine, piperidine, piperazine, and the like.

Basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain alkyl halides such as decyl; lauryl, myristyl, and stearyl chlorides, bromides, and iodides; arylalkyl halides such as benzyl and phenethyl bromides; and others. Products having modified solubility or dispersibility are thereby obtained.

Compositions comprising a compound of the invention formulated in a pharmaceutical acceptable carrier can be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Accordingly, there also is contemplated an article of manufacture, such as a container comprising a dosage form of a compound of the invention and a label containing instructions for use of the compound. Kits are also contemplated under the invention. For example, the kit can comprise a dosage form of a pharmaceutical composition and a package insert containing instructions for use of the composition in treatment of a medical condition. In either case, conditions indicated on the label can include treatment of inflammatory disorders, cancer, etc.

Methods of Administration of Inhibitors of PI3Ko Activity

Pharmaceutical compositions comprising an inhibitor of PI3Kδ activity can be administered to the subject by any conventional method, including parenteral and enteral techniques. Parenteral administration modalities include those in which the composition is administered by a route other than through the gastrointestinal tract, for example, intravenous, intraarterial, intraperitoneal, intramedullary, intramuscular, intraarticular, intrathecal, and intraventricular injections. Enteral administration modalities include, for example, oral (including buccal and sublingual) and rectal administration. Transepithelial administration modalities include, for example, transmucosal administration and transdermal administration. Transmucosal administration includes, for example, enteral administration as well as nasal, inhalation, and deep lung administration; vaginal administration; and rectal administration. Transdermal administration includes passive or active transdermal or transcutaneous modalities, including, for example, patches and iontophoresis devices, as well as topical application of pastes, salves, or ointments. Parenteral administration also can be accomplished using a high-pressure technique, e.g., POWDERJECT®.

Surgical techniques include implantation of depot (reservoir) compositions, osmotic pumps, and the like. A preferred route of administration for treatment of inflammation can be local or topical delivery for localized disorders such as

arthritis, or systemic delivery for distributed disorders, e.g., intravenous delivery for reperfusion injury or for systemic conditions such as septicemia. For other diseases, including those involving the respiratory tract, e.g., chronic obstructive pulmonary disease, asthma, and emphysema, administration can be accomplished by inhalation or deep lung administration of sprays, aerosols, powders, and the like.

For the treatment of neoplastic diseases, especially leukemias and other distributed cancers, parenteral administration is typically preferred. Formulations of the compounds to optimize them for biodistribution following parenteral administration would be desirable. The PI3K δ inhibitor compounds can be administered before, during, or after administration of chemotherapy, radiotherapy, and/or surgery.

Moreover, the therapeutic index of the PI3Kδ inhibitor compounds can be enhanced by modifying or derivatizing the compounds for targeted delivery to cancer cells expressing a marker that identifies the cells as such. For example, the compounds can be linked to an antibody that recognizes a marker that is selective or specific for cancer cells, so that the compounds are brought into the vicinity of the cells to exert their effects locally, as previously described (see for example, Pietersz et al., Immunol Rev, 129:57 (1992); Trail et al., Science, 261:212 (1993); and Rowlinson-Busza et al., Curr Opin Oncol, 4:1142 (1992)). Tumordirected delivery of these compounds enhances the therapeutic benefit by, inter alia, minimizing

potential nonspecific toxicities that can result from radiation treatment or chemotherapy. In another aspect, PI3Kō inhibitor compounds and radio-isotopes or chemotherapeutic agents can be conjugated to the same anti-tumor antibody.

For the treatment of bone resorption disorders or osteoclast-mediated disorders, the PI3Kō inhibitors can be delivered by any suitable method. Focal administration can be desirable, such as by intraarticular injection. In some cases, it can be desirable to couple the compounds to a moiety that can target the compounds to bone. For example, a PI3Kō inhibitor can be coupled to compounds with high affinity for hydroxyapatite, which is a major constituent of bone. This can be accomplished, for example, by adapting a tetracycline-coupling method developed for targeted delivery of estrogen to bone (Orme et al., Bioorg Med Chem Lett, 4(11):1375-80 (1994)).

To be effective therapeutically in modulating central nervous system targets, the agents used in the methods of the invention should readily penetrate the blood brain barrier when peripherally administered. Compounds that cannot penetrate the blood brain barrier, however, can still be effectively administered by an intravenous route.

As noted above, the characteristics of the agent itself and the formulation of the agent can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agent. Such pharmacokinetic and pharmacodynamic information can be collected through

preclinical in vitro and in vivo studies, later confirmed in humans during the course of clinical trials. Thus, for any compound used in the method of the invention, a therapeutically effective dose can be estimated initially from biochemical and/or cell-based assays. Then, dosage can be formulated in animal models to achieve a desirable circulating concentration range that modulates PI3Ko expression or activity. As human studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the "therapeutic index," which typically is expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices, i.e., the toxic dose is substantially higher than the effective dose, are preferred. The data obtained from such cell culture assays and additional animal studies can be used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity.

For the methods of the invention, any effective administration regimen regulating the timing and sequence of doses can be used. Doses of

the agent preferably include pharmaceutical dosage units comprising an effective amount of the agent. As used herein, "effective amount" refers to an amount sufficient to modulate PI3Kδ expression or activity and/or derive a measurable change in a physiological parameter of the subject through administration of one or more of the pharmaceutical dosage units.

Exemplary dosage levels for a human sub-.ject are of the order of from about 0.001 milligram of active agent per kilogram body weight (mg/kg) to about 100 mg/kg. Typically, dosage units of the active agent comprise from about 0.01 mg to about 10,000 mg, preferably from about 0.1 mg to about 1,000 mg, depending upon the indication, route of administration, etc. Depending on the route of administration, a suitable dose can be calculated according to body weight, body surface area, or organ size. The final dosage regimen will be determined by the attending physician in view of good medical practice, considering various factors that modify the action of drugs, e.g., the agent's specific activity, the identity and severity of the disease state, the responsiveness of the patient, the age, condition, body weight, sex, and diet of the patient, and the severity of any infection. Additional factors that can be taken into account include time and frequency of administration, drug combinations, reaction sensitivities, and tolerance/response to therapy. Further refinement of the dosage appropriate for treatment involving any of the formulations mentioned herein is done routinely by the skilled practitioner without undue experimentation, especially in light of the dosage information and assays disclosed, as well as the pharmacokinetic data observed in human clinical trials. Appropriate dosages can be ascertained through use of established assays for determining concentration of the agent in a body fluid or other sample together with dose response data.

The frequency of dosing will depend on the pharmacokinetic parameters of the agent and the route of administration. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Accordingly, the pharmaceutical compositions can be administered in a single dose, multiple discrete doses, continuous infusion, sustained release depots, or combinations thereof, as required to maintain desired minimum level of the agent. Shortacting pharmaceutical compositions (i.e., short half-life) can be administered once a day or more than once a day (e.g., two, three, or four times a day). Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks. Pumps, such as subcutaneous, intraperitoneal, or subdural pumps, can be preferred for continuous infusion.

The following Examples are provided to further aid in understanding the invention, and presuppose an understanding of conventional methods well-known to those persons having ordinary skill in the art to which the examples pertain, e.g., the construction of vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and

plasmids, or the introduction of vectors and plasmids into host cells. Such methods are described in detail in numerous publications including, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), Ausubel et al. (Eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994); and Ausubel et al. (Eds.), Short Protocols in Molecular Biology, 4th ed., John Wiley & Sons, Inc. (1999). The particular materials and conditions described hereunder are intended to exemplify particular aspects of the invention and should not be construed to limit the reasonable scope thereof.

EXAMPLE 1

Preparation and Purification of Recombinant PI3K α , β , and δ

Recombinant PI3K heterodimeric complexes consisting of a p110 catalytic subunit and a p85 regulatory subunit were overexpressed using the BAC-TO-BAC® HT baculovirus expression system (GIBCO/-BRL), and then purified for use in biochemical assays. The four Class I PI 3-kinases were cloned into baculovirus vectors as follows:

p1105: A FLAG®-tagged version of human p1105 (SEQ ID NO:1) (see Chantry et al., J Biol Chem, 272:19236-41 (1997)) was subcloned using standard recombinant DNA techniques into the BamH1-Xbal site of the insect cell expression vector pFastbac HTb (Life Technologies, Gaithersburg, MD), such that the clone was in frame with the His tag of

the vector. The FLAG® system is described in U.S. Patent Nos. 4,703,004; 4,782,137; 4,851,341; and 5,011,912, and reagents are available from Eastman Kodak Co.

p110α: Similar to the method used for p110δ, described above, a FLAG®-tagged version of p110α (see Volinia et al., Genomics, 24(3):427-477 (1994)) was subcloned in BamH1-HindIII sites of pFastbac HTb (Life Technologies) such that the clone was in frame with the His tag of the vector.

p110β: A p110β (see Hu et al., Mol Cell Biol, 13:7677-88 (1993)) clone was amplified from the human MARATHON® Ready spleen cDNA library (Clontech, Palo Alto CA) according to the manufacturer's protocol using the following primers:

5' Primer

5'-

GATCGAATTCGGCGCCACCATGGACTACAAGGACGACGATGACAAGTGCTTC AGTTTCATAATGCCTCC-3' (SEQ ID NO:3)

3' Primer

5'-GATCGCGGCCGCTTAAGATCTGTAGTCTTTCCGAACTGTGTG-3'
(SEQ ID NO:4)

The 5' primer was built to contain a FLAG® tag in frame with the p110 β sequence. After amplification, the FLAG®-p110 β sequence was subcloned using standard recombinant techniques into the <code>EcoR1-Not1</code> sites of pFastbac HTa (Life Technologies), such that the clone was in frame with the His tag of the vector.

p110γ: The p110γ cDNA (see Stoyanov et al., Science, 269:690-93 (1995)) was amplified from a human Marathon Ready spleen cDNA library (Clon-

tech) according to the manufacturer's protocol using the following primers:

5' Primer

5'-AGAATGCGGCCGCATGGAGCTGGAGAACTATAAACAGCCC-3' (SEQ ID NO:5)

3' Primer

5'-CGCGGATCCTTAGGCTGAATGTTTCTCTCTCTTTTTG-3' (SEQ ID NO:6)

A FLAG® tag was subsequently attached to the 5' end of the pl10Y sequence and was cloned in the BamH1-Spel sites of pFastbac HTb (Life Technologies) using standard recombinant DNA techniques, with the FLAG®-110Y sequence in-frame with the His tag of the vector.

p85 α : A BamH1-EcoR1 fragment of FLAG[®]-tagged p85 cDNA (see Skolnik et al., Cell, 65:83-89 (1991)) was subcloned into the BamH1-EcoR1 sites of the vector pFastbac dual (Life Technologies).

Recombinant baculoviruses containing the above clones were generated using manufacturer's recommended protocol (Life Technologies). Baculoviruses expressing His-tagged pl10α, pl10β, or pl10δ catalytic subunit and p85 subunit were coinfected into Sf21 insect cells. To enrich the heterodimeric enzyme complex, an excess amount of baculovirus expressing p85 subunit was infected, and the Histagged pl10 catalytic subunit complexed with p85 was purified on nickel affinity column. Since pl10γ does not associate with p85, Sf21 cells were infected with recombinant baculoviruses expressing Histagged pl10γ only. In an alternate approach, pl01 can be cloned into baculovirus, to permit coexpression with its preferred binding partner pl10γ.

The 72-hour post-infected Sf21 cells (3 liters) were harvested and homogenized in a hypotonic buffer (20 mM HEPES-KOH, pH 7.8, 5 mM KCl, complete protease inhibitor cocktail (Roche Biochemicals, Indianapolis, IN), using a Dounce homogenizer. The homogenates were centrifuged at 1,000 x q for 15 min. The supernatants were further centrifuged at 10,000 x g for 20 min, followed by ultracentrifugation at 100,000 x g for 60 min. The soluble fraction was immediately loaded onto 10 mL of HITRAP® nickel affinity column (Pharmacia, Piscataway, NJ) equilibrated with 50 mL of Buffer A (50 mM HEPES-KOH, pH 7.8, 0.5 M NaCl, 10 mM imidazole). The column was washed extensively with Buffer A, and eluted with a linear gradient of 10-500 mM imidazole. Free p85 subunit was removed from the column during the washing step and only the heterodimeric enzyme complex eluted at 250 mM . imidazole. Aliquots of nickel fractions were analyzed by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), stained with SYPRO® Red (Molecular Probes, Inc., Eugene, OR), and quantitated with STORM® PhosphoImager (Molecular Dynamics, Sunnyvale, The active fractions were pooled and directly loaded onto a 5 mL Hi-trap heparin column preequilibrated with Buffer B containing 50 mM HEPES-KOH, pH 7.5, 50 mM NaCl, 2 mM dithiothreitol (DTT). The column was washed with 50 mL of Buffer B and eluted with a linear gradient of 0.05-2 M NaCl. A single peak containing PI3K enzyme complex eluted at 0.8 M NaCl. SDS-polyacrylamide gel analysis showed that the purified PI3K enzyme fractions contained a 1:1 stoichiometric complex of p110 and p85 subunits.

The protein profile of the enzyme complex during heparin chromatography corresponded to that of lipid kinase activity. The active fractions were pooled and frozen under liquid nitrogen.

EXAMPLE 2

PI3Ko High Throughput Screen (HTS) and Selectivity Assay

A high throughput screen of a proprietary chemical library was performed to identify candidate inhibitors of PI3Kδ activity. PI3Kδ catalyzes a phosphotransfer from γ-[32P]ATP to PIP2/PS liposomes at the D3' position of the PIP2 lipid inositol ring. This reaction is MgCl2 dependent and is quenched in high molarity potassium phosphate buffer pH 8.0 containing 30 mM EDTA. In the screen, this reaction is performed in the presence or absence of library compounds. The reaction products (and all unlabelled products) are transferred to a 96-well, prewetted PVDF filter plate, filtered, and washed in high molarity potassium phosphate. Scintillant is added to the dried wells and the incorporated radioactivity is quantitated.

The majority of assay operations were performed using a BIOMEK® 1000 robotics workstations (Beckman) and all plates were read using Wallac liquid scintillation plate counter protocols.

The 3X assay stocks of substrate and enzyme were made and stored in a trough (for robotics assays) or a 96-well, V-bottom, polypropyl-

ene plate (for manual assays). Reagents were stable for at least 3 hours at room temperature.

The 3X substrate for the HTS contained 0.6 mM Na_2ATP , 0.10 mCi/mL γ -[^{32}P]ATP (NEN, Pittsburgh, PA), 6 μ M PIP_2/PS liposomes (Avanti Polar Lipids, Inc., Atlanta, GA), in 20 mM HEPES, pH 7.4.

The 3X enzyme stock for the HTS contained 1.8 nM PI3K δ , 150 µg/mL horse IgG (used only as a stabilizer), 15 mM MgCl₂, 3 mM DTT in 20 mM HEPES, pH 7.4.

The chemical high throughput screen (HTS) library samples (each containing a pool of 22 compounds) in dimethyl sulfoxide (DMSO) were diluted to 18.75 µM or 37.8 µM in double distilled water, and 20 µL of the dilutions were placed in the wells of a 96-well polypropylene plate for assaying. The negative inhibitor control (or positive enzyme control) was DMSO diluted in water, and the positive inhibitor controls employed concentrations of LY294002 sufficient to provide 50% and 100% inhibition.

To the 20 μL pooled chemical library dilutions, 20 μL of 3X substrate was added. The reaction was initiated with 20 μL of 3X enzyme, incubated at room temperature for 10 minutes. This dilution established a final concentration of 200 μM ATP in the reaction volume. The reaction was stopped with 150 μL quench buffer (1.0 M potassium phosphate pH 8.0, 30 mM EDTA). A portion of the quenched solution (180 μL) was then transferred to a PVDF filter plate (Millipore #MAIP NOB prewetted with sequential 200 μL washes of 100% methanol, water, and finally 1.0 M potassium phosphate pH 8.0 wash buffer).

The PVDF filter plate was aspirated under moderate vacuum (2-5 mm Hg), washed with 5 x 200 µL of wash buffer, and then dried by aspiration. The filter was subsequently blotted, allowed to air dry completely, and inserted into a Wallac counting cassette with 50 µL of Ecoscint scintillation cocktail added per well. The incorporated radioactivity was quantitated, and data were analyzed, after normalizing to the enzyme positive control (set at 100%), to identify the curve intersection at the 50% inhibition value to estimate IC50 values for the inhibitors.

A total of 57 pooled master wells were selected for deconvolution, based on combined criteria of <42% residual activity at the tested concentration, and a total accepted hir rate of no more than 0.2%. At 22 compounds per well, a total of 1254 compounds were identified through this deconvolution and individually assayed at the 1% concentration of 27.7 μM to identify which compounds exhibited the desired activity. From these assays, 73 compounds were selected and assayed further to develop IC₅₀ curves. From the IC₅₀ curve results, 34 compounds were selected for selectivity assays against PI3Kα and PI3Kβ (see assay protocol in Example 11).

From the selectivity assays, one compound, 3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (Compound D-000), was selected as being a relatively potent and selective compound. Catalog searches and selectivity assays of many analogous compounds of the potent and/or selective hits yielded only one compound that was both an

active and selective analogue of D-000. This compound was purchased from Contract Services Corporation (Catalog #7232154) and differed from D-000 in substituting a phenyl group for the 2-chlorophenyl group of D-000.

As described above, the PI 3-kinase inhibitor LY294002 (Calbiochem, La Jolla, CA) does not have significant selectivity among the different PI 3-kinase isoforms tested. Under our assay conditions, LY294002 inhibited all three isoforms of PI 3-kinases with an IC $_{50}$ of 0.3 to 1 μ M. However, when the compound D-000 was tested against the same PI 3-kinase isoforms distinct selectivity was observed. Specifically, as shown in Figure 1, D-000 inhibited the activity of the δ isoform of PI3K with an IC $_{50}$ of approximately 0.3 μ M, whereas under similar conditions it did not inhibit activities of the α and β isoforms at a limit of 100 μ M compound. These results show that D-000 selectively inhibits PI3K δ activity.

EXAMPLES 3-7

Since PI3Ko is expressed at significant levels only in leukocytes, it is important to study the effects of the PI3Kδ-selective inhibitor on leukocyte functions. Accordingly, the effects of PI3Kδ inhibition in several types of leukocytes were examined. Neutrophils were examined to determine the effects that selective inhibition of PI3Kδ might elicit (Example 3, below). It surprisingly was found that selective inhibition of PI3Ko activity appears to be significantly associated with inhibition of some but not all functions characteristic of activated neutrophils. In addition, the effects of $PI3K\delta$ inhibition on B cell and T cell function also were tested (Examples 4-5, below). Moreover, as PI3K δ also is expressed in osteoclasts, the effect of PI3Ko inhibition on the function of these specialized cells was studied (Example 6, below).

EXAMPLE 3

Characterization of Role of PI3Kδ in Neutrophil Function

. The effects of a PI3KO inhibitor of the invention, i.e., D-000, on neutrophil functions such as superoxide generation, elastase exocytosis, chemotaxis, and bacterial killing were tested.

A. Preparation of neutrophils from human blood

Aliquots (8 mL) of heparinized blood from healthy volunteers were layered on 3 mL cushions of 7.3% FICOLL® (Sigma, St. Louis, MO) and 15.4% HYPAQUE® (Sigma) and centrifuged at 900 rpm for 30 min at room temperature in a table top centrifuge (Beckman). The neutrophil-rich band just above the FICOLL®-HYPAQUE® cushion was collected and washed with Hanks' balanced salt solution (HBSS) containing 0.1% gelatin. Residual erythrocytes were removed by hypotonic lysis with 0.2% NaCl. The neutrophil preparation was washed twice with HBSS containing 0.1% gelatin and used immediately.

B. Measurement of superoxide production from neutrophils

Superoxide generation is one of the hall-marks of neutrophil activation. A variety of activators potentiate superoxide generation by neutrophils. The effect of the PI3Kδ inhibitor D-000 cn superoxide generation by three different agonists: TNF1α, IgG, and fMLP, each representing separate classes of activator, was measured. Superoxide generated by the neutrophils was measured by monitoring the change in absorbance upon reduction of cytochrome C by modification of the method described by Green et al., (pp. 14.5.1-14.5.11 in Supp. 12, Curr Protocols Immunol (Eds., Colligan et al.) (1994)), as follows. Individual wells of a 96-well plate were coated overnight at 4°C with 50 μL of 2

mg/mL solution of human fibrinogen or IgG. The wells were washed with PBS and the following reagents were added to each well: $50~\mu\text{L}$ of HBSS or superoxide dismutase (1 mg/mL), $50~\mu\text{L}$ of HBSS or TNF1 α (50~ng/mL), $50~\mu\text{L}$ cytochrome C (2.7~mg/mL), and $100~\mu\text{L}$ of purified human neutrophil suspension ($2~\text{x}~10^6~\text{cells/mL}$). The plate was centrifuged for 2 min at 200~rpm and absorbance at 550~nm was monitored for 2 hr. To measure the relative amounts of superoxide generated, values obtained from the superoxide dismutase-containing wells were subtracted from all, and normalized to the values obtained from the wells without any inhibitor.

As shown in Figure 2, the PI3K δ inhibitor D-000 inhibits TNF-induced superoxide generation by neutrophils in a concentration dependent manner. Superoxide generation induced by TNF was reduced to its half-maximal value at about 3 μ M D-000. Figure 2 also reveals that superoxide generation induced by IgG was not significantly inhibited by D-000. In fact, even at 10 μ M this PI3K δ inhibitor did not have any effect on superoxide generation induced by IgG.

Next, the effect of D-000 on superoxide generation induced by another potent inducer, the bacterial peptide, formylated-Met-Leu-Phe (fMLP) was studied. Like the TNF-induced superoxide generation, fMLP-induced superoxide generation also was inhibited by D-000 (Figure 3). These results show that the PI3Kδ inhibitor D-000 can prevent stimulus specific induction of superoxide generation by neutrophils, indicating that PI3Kδ is involved in this process.

C. Measurement of elastase exocytosis from neutrophils

In addition to superoxide generation, activated neutrophils also respond by releasing several proteases that are responsible for the destruction of tissues and cartilage during inflammation. As an indication of protease release, the effect of D-000 on elastase exocytosis was measured. Elastase exocytosis was quantitated by modification of the procedure described by Ossanna et al. (J ClinInvest, 77:1939-1951 (1986)), as follows. Purified human neutrophils (0.2 x 106) (treated with either DMSO or a serial dilution of D-000 in DMSO) were stimulated with fMLP in PBS containing 0.01 mg/mL cytochalasin B, 1.0 µM sodium azide (NaN,), 5 µg/mL L-methionine and 1 μM fMLP for 90 min at 37°C in a 96-well plate. At the end of the incubation period, the plate was centrifuged for 5 min at 1000 rpm, and 90 µL of the supernatant was transferred to 10 µL of 10 mM solution of an elastase substrate peptide, MeO-suc-Ala-Ala-Pro-Val-pNA, wherein MeO-suc = methoxy-succinyl; pNA = p-nitroanilide (Calbiochem, San Diego, CA). Absorbance at 410 nm was monitored for 2 hr in a 96-well plate reader. To measure the relative amounts of elastase excytosed, all absorbance values were normalized to the values without any inhibitor. As shown in Figure 4, the PI $3K\delta$ inhibitor D-000 inhibits fMLP-induced elastase exocytosis significantly, and does so in a dosedependent fashion. Inhibition was half-maximal at a concentration of about 2-3 µM D-000.

- 97 -

D. Measurement of fMLP-induced human neutrophil migration

Neutrophils have the intrinsic capacity to migrate through tissues, and are one of the first cell types to arrive at the sites of inflammation or tissue injury. The effect of D-000 on neutrophil migration towards a concentration gradient of fMLP was measured. The day before the migration assays were performed, 6-well plates were coated with recombinant ICAM-1/Fc fusion protein (Van der Vieren et al., Immunity, 3:683-690 (1995)) (25 µg/mL in bicarbonate buffer, pH 9.3) and left overnight at 4°C. After washing, 1% agarose solution, in RPMI-1640 with 0.5% bovine serum albumin (BSA), was added to wells with or without an inhibitor, and plates were placed into a refrigerator before punching holes in the gelled agarose to create plaques (1 central hole surrounded by 6 peripheral ones per well).

Human neutrophils were obtained as described above, and resuspended in RPMI medium supplemented with 0.5% BSA at 5 x 10° cells/mL. After combining equal volumes of neutrophil suspension and medium (either with DMSO or a serial dilution of the test compound in DMSO), neutrophils were aliquoted into the peripheral holes, while the central hole received fMLP (5 µM). Plates were incubated at 37°C in the presence of 5% CO₂ for 4 hr, followed by termination of migration by the addition of 1% glutaraldehyde solution in D-PBS. After removing the agarose layer, wells were washed with distilled water and dried.

Analysis of neutrophil migration was conducted on a Nikon DIAPHOT® inverted microscope (1x objective) video workstation using the NIH 1.61 program. Using Microsoft Excel and Table Curve 4 (SSPS Inc., Chicago IL) programs, a migration index was obtained for each of the studied conditions. Migration index was defined as the area under a curve representing number of migrated neutrophils versus the net distance of migration per cell.

As shown in Figure 5, the PI3K δ inhibitor D-000 had a profound effect on neutrophil migration, inhibiting this activity in a dose-dependent manner. The EC50 of this compound for inhibition of neutrophil migration in this assay is about 1 μ M. Based on a visual inspection of the recorded paths of the cells in this assay, it appears that the total path length for the neutrophils was not significantly affected by the test compound. Rather, the compound affected neutrophil orientation or sense of direction, such that instead of migrating along the axis of the chemoattractant gradient, the cells migrated in an undirected or less directed manner.

E. Measurement of bactericidal capacity of neutrophils

Given that the PI3Kō inhibitor D-000 affects certain neutrophil functions detailed above, it was of interest to see whether the compound affects neutrophil-mediated bacterial killing. The effect of D-000 on neutrophil-mediated Staphylococcus aureus killing was studied according to the method described by:Clark and Nauseef (pp. 7.23.4-

7.23.6 in Vol. 2, Supp. 6, Curr Protocols Immunol (Eds., Colligan et al.) (1994)). Purified human neutrophils (5 x 106 cells/mL) (treated with either DMSO or a serial dilution of D-000 in DMSO) were mixed with autologous serum. Overnight-grown S. aureus cells were washed, resuspended in HBSS, and added to the serum-opsonized neutrophils at a 10:1 ratio. Neutrophils were allowed to internalize the bacteria by phagocytosis by incubation at 37°C for The noninternalized bacteria were killed by 10 units/mL lysostaphin at 37°C for 5 min and the total mixture was rotated at 37°C. Samples were withdrawn at various times for up to 90 min and the neutrophils were lysed by dilution in water. Viable bacteria were counted by plating appropriate dilutions on trypticase-soy-agar plate and counting the S. aureus colonies after overnight growth.

As shown in Figure 6, neutrophil-mediated killing of S. aureus was similar in samples treated with DMSO (control) and with D-000. These results indicate that the PI3K δ inhibitor does not significantly affect the ability of neutrophils to kill S. aureus, suggesting that PI3K δ is not involved in this pathway of neutrophil function.

EXAMPLE 4

Characterization of Role of PI3Kō in B Lymphocyte Function

The effects of the PI 3-kinase inhibitor on B cell functions including classical indices such

as antibody production and specific stimulus-induced proliferation also were studied.

A. Preparation and stimulation of B cells from peripheral human blood

Heparinized blood (200 mL) from healthy volunteers was mixed with an equal volume of D-PBS, layered on 10 x 10 mL FICOLL-PAQUE® (Pharmacia), and centrifuged at 1600 rpm for 30 min at room temperature. Peripheral blood mononuclear cells (PBMC) were collected from the FICOLL®/serum interface, overlayed on 10 mL fetal bovine serum (FBS) and centrifuged at 800 rpm for 10 min to remove plate-After washing, cells were incubated with DYNAL® Antibody Mix (B cell kit) (Dynal Corp., Lake Success, NY) for 20 min at 4-8°C. Following the removal of unbound antibody, PBL were mixed with anti-mouse IgG coated magnetic beads (Dynal) for 20 min at 4-8°C with gentle shaking followed by elimination of labeled non-B cells on the magnetic bead separator. This procedure was repeated once more. The B cells were resuspended in RPMI-1640 with 10% FBS, and kept on ice until further use.

B. Measurement of antibody production by human B cells

To study antibody production, B cells were aliquoted at 50-75 x 10³ cells/well into 96-well plate with or without inhibitor, to which IL-2 (100 U/mL) and PANSORBIN® (Calbiochem) Staphylococcus aureus cells (1:90,000) were added. Part of the

media was removed after 24-36 hr, and fresh media (with or without inhibitor) and IL-2 were added. Cultures were incubated at 37°C, in the presence of a CO₂ incubator for additional 7 days. Samples from each condition (in triplicate) were removed, and analyzed for IgG and IgM, as measured by ELISA. Briefly, IMMULON® 4 96-well plates were coated (50 uL/well) with either 150 ng/mL donkey antihuman IgG (H+L) (Jackson ImmunoResearch, West Grove PA), or 2 ug/mL donkey antihuman IgG+IgM (H+L) (Jackson ImmunoResearch) in bicarbonate buffer, and left overnight at 4°C. After 3x washing with phosphate buffered saline containing 0.1% TWEEN®-80 (PBST) (350 µL/well), and blocking with 3% goat serum in PBST (100 µL/well) for 1 hr at room temperature, samples (100 µL/well) of B cell spent media diluted in PBST were added. For IgG plates the dilution range was 1:500 to 1:10000, and for IgM 1:50 to 1:1000. After 1 hr, plates were exposed to biotinconjugated antihuman IgG (100 ng/mL) or antihuman IgM (200 ng/mL) (Jackson ImmunoResearch) for 30 min, following by streptavidin-HRP (1:20000) for 30 min, and finally, to TMB solution (1:100) with H₂O₂ (1:10000) for 5 min, with 3 x PBST washing between steps. Color development was stopped by H2SO4 solution, and plates were read on an ELISA plate reader.

As shown in Figure 7, D-000 significantly inhibited antibody production. IgM production was affected more than IgG production: half-maximal inhibition of IgM production was observed at about 1 µM, versus about 7µM for comparable inhibition of IgG production.

- 102 -

C. Measurement of B Cell Proliferation in response to cell surface IgM stimulation

In the above experiment, the B cells were stimulated using PANSORBIN®. The effect of D-000 on B cell proliferation response when they were stimulated through their cell surface IgM using anti-IgM antibody also was measured. Murine splenocytes (Balb/c) were plated into 96-well microtiter plates at 2 x 105 cells per well in 10% FBS/RPMI. Appropriate dilutions of test inhibitor in complete medium were added to the cells and the plates were incubated for 30-60 minutes prior to the addition of stim-Following the preincubation with test inhibitor an F(ab'), preparation of goat antibody specific for the μ -chain of mouse IqM was added to the wells at a final concentration of 25 µg/mL. The plates were incubated at 37°C for 3 days and 1 µCi of [3H] thymidine was added to each well for the final four hours of culture. The plates were harvested onto fiber filters washed and the incorporation of radiolabel was determined using a beta counter (Matrix 96, Packard Instrument Co., Downers Grove, IL) and expressed as counts per minute (CPM).

Figure 8 shows the effect of D-000 on anti-IgM stimulated proliferation of B cells. The compound inhibited anti-IgM-stimulated B cell proliferation in a dose-dependent manner. At about 1 µM, proliferation was reduced to its half-maximal value.

Because the compound D-000 inhibits B cell proliferation, it is envisioned that this compound

and other PI3Kδ inhibitors could be used to suppress undesirable proliferation of B cells in clinical settings. For example, in B cell malignancy, B cells of various stages of differentiation show unregulated proliferation. Based on the results shown above, one can infer that PI3Kδ selective inhibitors could be used to control, limit, or inhibit growth of such cells.

EXAMPLE 5

Characterization of Role of PI3Kδ in T Lymphocyte Function

T cell proliferation in response to costimulation of CD3+CD28 was measured. T cells were purified from healthy human blood by negative selection using antibody coated magnetic beads according to the manufacturer's protocol (Dynal) and resuspended in RPMI. The cells were treated with either DMSO or a serial dilution of D-000 in DMSO and plated at 1 x 105 cells/well on a 96-well plate precoated with goat antimouse IgG. Mouse monoclonal anti-CD3 and anti-CD28 antibodies were then added to each well at 0.2 ng/mL and 0.2 $\mu g/mL$, respectively. The plate was incubated at 37°C for 24 hr and [3H] thymidine (1 µCi/well) was added. After another 18 hr incubation the cells were harvested with an automatic cell harvester, washed and the incorporated radioactivity was quantified.

Although the PI3Ko inhibitor D-000 inhibited anti-CD3- and anti-CD28-induced proliferation of T cells, its effect is not as strong as its

effect on B cells or on some of the functions of neutrophils. Half-maximal inhibition of thymidine incorporation was not achieved at the highest tested concentration, i.e., 10 µM D-000.

EXAMPLE 6

Characterization of Role of PI3Kδ in Osteoclast Function

To analyze the effect of the PI3Kδ inhibitor D-000 on osteoclasts, mouse bone marrow cells were isolated and differentiated them to osteoclasts by treating the cells with Macrophage Colony Stimulating Factor 1 (mCSF-1) and Osteoprotegerin Ligand (OPGL) in serum-containing medium (QMEM with 10% heat-inactivated FBS; Sigma) for 3 days. four, when the osteoclasts had developed, the medium was removed and cells were harvested. The osteoclasts were plated on dentine slices at 105 cells/well in growth medium, i.e., OMEM containing 1% serum and 2% BSA with 55 µg/mL OPGL and 10 ng/mL mCSF-1. After 3 hr, the medium was changed to 1% serum and 1% BSA, with or without osteopontin (25 μg/mL) and the PI3K inhibitors (100 nM). was changed every 24 hours with fresh osteopontin and the inhibitors. At 72 hr, the medium was removed, and the dentine surfaces were washed with water to remove cell debris and stained with acid hematoxylin. Excess stain was washed and the pit depths were quantitated using confocal microscopy.

As shown in Table 1, in two experiments, the PI 3-kinase inhibitors had an inhibitory effect

- 105 -

on osteoclast function. Both the nonspecific inhibitors LY294002 and wortmannin inhibited osteoclast activity. However, the PI3Kδ inhibitor D-000 had the most profound effect, as at 100 nM this compound almost completely inhibited the osteoclast activity.

Table 1			
Osteopontin (OPN)	D-000 + OPN	LY294002 + OPN	Wortmannin + OPN
10±0.5	1	4.6±0.22	5.7±0.6
9±0.4	1	5.8±0.5	5±0.5

EXAMPLE 7

Characterization of Role of PI3Kδ in Basophil Function

Assessment of the effect of a compound of the invention on basophil function was tested using a conventional histamine release assay, generally in accordance with the method described in Miura et al., J Immunol, 162:4198-206 (1999). Briefly, enriched basophils were preincubated with test compounds at several concentrations from 0.1 nM to 1,000 nM, for 10 min at 37°C. Then, polyclonal goat antihuman IgE (0.1 µg/mL) or fMLP was added, and allowed to incubate for an additional 30 min. Histamine released into the supernatant was measured using an automated fluorometric technique. Two compounds were tested, shown below.

- 106 -

D-026

D-999

A dose-dependent decrease in histamine release was observed for 3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-026) when the basophils were stimulated with anti-IgE. This suppression of histamine release was essentially 100% at 1,000 nM, with an EC₅₀ of about

25 nM. Another compound, 3-(2-chlorophenyl)-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanylmethyl)-3H-quinazolin-4-one (D-999), in which the purine ring structure is rearranged, was less efficacious in the inhibition of histamine release. Neither compound elicited any effect when the basophils were stimulated with fMLP. For comparison, the nonselective PI3K inhibitor LY294002 was tested at 0.1 nM and 10,000 nM, showing close to 100% inhibition of histamine release at the highest concentration.

These data indicate that inhibitors of PI 3-kinase delta activity can be used to suppress release of histamine, which is one of the mediators of allergy. Since the activity of various PI 3-kinases are required for protein trafficking, secretion, and exocytosis in many cell types, the above data suggest that histamine release by other cells, such as mast cells, also can be disrupted by PI 3-kinase delta-selective inhibitors.

CHEMICAL SYNTHESIS EXAMPLES

Specific nonlimiting examples of compounds of the invention are provided below. It is understood in the art that protecting groups can be employed where necessary in accordance with general principles of synthetic chemistry. These protecting groups are removed in the final steps of the synthesis under basic, acidic, or hydrogenolytic conditions readily apparent to those persons skilled in the art. By employing appropriate manipulation and protection of any chemical functionalities, synthesis of compounds of structural formula (I) not

specifically set forth herein can be accomplished by methods analogous to the schemes set forth below.

Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. All reactions and chromatography fractions were analyzed by thin-layer chromatography (TLC) on 250 mm silica gel plates, visualized with ultraviolet (UV) light or iodine (I₂) stain. Products and intermediates were purified by flash chromatography or reverse-phase high performance liquid chromatography.

The following abbreviations are used in the synthetic examples: aq (aqueous), H₂O (water), CHCl₃ (chloroform), HCl (hydrochloric acid), MeOH (methanol), NaOH (sodium hydroxide), NaOMe (sodium methoxide), TFA (trifluoroacetic acid), K₂CO₃ (potassium carbonate), SOCl₂ (thionyl chloride), CH₂Cl₂ (methylene chloride), EtOAC (ethyl acetate), DMF (dimethylformamide), EtOH (ethanol), DMSO (dimethyl sulfoxide), NaHCO₃ (sodium bicarbonate), TLC (thin layer chromatography), HPLC (high performance liquid chromatography), HOBT (hydroxybenzotriazole), EDC (ethyldiethylaminopropylcarbodiimide), DIEA (diisopropylethylamine), and HOAc (acetic acid).

- 109 -

I. General Procedures

Procedure A

Thionyl chloride was added to a rapidly stirring solution of anthranilic acid or benzoic acid in benzene, and the mixture was stirred at reflux for 5 to 18 hours. The reaction was concentrated in vacuo, and stripped down twice with benzene. The resulting oil was dissolved in CHCl₃ and to that solution was added the appropriate aniline. The reaction mixture was heated to reflux and stirred until complete, as determined by TLC, at which point the reaction mixture was cooled to ambient temperature. The precipitate was removed by filtration, and the filtrate concentrated in vacuo. The crude product was purified by chromatography and/or recrystallization from MeOH to provide amides la-1r.

Procedure B

To a rapidly stirring suspension of an amide in glacial acetic acid was added chloroacetyl chloride. The reaction mixture was heated to 120°C, and allowed to stir at that temperature until complete, as determined by TLC. After brief cooling, the reaction mixture was concentrated in vacuo. The crude residue was purified by extraction, chromatography, and/or recrystallization to provide chlorides 2a-2r.

- 110 -

Procedure C

A mixture of a chloride, either a nitrogen or a sulfur nucleophile, for example, mercaptopurine monohydrate or adenine, and K₂CO₃ in DMF was stirred at room temperature for 15-72 hours. The resulting suspension was poured into water, and kept at 4°C for several hours. The crude solid was filtered, washed with water, and purified by chromatography or recrystallization to provide the final products.

EXAMPLE_8

Preparation of Intermediate Compounds: Amides

2-Amino-N-(2-chlorophenyl)-4,5-dimethoxybenzamide (1a)

Prepared according to Procedure A using 4,5-dimethoxyanthranilic acid (5.0 g, 25.4 mmol) and SOCl₂ (5.5 mL, 76.1 mmol) in benzene (100 mL), followed by 2-chloroaniline (6.7 mL, 63.5 mmol) and CHCl₃ (75 mL). The product was washed with aqueous NaHCO₃ (2 x 25 mL) and HCl (0.5 M, 75 mL) and purified by chromatography in CH₂Cl₂ to provide 4.3 g of a brown foam (55%). ¹H NMR (CDCl₃) δ: 8.42 (dd, J=1.5, 8.3 Hz, 1H); 8.32 (br s, 1H); 7.40 (dd, J=1.4, 8.0 Hz, 1H); 7.31 (dt, J=1.4, 7.9 Hz, 1H); 7.05 (dt, J=1.5, 7.7 Hz, 1H); 7.03 (s, 1H); 6.24 (s, 1H); 3.88 (s, 3H); 3.87 (s, 3H). MS (ES): m/z 307.0 (M+).

- 111 -

2-Amino-5-bromo-N-(2-chlorophenyl)benzamide (1b)

Prepared according to Procedure A using 2-amino-5-bromobenzoic acid (5.0 g, 23.1 mmol) and SOCl₂ (7.0 mL, 95.9 mmol) in benzene (50 mL), followed by 2-chloroaniline (7.3 mL, 69.3 mmol) and CHCl₃ (50 mL). The product was purified by two chromatographies in CH₂Cl₂ to provide 1.48 g of a yellow orange solid (20%). ¹H NMR (CDCl₃) δ: 8.36 (dd, J=1.2, 8.2 Hz, 1H); 8.20 (br s, 1H); 7.62 (d, J=2.1 Hz, 1H); 7.42 (dd, J=1.3, 8.0 Hz, 1H); 7.34 (dd, J=2.2, 8.8 Hz, 1H); 7.28-7.33 (m, 1H); 7.09 (dt, J=1.4, 7.7 Hz, 1H); 6.62 (d, J=8.7 Hz, 1H); 5.57 (br s, 2H).

2-Amino-N-(2-chlorophenyl)-4-fluorobenzamide (1c)

Prepared according to Procedure A using 2-amino-4-fluorobenzoic acid (1.15 g, 7.41 mmol) and SOCl₂ (1.4 mL, 18.5 mmol) in benzene (25 mL), followed by 2-chloroaniline (1.6 mL, 14.8 mmol) and CHCl₃ (25 mL). The product was chromatographed in CH₂Cl₂, then triturated from hexanes to provide 1.02 g of an off-white solid (52%). ¹H NMR (CDCl₃) δ: 12.91 (br s, 1H); 8.72 (dd, J=2.7, 12 Hz, 1H); 8.34 (dd, J=6.4, 9.2 Hz, 1H); 8.29 (dd, J=5.9, 8.8 Hz, 1H); 7.81 (dd, J=6.2, 8.8 Hz, 1H); 7.28 (dt, J=2.4, 8.4 Hz, 1H); 7.21 (dd, J=2.4, 9.0 Hz, 1H); 6.92 (ddd, J=2.4, 7.3, 9.1 Hz, 1H); 6.54 (ddd, J=2.4, 7.8, 8.8 Hz, 1H); 6.45 (dd, J=2.4, 11 Hz, 1H); 5.93 (br s, 2H). MS (ES): m/z 265.0 (M+).

- 112 -

2-Amino-5-chloro-N-(2-chlorophenyl)benzamide (1d)

Prepared according to Procedure A using 2-amino-5-chlorobenzoic acid (2.0 g, 11.7 mmol) and SOCl₂ (2.2 mL, 29.2 mmol) in benzene (50 mL), followed by 2-chloroaniline (2.5 mL, 23.3 mmol) and CHCl₃ (50 mL). The product was purified by recrystallization from MeOH to provide 1.72 g cf a dark yellow solid (52%). ¹H NMR (CDCl₃) δ: 8.37 (dd, J=1.5, 8.3 Hz, 1H); 8.22 (br s, 1H); 7.48 (d, J=2.3 Hz, 1H); 7.42 (dd, J=1.5, 8.1 Hz, 1H); 7.31 (dt, J=1.4, 7.8 Hz, 1H); 7.22 (dd, J=2.4, 8.8 Hz, 1H); 7.09 (dt, J=1.5, 7.7 Hz, 1H); 6.67 (d, J=8.8 Hz, 1H); 5.56 (br s, 2H).

2-Amino-N-(2-chlorophenyl)-6-fluorobenzamide (1e)

Prepared according to Procedure A using 2-amino-6-fluorobenzoic acid (2.0 g, 12.9 mmol) and SOCl₂ (2.3 mL, 32.2 mmol) in benzene (50 mL), followed by 2-chloroaniline (2.7 mL, 25.8 mmol) and CHCl₃ (50 mL). The product was purified by chromatography in EtOAc/hexanes to provide 2.06 g of a pale orange solid (60%). ¹H NMR (CDCl₃) δ: 9.00 (d, J=17 Hz, 1H); 8.47 (d, J=8.3 Hz, 1H); 7.41 (d, J=8.0 Hz, 1H); 7.30 (t, J=7.9 Hz, 1H); 7.10-7.20 (m, 1H); 7.07 (t, J=7.7 Hz, 1H); 6.49 (d, J=8.3 Hz, 1H); 6.03 (br s, 2H). MS (ES): m/z 265.0 (M+).

- 113 -

2-Amino-6-chloro-N-(2-chlorophenyl)benzamide (1f)

Prepared according to Procedure A using 2-amino-6-chlorobenzoic acid (2.5 g, 14.6 mmol) and SOCl₂ (2.7 mL, 36.4 mmol) in benzene (75 mL), followed by 2-chloroaniline (3.1 mL, 29.1 mmol) and CHCl₃ (75 mL). The product chromatographed in CH₂Cl₂ to provide 1.05 g of a yellow orange solid (26%). ¹H NMR (CDCl₃) δ: 8.54 (d, J=8.1 Hz, 1H); 8.30 (br s, 1H); 7.41 (dd, J=1.5, 8.0 Hz, 1H); 7.33 (t, J=7.8 Hz, 1H); 7.10 (t, J=8.1 Hz, 1H); 7.09 (dt, J=1.6, 7.8 Hz, 1H); 6.78 (dd, J=0.4, 7.9 Hz, 1H); 6.63 (dd, J=0.9, 8.2 Hz, 1H); 4.69 (br s, 2H). MS (ES): m/z 303.0 (M+22), 281.0 (M+).

2-Amino-N-(2-chlorophenyl)-6-methylbenzamide (1g)

Prepared according to Procedure A using 2-amino-6-methylbenzoic acid (2.5 g, 16.5 mmol) and SOCl₂ (3.0 mL, 41.3 mmol) in benzene (75 mL), followed by 2-chloroaniline (3.5 mL, 33.0 mmol) and CHCl₃ (75 mL). The product was chromatographed in CH₂Cl₂ to provide 2.19 g of a brown oil (51%). ¹H NMR (CDCl₃) δ: 8.58 (d, J=8.1 Hz, 1H); 7.99 (br s, 1H); 7.40 (dd, J=1.4, 8.0 Hz, 1H); 7.34 (t, J=7.7 Hz, 1H); 7.11 (t, J=7.8 Hz, 1H); 7.09 (dt, J=1.5, 7.7 Hz, 1H); 6.64 (d, J=7.5 Hz, 1H); 6.59 (d, J=8.1 Hz, 1H); 4.29 (br s, 2H); 2.45 (s, 3H). MS (ES): m/z 283.0 (M+22).

- 114 -

2-Amino-3-chloro-N-(2-chlorophenyl)benzamide (1h)

Prepared according to Procedure A using 2-amino-3-chlorobenzoic acid (1.0 g, 5.82 mmol) and SOCl₂ (1.1 mL, 14.6 mmol) in benzene (25 mL), followed by 2-chloroaniline (1.2 mL, 11.7 mmol) and CHCl₃ (25 mL). The product was recrystallized from MeOH to provide 1.29 g of a yellow solid (78%). ¹H NMR (CDCl₃) δ: 8.43 (dd, J=1.4, 8.3 Hz, 1H); 8.30 (br s, 1H); 7.47 (dd, J=1.1, 8.0 Hz, 1H); 7.42 (d, J=8.0 Hz, 2H); 7.33 (dt, J=1.4, 7.9 Hz, 1H); 7.09 (dt, J=1.5, 7.7 Hz, 1H); 6.68 (t, J=7.9 Hz, 1H); 6.13 (br s, 2H). MS (ES): m/z 281.0 (M+).

2-Amino-N-biphenyl-2-yl-6-chlorobenzamide (1i)

Prepared according to Procedure A using 2-amino-6-chlorobenzoic acid (2.0 g, 11.7 mmol) and SOCl₂ (2.1 mL, 29.3 mmol) in benzene (60 mL), followed by 2-aminobiphenylamine (4.15 g, 24.5 mmol) and CHCl₃ (60 mL). The product was chromatographed in CH₂Cl₂ to provide 2.16 g of a foamy dark-amber residue (57%). ¹H NMR (CDCl₃) δ: 8.48 (d, J=8.2 Hz, 1H); 7.79 (br s, 1H); 7.34-7.46 (m, 6H); 7.20-7.30 (m, 2H); 7.00 (t, J=8.1 Hz, 1H); 6.63 (dd, J=0.6, 7.9 Hz, 1H); 6.54 (d, J=8.3 Hz, 1H); 4.58 (br s, 2H). MS (ES): m/z 323.1 (M+).

2-Amino-6-chloro-N-o-tolylbenzamide (1j)

Prepared according to Procedure A using 2-amino-6-chlorobenzoic acid (1.0 g, 5.83 mmol) and SOCl₂ (1.1 mL, 14.6 mmol) in benzene (30 mL), followed by o-toluidine (1.4 mL, 12.8 mmol) and CHCl₃ (30 mL). The product was chromatographed in CH₂Cl₂ to provide 840 mg of an oily yellow solid (55%). ¹H NMR (CDCl₃) δ: 7.96 (d, J=7.9 Hz, 1H); 7.60 (br s, 1H); 7.23-7.30 (m, 2H); 7.14 (t, J=7.5 Hz, 1H); 7.11 (t, J=8.3 Hz, 1H); 6.78 (d, J=7.9 Hz, 1H); 6.64 (d, J=8.2 Hz, 1H); 4.73 (br s, 2H); 2.35 (s, 3H). MS (ES): m/z 261.0 (M+).

2-Amino-6-chloro-N-(2-fluorophenyl)benzamide (1k)

Prepared according to Procedure A using 2-amino-6-chlorobenzoic acid (2.0 g, 11.7 mmol) and $SOCl_2$ (2.1 mL, 29.1 mmol) in benzene (60 mL), followed by 2-fluoroaniline (2.3 mL, 23.4 mmol) and $CHCl_3$ (60 mL). The product was chromatographed in CH_2Cl_2 to provide 1.05 g of a yellow solid (34%). ¹H NMR (CDCl₃) δ : 8.45 (t, J=8.0 Hz, 1H); 8.01 (br s, 1H); 7.02-7.22 (m, 4H); 6.78 (dd, J=0.5, 7.9 Hz, 1H); 6.64 (dd, J=0.8, 8.2 Hz, 1H); 4.73 (br s, 2H). MS (ES): m/z 265.0 (M+).

2-Amino-6-chloro-N-(2-methoxyphenyl)benzamide (11)

Prepared according to Procedure A using 2-amino-6-chlorobenzoic acid (2.0 g, 11.7 mmol) and SOCl₂ (2.1 mL, 29.1 mmol) in benzene (60 mL), followed by o-anisidine (2.6 mL, 23.4 mmol) and CHCl₃ (60 mL). The product was chromatographed in CH₂Cl₂ to provide 2.61 g of a dark yellow oil (81%). ¹H NMR (CDCl₃) δ: 8.53 (dd, J=1.7, 7.9 Hz, 1H); 8.39 (br s, 1H); 7.11 (dt, J=1.6, 7.8 Hz, 1H); 7.09 (t, J=8.1 Hz, 1H); 7.02 (dt, J=1.4, 7.8 Hz, 1H); 6.92 (dd, J=1.4, 8.0 Hz, 1H); 6.62 (dd, J=0.9, 8.2 Hz, 1H); 4.66 (br s, 2H); 3.87 (s, 3H). MS (ES): m/z 277.0 (M+).

2-Amino-N-(2-chlorophenyl)-3-trifluoromethylbenzamide (lm)

Prepared according to Procedure A using 3-trifluoromethylanthranilic acid (2.0 g, 9.75 mmol) and SOCl₂ (1.8 mL, 24.4 mmol) in benzene (50 mL), followed by 2-chloroaniline (2.1 mL, 19.5 mmol) and CHCl₃ (50 mL). The product was purified by recrystallization from MeOH to provide 2.38 g yellow crystals (78%). ¹H NMR (CDCl₃) δ : 8.40 (dd, J=1.4, 8.3 Hz, 1H); 8.25 (br s, 1H); 7.71 (d, J=7.8 Hz, 1H); 7.60 (d, J=7.8 Hz, 1H); 7.43 (dd, J=1.4, 8.0 Hz, 1H); 7.34 (dt, J=1.3, 7.9 Hz, 1H); 7.11 (dt, J=1.5, 7.7 Hz, 1H); 6.77 (t, J=7.8 Hz, 1H); 6.24 (br s, 2H). MS (ES): m/z 315.0 (M+).

- 117 -

3-Aminonaphthalene-2-carboxylic acid (2-chlorophen-yl)amide (1n)

Prepared according to Procedure A using 3-amino-2-napthoic acid (2.0 g, 10.7 mmol) and SOCl₂ (1.9 mL, 26.7 mmol) in benzene (50 mL), followed by 2-chloroaniline (2.3 mL, 21.4 mmol) and CHCl₃ (50 mL). The product was recrystallized from MeOH to provide 1.71 g of a brown solid (54%). ¹H NMR (CDCl₃) δ: 10.88 (br s, 1H); 9.21 (s, 1H); 8.91 (s, 1H); 8.70 (dd, J=1.0, 8.3 Hz, 1H); 7.95-8.01 (m, 1H); 7.87-7.94 (m, 1H); 7.60-7.68 (m, 2H); 7.41 (dd, J=1.3, 8.0 Hz, 1H); 7.34 (dt, J=1.2, 7.8 Hz, 1H); 7.07 (dt, J=1.4, 7.7 Hz, 1H). MS (ES): m/z 297.1 (M+).

2-Amino-N-(2-chlorophenyl)-4-nitrobenzamide (10)

Prepared according to Procedure A using 4-nitroanthranilic acid (5.0 g, 27.5 mmol) and SOCl₂ (5.0 mL, 68.6 mmol) in benzene (150 mL), followed by 2-chloroaniline (5.8 mL, 55.0 mmol) and CHCl₃ (150 mL). The product was purified by chromatography in CH₂Cl₂ followed by recrystallization from MeOH to provide 2.20 g of an orange-brown solid (31%). ¹H NMR (CDCl₃) δ: 8.41 (dd, J=1.3, 8.3 Hz, 1H); 8.31 (br s, 1H); 7.67 (d, J=8.6 Hz, 1H); 7.57 (d, J=2.1 Hz, 1H); 7.52 (dd, J=2.2, 8.5 Hz, 1H); 7.44 (dd, J=1.3, 8.1 Hz, 1H); 7.35 (dt, J=1.3, 7.9 Hz, 1H); 7.13 (dt, J=1.4, 7.8 Hz, 1H); 5.88 (br s, 2H). MS (ES): m/z 292.0 (M+).

- 118 -

2-Amino-N-(2-chlorophenyl)-5-hydroxybenzamide (1p)

Prepared according to Procedure A using 2-amino-5-hydroxybenzoic acid (5.0 g, 32.7 mmol) and SOCl₂ (6.0 mL, 81.6 mmol) in benzene (150 mL), followed by 2-chloroaniline (6.9 mL, 65.4 mmol) and CHCl₃ (150 mL). The product was purified by two chromatographies in MeOH/CH₂Cl₂ to provide 990 mg of a brown solid (12%). ¹H NMR (MeOH-d₄) δ: 7.92 (dd, J=1.6, 8.1 Hz, 1H); 7.48 (dd, J=1.5, 7.7 Hz, 1H); 7.34 (dt, J=1.5, 7.7 Hz, 1H); 7.20 (dt, J=1.7, 7.7 Hz, 1H); 7.16 (d, J=2.7 Hz, 1H); 6.83 (dd, J=2.7, 8.7 Hz, 1H); 6.76 (d, J=8.7 Hz, 1H); [6.24 (br s, 2H)). MS (ES): m/z 263.0 (M+).

2-Amino-N-(2-chlorophenyl)-4,5-difluorobenzamide (1q)

Prepared according to Procedure A using 4,5-difluoroanthranilic acid (2.0 g, 11.6 mmol) and SOCl₂ (2.1 mL, 28.9 mmol) in benzene (60 mL), followed by 2-chloroaniline (2.4 mL, 23.2 mmol) and CHCl₃ (60 mL). The product was purified by two chromatographies in CH₂Cl₂ and EtOAc/hexanes to provide 769 mg of a yellow solid (23%). ¹H NMR (CDCl₃) 5: 8.69-8.82 (m, 1H); 8.00 (dd, J=8.4, 9.0 Hz, 1H); 7.90 (dd, J=8.9, 12 Hz, 1H); 7.39 (dd, J=6.8, 10 Hz, 1H); 6.53 (dd, J=6.6, 12 Hz, 1H); 6.41 (br s, 2H); 5.79 (br s, 1H). MS (ES): m/z 283.1 (M+).

- 119 -

2-Amino-N-(2-chlorophenyl)-5-fluorobenzamide (1r)

Prepared according to Procedure A using 2-amino-5-fluorobenzoic acid (1.0 g, 6.45 mmol) and $SOCl_2$ (1.2 mL, 16.1 mmol) in benzene (30 mL), followed by 2-chloroaniline (1.4 mL, 12.9 mmol) and $CHCl_3$ (30 mL). The product was triturated from CH_2Cl_2 to provide 985 mg of a mustard-yellow solid (58%). ¹H NMR (CDCl₃) δ : 7.66 (dd, J=2.9, 8.7 Hz, 1H); 7.52-7.55 (m, 1H); 7.32-7.37 (m, 3H); 7.09 (dt, J=3.0, 8.5 Hz, 1H); 6.71 (dd, J=4.3, 8.7 Hz, 1H). MS (ES): m/z 305.0 (M+40).

EXAMPLE 9

Preparation of Intermediate Compounds: Chlorides

2-Chloromethyl-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one (2a)

Prepared according to Procedure B with 1a (2.95 g, 9.63 mmol) and chloroacetyl chloride (2.3 mL, 28.9 mmol) in acetic acid (30 mL). Purified by extraction from aq. K_2CO_3 and recrystallization from isopropanol to afford 1.61 g of a brown crystalline solid (46%). ¹H NMR (CDCl₃) δ : 7.59-7.66 (m, 2H); 7.45-7.56 (m, 3H); 7.20 (s, 1H); 4.37 (d, J=12 Hz, 1H), 4.08 (d, J=12 Hz, 1H); 4.04 (s, 3H); 4.00 (s, 3H). MS (ES): m/z 365.0 (M+).

6-Bromo-2-chloromethyl-3-(2-chlorophenyl)-3H-quinazolin-4-one (2b)

Prepared according to Procedure B with 1b (500 mg, 1.54 mmol) and chloroacetyl chloride (0.37 mL, 4.61 mmol) in acetic acid (10 mL). Purified by recrystallization from isopropanol to afford 490 mg of an off-white solid (83%). ¹H NMR (CDCl₃) δ: 8.43 (d, J=2.3 Hz, 1H); 7.91 (dd, J=2.3, 8.7 Hz, 1H); 7.67 (d, J=8.7 Hz, 1H); 7.60-7.65 (m, 1H); 7.47-7.56 (m, 2H); 7.52 (t, J=5.3 Hz, 1H); 7.47-7.56 (m, 1H); 4.37 (d, J=12 Hz, 1H), 4.06 (d, J=12 Hz, 1H). MS (ES): m/z 385.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-7-fluoro-3H-quin-azolin-4-one (2c)

Prepared according to Procedure B with 1c (500 mg, 1.89 mmol) and chloroacetyl chloride (0.45 mL, 5.67 mmol) in acetic acid (10 mL). Purified by extraction from aqueous K_2CO_3 , followed by recrystallization from isopropanol to afford 501 mg of a yellow crystalline solid (82%). ¹H NMR (CDCl₃) δ : 8.32 (dd, J=6.0, 8.9 Hz, 1H); 7.59-7.66 (m, 1H); 7.50-7.55 (m, 3H); 7.44 (dd, J=2.4, 9.4 Hz, 1H); 7.27 (dt, J=2.5, 8.5 Hz, 1H); 4.37 (d, J=12 Hz, 1H), 4.07 (d, J=12 Hz, 1H). MS (ES): m/z 323.0 (M+).

- 121 -

6-Chloro-2-chloromethyl-3-(2-chlorophenyl)-3H-quinazolin-4-one (2d)

Prepared according to Procedure B with 1d (500 mg, 1.78 mmol) and chloroacetyl chloride (0.42 mL, 5.33 mmol) in acetic acid (10 mL). Purified by recrystallization from isopropanol to afford 555 mg of a yellow solid (92%). 1 H NMR (CDCl₃) δ : 8.27 (d, J=1.9 Hz, 1H); 7.74-7.78 (m, 2H); 7.60-7.66 (m, 1H); 7.48-7.57 (m, 3H); 4.37 (d, J=12 Hz, 1H), 4.07 (d, J=12 Hz, 1H). MS (ES): m/z 339.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-5-fluoro-3H-quin-azolin-4-one (2e)

Prepared according to Procedure B with 1e (500 mg, 1.89 mmol) and chloroacetyl chloride (0.45 mL, 5.67 mmol) in acetic acid (10 mL). Purified by extraction from aq. K_2CO_3 and recrystallization from isopropanol to afford 430 mg of an off-white crystalline solid (70%). ¹H NMR (CDCl₃) δ : 7.76 (dt, J=5.3, 8.2 Hz, 1H); 7.56-7.65 (m, 2H); 7.47-7.56 (m, 3H); 7.16-7.25 (m, 1H); 4.35 (d, J=12 Hz, 1H), 4.07 (d, J=12 Hz, 1H). MS (ES): m/z 323.0 (M+).

5-Chloro-2-chloromethyl-3-(2-chlorophenyl)-3H-quinazolin-4-one (2f)

Prepared according to Procedure B with 1f (1.00 g, 3.56 mmol) and chloroacetyl chloride (0.85 mL, 10.7 mmol) in acetic acid (15 mL). Purified by recrystallization from isopropanol to afford 791 mg of an off-white crystalline solid (65%). ¹H NMR

(CDCl₃) δ: 7.70 (s, 1H); 7.68 (d, J=3.8 Hz, 1H); 7.61-7.65 (m, 1H); 7.55 (dd, J=2.7, 6.4 Hz, 1H); 7.51 (d, J=3.1 Hz, 1H); 7.50 (s, 2H); 4.35 (d, J=12 Hz, 1H), 4.05 (d, J=12 Hz, 1H). MS (ES): m/z 339.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-5-methyl-3H-quinazolin-4-one (2g)

Prepared according to Procedure B with 1g (2.18 g, 8.36 mmol) and chloroacetyl chloride (2.0 mL, 25.1 mmol) in acetic acid (40 mL). Purified by two chromatographies in CH_2Cl_2 and EtOAc/hexanes, followed by recrystallization from isopropanol to afford 638 mg of an off-white crystalline solid (24%). ¹H NMR (DMSO-d₆) δ : 7.73-7.80 (m, 3H); 7.58-7.64 (m, 3H); 7.41 (d, J=7.4 Hz, 1H); 4.40 (d, J=12 Hz, 1H), 4.26 (d, J=12 Hz, 1H); 2.74 (s, 3H). MS (ES): m/z 319.0 (M+).

8-Chloro-2-chloromethyl-3-(2-chlorophenyl)-3H-quinazolin-4-one (2h)

Prepared according to Procedure B with 1h (500 mg, 1.78 mmol) and chloroacetyl chloride (0.49 mL, 6.13 mmol) in acetic acid (10 mL). Purified by extraction from aqueous K_2CO_3 , followed by recrystallization from isopropanol to afford 448 mg of a yellow solid (74%). ¹H NMR (CDCl₃) δ : 8.23 (dd, J=1.4, 8.0 Hz, 1H); 7.90 (dd, J=1.4, 7.8 Hz, 1H); 7.61-7.66 (m, 1H); 7.51-7.55 (m, 3H); 7.47 (t, J=8.0 Hz, 1H); 4.48 (d, J=12 Hz, 1H), 4.12 (d, J=12 Hz, 1H). MS (ES): m/z 339.0 (M+).

3-Biphenyl-2-yl-5-chloro-2-chloromethyl-3H-quinazolin-4-one (2i)

Prepared according to Procedure B with 1i (2.0 g, 6.20 mmol) and chloroacetyl chloride (1.5 mL, 18.6 mmol) in acetic acid (30 mL). Purified by chromatography in CH2Cl2, followed by recrystallization from isopropanol to afford 1.44 g of an offwhite solid (61%). ¹H NMR (CDCl₃) δ : 7.61-7.64 (m, · 1H); 7.58-7.59 (m, 1H); 7.54-7.57 (m, 2H); 7.52-7.53 (m, 1H); 7.45-7.52 (m; 2H); 7.24 (s, 5H); 3.92-4.03 (m, 2H). MS (ES): m/z 381.0 (M+).

5-Chloro-2-chloromethyl-3-o-tolyl-3H-quinazolin-4one (2j)

Prepared according to Procedure B with 1j (750 mg, 2.88 mmol) and chloroacetyl chloride (0.69 mL, 8.63 mmol) in acetic acid (15 mL). Purified by chromatography in CH2Cl2, followed by recrystallization from isopropanol to afford 340 mg of a white solid (37%). ¹H NMR (CDCl₃) δ : 7.69 (d, J=2.1 Hz, 1H); 7.68 (q, J=7.4 Hz, 1H); 7.54 (dd, J=2.2, 7.0 Hz, 1H); 7.35-7.47 (m, 3H); 7.21-7.25 (m, 1H); 4.27(d, J=12 Hz, 1H); 4.11 (d, J=12 Hz, 1H); 2.18 (s, -3H). MS (ES): m/z 319.0 (M+).

5-Chloro-2-chloromethyl-3-(2-fluorophenyl)-3Hquinazolin-4-one (2k)

Prepared according to Procedure B with 1k (1.0 g, 3.78 mmol) and chloroacetyl chloride (0.90 mL, 11.3 mmol) in acetic acid (20 mL). Purified by chromatography in CH2Cl2 to afford 484 mg of a pale

- 124 -

pink solid (40%). ¹H NMR (CDCl₃) δ : 7.69 (s, 1H); 7.68 (d, J=3.2 Hz, 1H); 7.56 (d, J=3.0 Hz, 1H); 7.54 (d, J=3.0 Hz, 1H); 7.40-7.47 (m, 1H); 7.35-7.38 (m, 1H); 7.27-7.32 (m, 1H); 4.35 (d, J=12 Hz, 1H); 4.18 (d, J=12 Hz, 1H). MS (ES): m/z 323.0 (M+).

5-Chloro-2-chloromethyl-3-(2-methoxyphenyl)-3H-quinazolin-4-one (21)

Prepared according to Procedure B with 11 (2.6 g, 9.41 mmol) and chloroacetyl chloride (2.2 mL, 28.2 mmol) in acetic acid (40 mL). Purified by chromatography in CH₂Cl₂, followed by recrystallization from isopropanol to afford 874 mg of a pale yellow solid (28%). ¹H NMR (CDCl₃) δ: 7.55-7.74 (m, 2H); 7.47-7.54 (m, 2H); 7.34 (dd, J=1.7, 7.8 Hz, 1H); 7.13 (dt, J=1.2, 7.7 Hz, 1H); 7.08 (dd, J=1.0, 8.4 Hz, 1H); 4.29 (d, J=12 Hz, 1H); 4.11 (d, J=12 Hz, 1H); 3.80 (s, 3H). MS (ES): m/z 335.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-8-trifluoromethyl-3H-quinazolin-4-one (2m)

Prepared according to Procedure B with 1m (500 mg, 1.59 mmol) and chloroacetyl chloride (0.38 mL, 4.77 mmol) in acetic acid (10 mL). Purified by recrystallization from isopropanol to afford 359 mg of a white crystalline solid (61%). ¹H NMR (CDCl₃) δ: 8.51 (dd, J=1.0, 8.0 Hz, 1H); 8.14 (d, J=7.3 Hz, 1H); 7.65 (dd, J=2.5, 5.6 Hz, 1H); 7.62 (d, J=3.9 Hz, 1H); 7.48-7.60 (m, 3H); 4.44 (d, J=12 Hz, 1H), 4.12 (d, J=12 Hz, 1H). MS (ES): m/z 373.0 (M+).

- 125 -

2-Chloromethyl-3-(2-chlorophenyl)-3H-benzo[g]quin-azolin-4-one (2n)

Prepared according to Procedure B with 1n (500 mg, 1.68 mmol) and chloroacetyl chloride (0.40 mL, 5.05 mmol) in acetic acid (10 mL). Purified by chromatography in CH₂Cl₂ followed by recrystallization from isopropanol to afford 232 mg of a light-brown solid (39%). ¹H NMR (CDCl₃) 5: 8.92 (s, 1H); 8.29 (s, 1H); 8.81 (d, J=8.3, 1H); 8.32 (d, J=8.3 Hz, 1H); 7.51-7.69 (m, 4H); 7.55 (d, J=5.2 Hz, 1H); 7.53 (d, J=3.8 Hz, 1H); 4.43 (d, J=12 Hz, 1H), 4.12 (d, J=12 Hz, 1H). MS (ES): m/z 355.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-7-nitro-3H-quin-azolin-4-one (20)

Prepared according to Procedure B with 10 (500 mg, 1.71 mmol) and chloroacetyl chloride (0.41 mL, 5.14 mmol) in acetic acid (10 mL). Purified by extraction from aqueous K₂CO₃, followed by two chromatographies in CH₂Cl₂ to afford 338 mg of a yellow oil (56%). ¹H NMR (CDCl₃) δ: 8.64 (d, J=2.2 Hz, 1H); 8.48 (d, J=8.8 Hz, 1H); 8.32 (dd, J=2.2, 8.7 Hz, 1H); 7.66 (dd, J=2.5, 6.0 Hz, 1H); 7.52-7.59 (m, 3H); 4.41 (d, J=12 Hz, 1H), 4.10 (d, J=12 Hz, 1H). MS (ES): m/z 350.0 (M+).

Acetic acid 2-chloromethyl-3-(2-chlorophenyl)-4-oxo-3,4-dihydro-quinazolin-6-yl ester (2p)

Prepared according to Procedure B with 1p (670 mg, 2.55 mmol) and chloroacetyl chloride (0.61 mL, 7.65 mmol) in acetic acid (10 mL). Purified by

chromatography in 0-3% MeOH/CH₂Cl₂, followed by recrystallization from isopropanol to afford 523 mg of the acetate as pale-peach crystals (57%). ¹H NMR (CDCl₃) δ : 8.00 (d, J=2.7 Hz, 1H); 7.82 (d, J=8.8 Hz, 1H); 7.60-7.66 (m, 1H); 7.56 (dd, J=2.7, 8.8 Hz, 1H); 7.51 (t, J=4.7 Hz, 2H); 7.50 (s, 1H); 4.38 (d, J=12 Hz, 1H), 4.08 (d, J=12 Hz, 1H); 2.36 (s, 3H). MS (ES): m/z 363.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-6,7-difluoro-3H-quinazolin-4-one (2q)

Prepared according to Procedure B with 1q (700 mg, 2.48 mmol) and chloroacetyl chloride (0.60 mL, 7.43 mmol) in acetic acid (12 mL). Purified by chromatography in CH_2Cl_2 , followed by recrystallization from isopropanol to afford 219 mg of a yellow crystalline solid (26%). ¹H NMR (CDCl₃) δ : 8.07 (dd, J=8.5, 9.7 Hz, 1H); 7.64 (dd, J=2.5, 5.6 Hz, 1H); 7.60 (dd, J=3.5, 11 Hz, 1H); 7.55 (q, J=2.9 Hz, 3H); 7.52 (d, J=1.9 Hz, 1H); 7.49-7.51 (m, 1H); 4.36 (d, J=12 Hz, 1H), 4.06 (d, J=12 Hz, 1H). MS (ES): m/z 341.0 (M+).

2-Chloromethyl-3-(2-chlorophenyl)-6-fluoro-3H-quinazolin-4-one (2r)

Prepared according to Procedure B with 1r (850 mg, 3.21 mmol) and chloroacetyl chloride (0.77 mL, 9.63 mmol) in acetic acid (15 mL). Purified by extraction from aqueous K_2CO_3 , followed by chromatography in EtOAc/hexanes. A second chromatography in acetone/hexanes afforded 125 mg of a white solid

- 127 -

(12%). ¹H NMR (CDCl₃) δ: 7.95 (dd, J=2.9, 8.2 Hz, 1H); 7.81 (dd, J=4.8, 9.0 Hz, 1H); 7.61-7.66 (m, 1H); 7.57 (dd, J=2.7, 8.6 Hz, 1H); 7.57 (dd, J=2.7, 8.6 Hz, 1H); 7.52 (dd, J=3.2, 6.9 Hz, 1H); 7.52 (br s, 2H); 4.38 (d, J=12 Hz, 1H), 4.08 (d, J=12 Hz, 1H). MS (ES): m/z 323.0 (M+).

EXAMPLE 10

Preparation of PI3Ko Inhibitor Compounds

Compound D-001

2-(6-Aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2a (200 mg, 0.546 mmol), adenine (81 mg, 0.601 mmol), K_2CO_3 (83 mg, 0.601 mmol); and DMF (4 mL). The crude product was recrystallized from ethanol (EtOH) to provide 164 mg of a beige solid (65%), mp 281.5-282.7°C (decomposes). ¹H NMR (DMSO d_6) δ : 8.06 (s, 1H); 8.04 (s, 1H); 7.76-7.81 (m, 1H); 7.70-7.76 (m, 1H); 7.60-7.67 (m, 2H); 7.45 (s, 1H); 7.22 (s, 2H); 6.90 (s, 1H); 5.08 (d, J=17 Hz, 1H); 4.91 (d, J=17 Hz, 1H); 3.87 (s, 3H); 3.87 (s, 3H). 13 C NMR (DMSO- d_6) ppm: 159.9, 156.2, 155.4, 152.9, 150.0, 149.7, 149.4, 143.0, 141.9, 133.7, 132.1, 131.9, 131.2, 130.8, 129.3, 118.4, 113.6, 108.4, 105.8, 56.5, 56.1, 44.7. MS (ES): m/z 464.1 (M+). Anal. calcd. for $C_{22}H_{18}ClN_7O_3 \cdot 0.1C_2H_6O \cdot 0.05KCl$: C, 56.47; H, 3.97; Cl, 7.88; N, 20.76. Found: C, 56.54; H, 4.05; Cl, 7.77; N, 20.55.

PCT/US01/13315 WO 01/81346

- 128 -

Compound D-002

2-(6-Aminopurin-o-ylmethyl)-6-bromo-3-(2chlorophenyl) -3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2b (100 mg, 0.260 mmol), adenine (39 mg, 0.286 mmol), K_2CO_3 (40 mg, 0.286 mmol), and DMF. (2 mL). The crude product was recrystallized from EtOH to provide 52 mg of an off-white solid (41%), mp 284.2-284.7°C (decomposes). ¹H NMR (DMSO- d_6) δ : 8.24 (d, J=2.0 Hz, 1H); 8.05 (s, 1H); 8.03 (s, 1H); 7.98 (dd, J=1.9, 8.6 Hz, 1H); 7.74-7.83 (m, 2H); 7.59-7.68 (m, 2H); 7.46 (d, J=8.7 Hz, 1H); 7.22 (s, 2H); 5.12 (d, J=17 Hz, 1H); 4.94 (d, J=17 Hz, 1H). 13 C NMR (DMSO-d₅) ppm: 159.5, 156.2, 152.9, 152.0, 150.1, 145.8, 141.8, 138.4, 133.1, 132.2, 131.9, 131.1, 130.9, 130.1, 129.4, 128.9, 122.4, 120.4, 118.4, 45.0. MS (ES): m/z 482.0 (M+). Anal. calcd. for C₂₀H₁₃ClBrN₇O•0.1KCl: C, 49.01; H, 2.67; Cl, 7.96; N, 20.00. Found: C, 48.82; H, 2.82; Cl, 8.00; N, 19.79.

Compound D-003

2-(6-Aminopurin-o-ylmethyl)-3-(2-chlorophenyl)-7fluoro-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2c (100 mg, 0.310 mmol); adenine (46 mg, 0.340 mmol), K_2CO_3 (47 mg, 0.340 mmol), and DMF (1 mL). The crude product was recrystallized from EtOH to provide 57 mg of a beige solid (44%), mp 216.8-217.2°C. ¹H NMR (DMSO- d_6) δ : 8.22 (dd, J=6.3, 8.7 Hz, 1H); 8.05 (s, 1H); 8.03 (s, 1H); 7.78-7.80

(m, 2H); 7.61-7.64 (m, 2H); 7.46 (dt, J=2.1, 8.6 Hz, 1H); 7.32 (d, J=9.8 Hz, 1H); 7.22 (s, 2H); 5.13 (d, J=17 Hz, 1H); 4.95 (d, J=17 Hz, 1H). ¹³C NMR (DMSO-d₆) ppm: 166.1 (d, J=253 Hz), 159.6, 155.8, 152.5, 149.7, 148.6 (d, J=14 Hz), 141.4, 132.8, 131.8, 131.6, 130.8, 130.5, 129.8 (d, J=11 Hz), 129.0, 118.1, 117.4, 116.2 (d, J=24 Hz), 112.7 (d, J=22 Hz), 44.6. MS (ES): m/z 422.0 (M+). Anal. calcd. for $C_{20}H_{13}ClFN_7O \cdot 0.1H_2O(0.15KCl: C, 55.25; H, 3.06; Cl, <math>9.38$; N, 22.55. Found: C, 55.13; H, 2.92; Cl, 9.12; N, 22.30.

Compound D-004

2-(6-Aminopurin-9-ylmethyl)-6-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2d (100 mg, 0.294 mmol); adenine (44 mg, 0.323 mmol), K_2CO_3 (45 mg, 0.323 mmol), and DMF The crude product was recrystallized from EtOH to provide 50 mg of a yellow solid (39%), mp 294.5-294.8°C (decomposes). ¹H NMR (DMSO- d_6) δ : 8.10 (d, J=2.2 Hz, 1H); 8.05 (s, 1H); 8.03 (s, 1H); 7.86 (dd, J=2.4, 8.8 Hz, 1H); 7.75-7.82 (m, 2H); 7.59-7.67 (m, 2H); 7.53 (d, J=8.7 Hz, 1H); 7.22 (br s, 2H); 5.13 (d, J=17 Hz, 1H); 4.95 (d, J=17 Hz, ¹³C NMR (DMSO-d₆) ppm: 159.7, 156.2, 152.9, 151.9, 150.1, 145.5, 141.8, 135.7, 133.1, 132.3, 132.2, 131.9, 131.1, 130.9, 130.0, 129.4, 125.9, 122.0, 118.4, 44.9. MS (ES): m/z 438.0 (M+). Anal. calcd. for C₂₀H₁₃Cl₂N₂O: C, 54.81; H, 2.99; N, 22.37. Found: C, 54.72; H, 2.87; N, 22.18.

Compound D-005

2-(6-Aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2e (200 mg, 0.619 mmol), adenine (92 mg, 0.681 mmol), K_2CO_3 (94 mg, 0.680 mmol), and DMF The crude product was chromatographed in MeOH/CH₂Cl₂ to provide 168 mg of an off-white solid (64%), mp 159-172°C (gradually decomposes). ¹H NMR 8.10 (s, 1H); 8.08 (s, 1H); 7.73-7.89 (DMSO- d_6) δ : (m, 3H); 7.57-7.71 (m, 2H); 7.37-7.48 (m, 2H); 7.34 (d, J=11 Hz, 1H); 7.30 (d, J=8.3 Hz, 1H); 5.14 (d, J=17 Hz, 1H); 4.94 (d, J=17 Hz, 1H). ¹³C NMR (DMSO-160.8 (d, J=264 Hz), 157.5 (d, J=4.2 Hz), 155.8, 152.4, 152.4, 150.0, 148.7, 142.1, 136.4 (d, J=11 Hz), 133.0, 132.2, 132.1, 131.2, 130.9, 129.4, 123.8 (d, J=3.6 Hz), 118.4, 114.5 (d, J=20 Hz), 110.2 (d, J=6.0 Hz), 44.9. MS (ES): m/z 422.0 (M+). Anal. calcd. for $C_{20}H_{13}ClFN_7O$: C, 56.95; H, 3.11; Cl, 8.40; N, 23.24. Found: C, 54.62; H, 3.32; Cl, 9.40; N, 21.29.

Compound D-006

2-(6-Aminopurin-o-ylmethyl)-5-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2f (300 mg, 0.883 mmol), adenine (131 mg, 0.972 mmol), K_2CO_3 (134 mg, 0.972 mmol), and DMF (4 mL). The crude product was chromatographed in MeOH/CH₂Cl₂ and recrystallized from EtOH to provide 188 mg of a pale orange crystalline solid (49%), mp

245.7-246.0© (starts to sweat at 220°C). H NMR (DMSO- d_6) δ : 8.06 (s, 1H); 8.04 (s, 1H); 7.76-7.81 (m, 2H); 7.72 (d, J=8.0 Hz, 1H); 7.59-7.66 (m, 3H); 7.41 (d, J=8.1 Hz, 1H); 7.26 (br s, 2H); 5.11 (d, J=17 Hz, 1H); 4.93 (d, J=17 Hz, 1H). C NMR (DMSO- d_6) ppm: 158.5, 156.2, 152.9, 152.2, 150.1, 149.2, 141.8, 135.4, 133.3, 133.2, 132.1, 132.0, 131.2, 130.9, 130.4, 129.4, 127.3, 118.4, 117.7, 44.9. MS (ES): m/z 438.0 (M+). Anal. calcd. for $C_{20H13}Cl_2N_7O \cdot 0.1C_2H_6O \cdot 0.05H_2O$: C, 54.67; H, 3.11; Cl, 15.98; N, 22.09. Found: C, 54.35; H, 3.00; Cl, 15.82; N, 22.31.

Compound D-007

2-(6-Aminopurin-9-ylmethyl)-3-(2-chlcrophenyl)-5-methyl-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2g (250 mg, 0.783 mmol), adenine (116 mg, 0.862 mmol), K₂CO₃ (119 mg, 0.862 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 93 mg of a pale yellow solid (28%), mp 190.7-190.9°C. ¹H NMR (DMSO- d_6) δ : 8.05 (s, 1H); 8.03 (s, 1H); 7.76-7.79 (m, 1H); 7.71-7.74 (m, 1H); 7.59-7.67 (m, 1H); 7.34 (d, J=7.4 Hz, 1H); 7.28 (d, J=8.2 Hz, 1H); 7.24 (br s, 2H); 5.07 (d, J=17 Hz, 1H); 4.92 (d, J=17 Hz, 1H); 2.73 (s, 3H). ¹³C NMR $(DMSO-d_5)$ ppm: 161.1, 156.2, 152.8, 150.9, 150.1, 148.3, 141.9, 141.0, 134.6, 133.6, 132.2, 131.9, 131.3, 130.8, 130.3, 129.3, 125.9, 119.1, 118.4, 44.8, 22.8. MS (ES): m/z 418.1 (M+). Anal. calcd. for $C_{21}H_{16}ClN_7O \bullet H_2O$: C, 57.87; H, 4.16; Cl, 8.13; N,

- 132 -

22.49. Found: C, 57.78; H, 3.99; Cl, 8.38; N, 22.32.

Compound D-008

2-(6-Aminopurin-9-ylmethyl)-8-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2h (100 mg, 0.294 mmol), adenine (44 mg, 0.324 mmol), K_2CO_3 (45 mg, 0.324 mmol), and DMF (1 mL). The crude product was chromatographed in MeOH/CH,Cl, to provide 50 mg of a pale yellow solid (39%), mp 273.3-273.5°C (discolors). ¹H NMR (DMSO d_6) δ : 8.11 (dd, J=1.3, 8.0 Hz, 1H); 8.08 (s, 1H); 8.05 (s, 1H); 8.00 (dd, J=1.3, 7.8 Hz, 1H); 7.79-7.83 (m, 2H); 7.63-7.66 (m, 2H); 7.56 (t, J=7.9 Hz)1H); 7.21 (br s, 2H); 5.17 (d, J=17 Hz, 1H); 4.97 (d, J=17 Hz, 1H). ¹³C NMR (DMSO-d₆) ppm: 160.2. 156.1, 152.8, 152.2, 150.2, 143.3, 142.0, 135.6, 133.1, 132.3, 131.9, 131.1, 131.0, 130.9, 129.4, 128.4, 126.0, 122.5, 118.4, 45.0. MS (ES): m/z438.0 (M+). Anal. calcd. for $C_{20}H_{13}Cl_2N_7O \bullet 0.1CH_4O \bullet 0.6H_2O(0.15KCl: C, 52.09; H,$ 3.18; N, 21.15. Found: C, 51.85; H, 2.93; N, 21.01.

Compound D-009

2-(6-Aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5chloro-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2i (400 mg, 1.05 mmol), adenine (155 mg, 1.15 mmol), K_2CO_3 (159 mg, 1.15 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH

to provide 344 mg of a white solid (68%), mp 299.9-300.1°C (discolors). 1 H NMR (DMSO-d₆) δ : 8.08 (s, 1H); 7.89 (s, 1H); 7.58-7.73 (m, 5H); 7.51 (d, J=7.9 Hz, 1H); 7.46 (d, J=7.5 Hz, 2H); 7.27-7.41 (m, 3H); 7.14-7.27 (m, 3H); 5.14 (d, J=17 Hz, 1H); 4.82 (d, J=17 Hz, 1H). 13 C NMR (DMSO-d₆) ppm: 159.6, 156.2, 152.8, 152.5, 150.0, 149.0, 141.7, 140.2, 137.7, 135.0, 133.3, 133.2, 131.8, 130.7, 130.1, 129.8, 129.5, 128.8, 128.6, 128.4, 127.1, 118.4, 117.6, 45.3. MS (ES): m/z 480.1 (M+). Anal. calcd. for $C_{26}H_{18}ClN_7O$: C, 65.07; H, 3.78; Cl, 7.39; N, 20.43. Found: C, 64.77; H, 3.75; Cl, 7.43; N, 20.35.

Compound D-010

5-Chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2j (200 mg, 0.626 mmol), 6-mercaptopurine monohydrate (93 mg, 0.546 mmol), K_2CO_3 (95 mg, 0.689 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 125 mg of an off-white solid (46%), mp 213.9°C. ¹H NMR (DMSO-d₆) δ : 13.53 (br s, 1H); 8.49 (s, 1H); 8.44 (s, 1H); 7.78 (t, J=7.9 Hz, 1H); 7.63 (d, J=8.2 Hz, 1H); 7.59 (d, J=7.7 Hz, 1H); 7.49 (d, J=6.9 Hz, 1H); 7.24-7.41 (m, 3H); 4.32-4.45 (m, 2H); 2.14 (s, 3H). ¹³C NMR (DMSO-d₆) ppm: 158.9, 157.2, 154.2, 151.5, 149.7, 149.6, 143.5, 136.1, 135.9, 135.1, 133.2, 131.3, 130.3, 130.0, 129.9, 129.1, 127.6, 127.1, 117.8, 32.4, 17.5. MS (ES): m/z 438.0 (M+). Anal. calcd. for $C_{21}H_{15}ClN_6OS$: C, 58.00; H, 3.48; Cl, 8.15;

- 134 -

N, 19.32; S, 7.37. Found: C, 58.05; H, 3.38; Cl, 8.89; N, 18.38; S, 7.00.

Compound D-011

5-Chloro-3-(2-fluorophenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2k (210 mg, 0.650 mmol), 6-mercaptopurine monohydrate (122 mg, 0.715 mmol), K2CO3 (99 mg, 0.715 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 240 mg of an off-white solid (84%), mp 244.0°C. H NMR (DMSO-ds) 13.56 (br s, 1H); 8.50 (s, 1H); 8.45 (s, 1H); 7.81 (t, J=8.0 Hz, 1H); 7.74 (t, J=7.7 Hz, 1H); 7.67 (d, J=8.1 Hz, 1H); 7.62 (d, J=7.7 Hz, 1H); 7.46-7.55 (m, 1H); 7.29-7.42 (m, 2H); 4.47-4.59 (m, 2H). ¹³C NMR (DMSO- d_6) ppm: 158.4, 157.3 (d, J=249 Hz), 156.4, 153.8, 151.0, 149.1, 143.2, 135.0, 132.9, 131.8 (d, J=8.0 Hz), 130.8, 129.9, 126.7, 125.3 (d, J=3.5 Hz), 123.6 (d, J=13 Hz), 117.0, 116.2 (d, J=19Hz), 31.7. MS (ES): m/z 439.0 (M+). Anal. calcd. for C₂₀H₁₂ClFN₆OS: C, 54.74; H, 2.76; Cl, 8.08; N, 19.15; S, 7.31. Found: C, 54.42; H, 2.88; Cl, 8.08; N, 18.87; S, 7.08.

- 135 -

Compound D-012

2-(6-Aminopurin-9-ylmethyl)-5-chloro-3-(2-fluorophenyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2k (210 mg, 0.650 mmol), adenine (97 mg, 0.715 mmol), K_2CO_3 (99 mg, 0.715 mmol), and DMF The crude product was recrystallized from EtOH to provide 137 mg of a tan solid (50%), mp 295.6-295.8°C (decomposes). ^{1}H NMR (DMSO- d_{6}) δ : 8.05 (s, 1H); 8.04 (s, 1H); 7.75 (t, J=7.6 Hz, 1H); 7.74 (t, J=7.9 Hz, 1H); 7.62-7.69 (m, 1H); 7.61 (d, J=7.6 Hz, 1H); 7.47-7.55 (m, 1H); 7.48 (d, J=7.8 Hz)1H); 7.41 (d, J=8.0 Hz, 1H); 7.24 (br s, 2H); 5.19 (d, J=17 Hz, 1H); 5.03 (d, J=17 Hz, 1H). ¹³C NMR $(DMSO-d_6)$ ppm: 158.7, 157.6 (d, J=250 Hz), 156.2, 152.8, 152.4, 150.0, 149.2, 141.8, 135.4, 133.3, 132.5 (d, J=8.0 Hz), 131.0, 130.4, 127.3, 126.2 (d, J=3.5 Hz), 123.1 (d, J=14 Hz), 118.4, 117.6, 117.2 (d, J=19 Hz), 45.1. MS (ES): m/z 422.0 (M+). Anal.calcd. for $C_{20}H_{13}ClFN_7O \cdot 0.05C_2H_6O$: C, 56.92; H, 3.16; Cl, 8.36; N, 23.12. Found: C, 56.79; H, 3.20; Cl, 8.46; N, 22.79.

Compound D-013

3-Biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-methyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2i (400 mg, 1.05 mmol), 6-mercaptopurine monohydrate (196 mg, 1.15 mmol), K₂CO₃ (159 mg, 1.15 mmol), and DMF (5 mL). The crude product was chromatographed in MeOH/CH₂Cl₂ and subsequently

recrystallized from EtOH to provide 439 mg of a pale yellow crystalline solid (84%), mp 222.0-222.5°C (dec). 1 H NMR (DMSO-d₆) δ : 13.56 (br s, 1H); 8.55 (s, 1H); 8.45 (s, 1H); 7.73 (t, J=8.0 Hz, 1H); 7.64 (d, J=7.7 Hz, 1H); 7.50-7.59 (m, 4H); 7.41-7.48 (m, 1H); 7.25-7.38 (m, 5H); 4.41 (d, J=16 Hz, 1H); 4.16 (d, J=16 Hz, 1H). 13 C NMR (DMSO-d₆) ppm: 160.2, 157.0, 153.7, 151.5, 149.7, 149.3, 143.5, 139.9, 137.8, 135.1, 134.1, 133.3, 131.5, 130.5, 130.3, 130.1, 129.1, 128.9, 128.4, 128.4, 126.9, 117.5, 32.3. MS (ES): m/z 497.0 (M+). Anal. calcd. for $C_{26}H_{17}ClN_6OS$: C, 62.84; H, 3.45; Cl, 7.13; N, 16.91; S, 6.45. Found: C, 62.60; H, 3.47; Cl, 7.15; N, 16.65; S, 6.41.

Compound D-014

5-Chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 21 (250 mg, 0.746 mmol), 6-mercapto-purine monohydrate (140 mg, 0.821 mmol), K₂CO₃ (113 mg, 0.821 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 254 mg of an off-white solid (76%), mp 237.0°C (dec; discolors at 154.6°C). ¹H NMR (DMSO-d₆) δ: 13.53 (br s, 1H); 8.52 (s, 1H); 8.45 (s, 1H); 7.78 (t, J=7.9 Hz, 1H); 7.64 (d, J=8.0 Hz, 1H); 7.59 (d, J=7.7 Hz, 1H); 7.48 (d, J=7.3 Hz, 1H); 7.42 (t, J=7.7 Hz, 1H); 7.15 (d, J=8.2 Hz, 1H); 7.03 (t, J=7.5 Hz, 1H); 4.45 (s, 2H); 3.76 (s, 3H). ¹³C NMR (DMSO-d₆) ppm: 158.9, 157.1, 154.8, 154.7, 151.5, 149.6, 143.6, 135.1, 133.2, 131.3, 130.4, 130.0, 127.0, 124.8, 121.2, 117.8,

- 137 -

112.7, 56.1, 32.0. MS (ES): m/z 451.0 (M+). Anal. calcd. for $C_{21}H_{15}ClN_6O_2S \bullet 0.15C_2H_6O \bullet 0.05KCl$: C, 55.43; H, 3.47; Cl, 8.07; N, 18.21; S, 6.95. Found: C, 55.49; H, 3.68; Cl, 7.95; N, 17.82; S, 6.82.

Compound D-015

3-(2-Chlorophenyl)-5-fluoro-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2e (200 mg, 0.619 mmol), 6-mercaptopurine monohydrate (116 mg, 0.681 mmol), K₂CO₃ (94 mg, 0.681 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH to provide 152 mg of a white solid (56%), mp 222.7-223.8°C (discolors). ¹H NMR (DMSO- d_6) δ : 13.56 (br s, 1H); 8.48 (s, 1H); 8.44 (s, 1H); 7.89 (dt, J=5.6, 8.1 Hz, 1H); 7.76 (dd, J=1.6, 7.3 Hz, 1H); 7.67 (d, J=7.4 Hz, 1H); 7.56 (d, J=8.1 Hz, 1H); 7.47 (t, J=7.1 Hz, 1H), 7.41-7.53 (m, 2H); 7.37 (dd, J=8.7, 11 Hz, 1H); 4.38-4.52 (m, 2H). 13 C NMR (DMSO- d_6) ppm: 160.9 (d, J=264 Hz), 157.6, 156.8, 154.1, 151.5, 149.6, 149.0, 143.6, 136.4 (d, J=11 Hz), 133.9, 132.2, 131.7, 131.6, 130.5, 130.2, 128.8, 123.6, 114.4 (d, J=20 Hz), 110.2, 32.0. MS (ES): m/z 439.0 (M+). Anal. calcd. for C₂₀H₁₂ClFN₆OS•0.5C₂H₆O: C, 54.61; H, 3.27; Cl, 7.68; N, 18.19; S, 6.94. Found: C, 54.37; H, 3.26; Cl, 7.89; N, 18.26; S, 6.55.

- 138 -

Compound D-016

3-(2-Chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2a (200 mg, 0.546 mmol), 6-mercaptopurine monohydrate (102 mg, 0.601 mmol), K₂CO₃ (83 mg, 0.601 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH to provide 172 mg of an off-white solid (65%), mp 160-180°C (gradually decomposes). ¹H NMR (DMSO- d_6) δ : 13.55 (br s, 1H); 8.49 (s, 1H); 8.44 (s, 1H); 7.72 (d, J=6.9 Hz, 1H); 7.66 (d, J=6.9 Hz, 1H) 7.38-7.54 (m, 3H); 7.22 (s, 1H); 4.36-4.52 (m, 2H); 3.94 (s, 3H); 3.89 (s, 3H). ¹³C NMR (DMSO-d₅) ppm: 160.1, 155.4, 151.5, 151.1, 149.4, 143.2, 134.6, 132.3, 131.6, 131.5, 130.4, 128.7, 113.6, 108.4, 105.8, 56.5, 56.1, 32.0. MS (ES): m/z 481.1 (M+). Anal. calcd. for $C_{22}H_{17}ClN_6O_3S \bullet 0.5C_2H_6O \bullet 0.05KCl:$ C, 54.41; H, 3.97; Cl, 7.33; N, 16.55; S, 6.32. Found: C, 54.43; H, 3.94; Cl, 7.69; N, 16.69; S, 6.52.

Compound D-017

6-Bromo-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2b (200 mg, 0.519 mmol), 6-mercapto-purine monohydrate (97 mg, 0.570 mmol), K_2CO_3 (79 mg, 0.572 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH to provide 123 mg of an off-white solid (47%), mp 212-242°C (gradually decomposes). ¹H NMR (DMSO-d₆) δ : 13.07 (br s, 1H);

- 139 -

8.48 (s, 1H); 8.44 (s, 1H); 8.24 (d, J=2.3 Hz, 1H); 8.06 (dd, J=2.3, 8.7 Hz, 1H); 7.76 (dd, J=1.9, 7.4 Hz, 1H); 7.70 (d, J=8.7 Hz, 1H); 7.66 (d, J=8.1 Hz, 1H); 7.51 (dd, J=2.1, 7.9 Hz, 1H); 7.46 (dd, J=1.9, 7.9 Hz, 1H); 4.47 (s, 2H). ¹³C NMR (DMSO-d₆) ppm: 159.7, 156.8, 153.6, 151.5, 146.1, 143.6, 138.5, 134.0, 132.1, 131.8, 131.5, 130.5, 130.2, 129.9, 128.9, 128.8, 122.2, 120.3, 32.0. MS (ES): m/z 499.0 (M+). Anal. calcd. for C₂₀H₁₂ClBrN₆OS•0.2C₂H₆O•0.05KCl: C, 47.79; H, 2.59; N, 16.39; S, 6.25. Found: C, 47.56; H, 2.54; N, 16.25; S, 6.58.

Compound D-018

3-(2-Chlorophenyl)-(9H-purin-6-ylsulfanylmethyl)-trifluoromethyl-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2m (200 mg, 0.536 mmol), 6-mercaptopurine monohydrate (100 mg, 0.588 mmol), K₂CO₃ (82 mg, 0.593 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 148 mg of a white solid (56%), mp 218.5-219.4°C. ¹H NMR (DMSO-d₆) δ: 13.52 (br s, 1H); 8.48 (s, 1H); 8.44 (s, 1H); 8.43 (d, J=6.0 Hz, 1H); 8.26 (d, J=7.5 Hz, 1H); 7.84 (dd, J=2.5, 6.7 Hz, 1H); 7.70-7.75 (m, 2H); 7.51-7.59 (m, 2H); 4.40-4.55 (m, 2H). ¹³C NMR (DMSO-d₆) ppm: 160.0, 157.2, 154.2, 151.4, 149.6, 144.4, 143.4, 133.8, 133.0 (q, J=5.1 Hz), 132.0, 131.9, 131.6, 131.4, 130.6, 129.0, 127.3, 125.2 (q, J=30 Hz), 123.6 (q, J=273 Hz), 121.8, 32.6. MS (ES): m/z 489.0 (M+). Anal. calcd. for C₂₁H₁₂ClF₃N₆OS: C,

- 140 **-**

51.59; H, 2.47; Cl, 7.25; N, 17.19; S, 6.56. Found: C, 51.51; H, 2.55; Cl, 7.37; N, 17.05; S, 6.38.

Compound D-019

3-(2-Chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-benzo[g]quinazolin-4-one

Prepared according to Procedure C using Intermediate 2n (200 mg, 0.563 mmol), 6-mercaptopurine monohydrate (105 mg, 0.619 mmol), K2CO3 (86 mg, 0.619 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 128 mg of a dark yellow solid (48%), mp 247.8-254.4°C (decomposes). ${}^{1}H$ NMR (DMSO-d₆) δ : 13.56 (br s, 1H); 8.90 (s, 1H); 8.50 (s, 1H); 8.46 (s, 1H); 8.34 (s, 1H); 8.27 (d, J=8.2 Hz, 1H); 8.16 (d, J=8.2 Hz, 1H); 7.81 (dd, J=1.6, 7.3 Hz, 1H); 7.70 (t, J=7.5 Hz, 1H); 7.61-7.74 (m, 2H); 7.49 (t, J=7.5 Hz, 1H); 7.44-7.53 (m, 1H); 4.44-4.56 (m, 2H). ¹³C NMR (DMSO-d₆) ppm: 161.3, 151.6, 151.5, 143.9, 142.2, 136.7, 134.4, 132.5, 131.8, 131.6, 130.5, 129.7, 129.3, 128.8, 128.6, 128.3, 128.3, 127.1, 125.2, 119.5, 32.4. MS (ES): m/z 471.0 (M+). Anal. calcd. for $C_{24}H_{15}ClN_6OS \bullet 0.2C_2H_6O \bullet 0.05KCl:$ C, 60.57; H, 3.37; Cl, 7.69; N, 17.37; S, 6.63. Found: C, 60.24; H, 3.46; ·Cl, 7.50; N, 17.34; S, 6.69.

- 141 - -

Compound D-020

6-Chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2d (200 mg, 0.587 mmol), 6-mercaptopurine monohydrate (110 mg, 0.646 mmol), K2CO3 (90 mg, 0.651 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH to provide 113 mg of a yellow crystalline solid (42%), mp 237.1-238.2°C (decomposes). ¹H NMR (DMSO- d_6) δ : 13.55 (br s, 1H); 8.48 (s, 1H); 8.44 (s, 1H); 8.11 (s, 1H); 7.94 (d, J=8.3 Hz, 1H); 7.78 (d, J=8.1 Hz, 2H); 7.66 (d, J=6.7 Hz, 1H); 7.48-7.56 (m, 2H); 4.48 (s, 2H). NMR (DMSO- d_6) ppm: 159.8, 156.8, 153.5, 151.5, 149.6, 145.8, 143.6, 135.7, 134.0, 132.2, 132.1, 131.7, 131.5, 130.5, 130.2, 129.8, 128.8, 125.8, 121.9, 32.0. MS (ES): m/z 455.0 (M+). Anal. calcd. for $C_{20}H_{12}Cl_2N_6OS \cdot 0.1C_2H_6O \cdot 0.6H_2O(0.15KCl: C, 50.34; H,$ 2.89; Cl, 15.82; N, 17.44; S, 6.65. Found: C, 50.02; H, 2.63; Cl, 15.51; N, 17.39; S, 6.81.

Compound D-021

8-Chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2h (200 mg, 0.589 mmol), 6-mercaptopurine monohydrate (124 mg, 0.726 mmol), $\rm K_2CO_3$ (100 mg, 0.726 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 202 mg of a white solid (75%), mp 211.9-212.7 $^{\circ}$ (decomposes). 1 H NMR (DMSO-d₆) δ : 13.54 (br s, 1H); 8.47 (s, 1H);

8.44 (s, 1H); 8.12 (d, J=7.9 Hz, 1H); 8.07 (d, J=7.6 Hz, 1H); 7.78 (d, J=7.5 Hz, 1H); 7.67 (d, J=7.1 Hz, 1H); 7.58 (t, J=7.9 Hz, 1H); 7.42-7.54 (m, 2H); 4.52 (s, 2H). 13 C NMR (DMSO-d₆) ppm: 160.3, 156.9, 153.9, 151.5, 149.7, 143.5, 135.7, 134.0, 132.1, 131.8, 131.4, 131.1, 130.5, 130.3, 128.9, 128.3, 126.1, 122.4, 32.5. MS (ES): m/z 455.0 (M+). Anal. calcd. for $C_{20}H_{12}Cl_{2}N_{6}OS$: C, 52.76; H, 2.66; Cl, 15.57; N, 18.46; S, 7.04. Found: C, 52.65; H, 2.79; Cl, 15.32; N, 18.47; S, 7.18.

Compound D-022

3-(2-Chlorophenyl)-7-fluoro-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2c (200 mg, 0.619 mmol), 6-mercaptopurine monohydrate (116 mg, 0.681 mmol), K₂CO₃ (95 mg, 0.687 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 143 mg of a white crystalline solid (53%), mp 151.4-154.2°C (discolors). ¹H NMR (DMSO- d_6) δ : 13.55 (br s, 1H); 8.48 (s, 1H); 8.44 (s, 1H); 8.23 (dd, J=6.3, 8.7 Hz, 1H); 7.77 (dd, J=1.7, 7.4 Hz, 1H); 7.64 (d, J=7.4 Hz, 1H); 7.57 (d, J=9.8 Hz, 1H); 7.45-7.52 (m, 3H); 4.48 (s, 2H). 13 C NMR (DMSO-d₆) ppm: 169.0 (d, J=253 Hz), 162.6, 159.3, 157.0, 154.0, 152.2, 151.7 (d, J=13 Hz), 146.1, 136.5, 134.7, 134.2, 134.0, 133.0, 132.6 (d, J=11 Hz), 131.3, 120.2, 118.9 (d, J=24 Hz), 115.3 (d, J=22 Hz), 34.6. MS (ES): m/z439.0 (M+). Anal. calcd. for C₂₀H₁₂ClFN₆OS • 0.4 - $C_2H_6O \cdot 0.4H_2O(0.15KCl: C, 52.52; H, 3.22; Cl, 8.57;$

- 143 -

N, 17.67. Found: C, 52.25; H, 3.11; Cl, 8.20; N, 17.69.

Compound D-023

3-(2-Chlorophenyl)-7-nitro-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 20 (216 mg, 0.617 mmol), 6-mercaptopurine monohydrate (116 mg, 0.681 mmol), K2CO3 (94 mg, 0.680 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 212 mg of a yellow crystalline solid (74%), mp 218.0-218.3°C (decomposes). ¹H NMR (DMSO-d₆) δ : 13.56 (br s, 1H); 8.49 (s, 1H); 8.42 (s, 1H); 8.38-8.45 (m, 2H); 8.31 (d, J=8.4 Hz, 1H); 7.81 (d, J=6.5 Hz, 1H); 7.68 (d,J=6.7 Hz, 1H); 7.43-7.58 (m, 2H); 4.53 (s, 2H). NMR (DMSO- d_6) ppm: 157.7, 154.4, 153.3, 149.8, 149.3, 147.6, 145.2, 141.4, 131.5, 129.8, 129.7, 129.2, 128.4, 127.1, 126.7, 122.7, 120.3, 119.4, 29.9. MS (ES): m/z 466.0 (M+). Anal. calcd. for $C_{20}H_{12}ClN_7O_3S \bullet 0.4C_2H_6O \bullet 0.05KCl:$ C, 51.19; H, 2.97; Cl, 7.63; N, 20.09; S, 6.57. Found: C, 51.27; H, 2.88; Cl, 7.40; N, 20.04; S, 6.52.

Compound D-024

3-(2-Chlorophenyl)-6-hydroxy-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2p (200 mg, 0.552 mmol), 6-mercaptopurine monohydrate (117 mg, 0.685 mmol), K_2CO_3 (95 mg, 0.687 mmol), and DMF (4 mL). The crude product

was recrystallized from EtOH to provide 182 mg of a white solid, a mixture of the desired product and the acetyl derivative. A portion of this material (120 mg) was suspended in a mixture of MeOH (2 mL) and aqueous NaHCO3 (satd., 1 mL) and stirred rapidly for 4 hours. The mixture was concentrated in vacuo. suspended in H2O (10 mL), and stored at 4°C overnight. The white solid was collected and dried to 103 mg (66%), mp 186-214°C (gradually decomposes). ¹H NMR (DMSO- d_6) δ : 8.48 (s, 1H); 8.45 (s, 1H); 7.71 (d, J=6.8 Hz, 1H); 7.62-7.64 (m, 2H); 7.43-7.51 (m, 2H); 7.40-7.43 (m, 1H); 7.35 (d, J=8.8 Hz, 1H); 4.39-4.52 (m, 2H). ¹³C NMR (DMSO-d₆) ppm: 157.1, 156.2, 151.4, 150.8, 149.3, 144.1, 140.2, 134.5, 132.2, 131.6, 131.4, 130.4, 129.3, 128.7, 124.8, 121.7, 109.8, 32.0. MS (ES): m/z 437.0 (M+). Anal. calcd. for $(2 C_{20}H_{13}ClN_6O_2S \bullet 0.1C_2H_6O.6H_2O)$: C, 49.68; H, 3.88; Cl, 7.26; N, 17.21; S, 6.57. Found: C, 49.43; H, 3.62; Cl, 7.32; N, 17.07; S, 6.58.

Compound D-025

5-Chloro-3-(2-chlorophenyl)-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2f (300 mg, 0.883 mmol), 6-mercaptopurine monohydrate (165 mg, 0.972 mmol), K_2CO_3 (134 mg, 0.972 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 341 mg of a pale orange crystalline solid (85%), mp 233.7-234.4°C (decomposes). ¹H NMR (DMSO-d₆) δ : 13.58 (br s, 1H); 8.50 (s, 1H); 8.47 (s, 1H); 7.77-7.85 (m, 2H); 7.68 (d; J=8.1 Hz, 2H); 7.65 (d, J=7.7 Hz, 1H);

7.41-7.56 (m, 2H); 4.45 (d, J=1.2 Hz, 2H). 13 C NMR (DMSO-d₆) ppm: 158.7, 156.8, 153.8, 151.5, 149.6, 149.5, 143.5, 135.4, 134.1, 133.3, 132.2, 131.6, 131.6, 130.5, 130.2, 128.8, 127.1, 117.6, 32.0. MS (ES): m/z 455.0 (M+). Anal. calcd. for $C_{20}H_{12}Cl_2N_6-OS \cdot C_2H_6O \cdot 0.3H_2$: C, 52.14; H, 3.70; Cl, 13.99; N, 16.58; S, 6.33. Found: C, 52.07; H, 3.37; Cl, 13.40; N, 16.65; S, 6.42.

Compound D-026

3-(2-Chlorophenyl)-5-methyl-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2g (300 mg, 0.940 mmol), 6-mercaptopurine monohydrate (176 mg, 1.03 mmol), K2CO3 (142 mg, 1.03 mmol), and DMF (5 mL). The crude product was recrystallized from EtOH to provide 324 mg of a white crystalline solid (79%), mp 227.8-230.1°C (decomposes). ¹H NMR (DMSO- d_6) δ : 13.57 (br s, 1H); 8.49 (s, 1H); 8.47 (s, 1H); 7.69-7.78 (m, 2H); 7.66 (d, J=7.3 Hz, 1H); 7.55 (d, J=7.9 Hz, 1H); 7.39-7.52 (m, 2H); 7.36 (d, J=6.9 Hz, 1H); 4.38-4.50 (m, 2H); 2.74 (s, 3H). 13 C NMR (DMSO- d_6) ppm: 161.2, 156.3, 152.4, 151.5, 148.6, 143.9, 141.0, 134.6, 134.5, 132.3, 131.7, 131.4, 130.4, 130.2, 128.7, 125.7, 119.0, 32.0, 22.8. MS (ES): m/z: 435.0 (M+). Anal. calcd. for $C_{21}H_{15}ClN_6OS \cdot 0.65C_2H_6O \cdot 0.1H_2O$: C, 57.40; H, 4.13; Cl, 7.60; N, 18.01; S, 6.87. Found: C, 57.11; H, 3.96; Cl, 7.45; N, 17.79; S, 6.90.

- 146 -

Compound D-027

3-(2-Chlorophenyl)-6,7-difluoro-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2q (200 mg, 0.586 mmol), 6-mercaptopurine monohydrate (110 mg, 0.645 mmol), K2CO3 (89 mg, 0.645 mmol), and DMF (4 mL). The crude product was recrystallized from EtOH to provide 143 mg of a pale yellow crystalline solid (53%), mp 207.8°C (discolors; sweats at 136(C). 1 H NMR (DMSO- d_{6}) δ : 13.57 (br s, 1H); 8.49 (s, 1H); 8.46 (s, 1H); 8.11 (t, J=9.4 Hz, 1H); 7.88 (dd, J=7.3, 11 Hz, 1H); 7.77 (dd, J=1.7, 7.3 Hz, 1H); 7.67 (d, J=7.4 Hz, 1H);7.42-7.55 (m, 2H); 4.48 (s, 2H). ¹³C NMR (DMSO-d₆) 159.5 (d, J=2.5 Hz), 154.6 (dd, J=14, 255 Hz), 154.0 (d, J=1.5 Hz), 151.5, 149.3 (dd, J=14, 250 Hz), 145.1 (d, J=12 Hz), 143.9, 133.9, 132.1, 131.8, 131.4, 130.5, 128.9, 118.0 (d, J=4.9 Hz), 115.8 (d, J=18 Hz), 114.6 (d, J=20 Hz), 32.0. MS (ES): m/z 457.0 (M+). Anal. calcd. for $C_{20}H_{11}ClF_2N_6OS$: C, 52.58; H, 2.43; Cl, 7.76; N, 18.40; S, 7.02. Found: C, 51.81; H, 2.37; Cl, 7.49; N, 18.04; S, 7.55.

Compound D-028

3-(2-Chlorophenyl)-6-fluoro-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Prepared according to Procedure C using Intermediate 2r (118 mg, 0.365 mmol), 6-mercaptopurine monohydrate (68 mg, 0.402 mmol), $K_2\text{CO}_3$ (56 mg, 0.402 mmol), and DMF (2 mL). The crude product was recrystallized from EtOH to provide 103 mg of an

- 147 -

off-white crystalline solid (64%), mp 232.8-233.0°C (discolors). 1 H NMR (DMSO-d₆) δ : 13.56 (br s, 1H); 8.48 (s, 1H); 8.44 (s, 1H); 7.81-7.86 (m, 3H); 7.76 (d, J=7.5 Hz, 1H); 7.67 (d, J=7.5 Hz, 1H); 7.40-7.54 (m, 2H); 4.48 (br s, 2H). 13 C NMR (DMSO-d₆) ppm: 160.8 (d, J=247 Hz), 160.2 (d, J=3.3 Hz), 156.9, 152.3 (d, J=1.9 Hz), 151.5, 149.7, 144.0, 143.6, 134.1, 132.1, 131.7, 131.5, 130.5, 130.4, 130.2, 128.8, 124.0 (d, J=24 Hz), 122.0 (d, J=8.7 Hz), 111.7 (d, J=24 Hz), 32.0. MS (ES): m/z 439.0 (M+). Anal. calcd. for $C_{20}H_{12}$ ClFN₆OS•0.2 $C_{2}H_{6}$ O•0.1 H_{2} O: C, 54.46; H, 3.00; Cl, 7.88; N, 18.68. Found: C, 54.09; H, 2.73; Cl, 7.80; N, 18.77.

Compound D-029

2-(6-Aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-methyl-3H-quinazolin-4-one

Thionyl chloride (2.2 mL, 30 mmol) was added to a stirred solution of 2-amino-6-methylbenzoic acid (1.51 g, 10 mmol) in benzene (50 mL) and the mixture was heated at reflux for 18 h. Once cooled, the solvent was removed in vacuo and stripped down twice with benzene (25 mL). The residue was dissolved in CHCl₃ (50 mL) and treated with 2-isopropylaniline (2.83 mL, 20 mmol). The slurry was then heated at reflux for 3 h. At that time TLC (50% EtOAc/hexane) indicated that the reaction was complete. After cooling to room temperature, the reaction mixture was poured atop a 4 cm plug of silica gel and flushed through with 20% EtOAc/hexane. The product containing fractions were combined and concentrated in vacuo. The residue was

dissolved in HOAc (50 mL) and treated with chloroactyl chloride (1.6 mL, 20 mmol) and the mixture was heated at reflux for 18 h. The reaction was cooled and concentrated in vacuo. The remaining HOAc was removed by azeotroping with toluene (25 mL) three times. The residue was dissolved in toluene (10 mL) and poured through a 4 cm plug of silica gel, flushing through with 20 % EtOAc/hexane. The product containing fractions were identified by LCMS (MS (ES): m/z 327 (M+)), and concentrated in vacuo to afford 975 mg (30%) as a white foam. The white foam chloride (450 mg, 1.36 mmol) was dissolved in DMF (10 mL) and treated with adenine (275 mg, 2.04 mmol) and K2CO3 (281 mg, 2.04 mmol) and the mixture was stirred overnight at room temperature. The suspension was then poured into 200 mL of water, stirred at room temperature for 30 min then chilled in the refrigerator for 30 min. The resultant solid was collected by vacuum filtration and recrystallized from EtOH to afford 285 mg (49%) of an off white solid. mp 258.0-258.2°C. ¹H NMR (DMSO- d_6) δ : (s, 1H), 8.09 (s, 1H), 7.60 (m, 3H), 7.45 (m, 2H), 7.23 (m, 3H), 5.11 (d, J=17.5 Hz, 1H), 4.71 (d, J=17.5 Hz, 1H), 2.68 (s, 3H), 2.73 (q, J=6.9 Hz, 1H), 1.34 (d, J=6.8 Hz, 3H), 1.13 (d, J=6.8 Hz, 3H). 13 C NMR (DMSO- d_6) ppm: 161.9, 156.2, 152.8, 151.6, 150.1, 148.4, 146.1, 142.2, 140.8, 134.3, 133.7, 130.6, 130.0, 129.0, 127.7, 127.6, 125.8, 119.2, 118.4, 44.8, 28.3, 24.4, 23.3, 22.9. MS (ES): m/z 426.4 (M+). Anal. calcd. for $C_{24}H_{23}N_7O$: C, 67.75; H, 5.45; N, 23.04. Found: C, 67.60; H, 5.45; N, 22.82.

- 149 -

Compound D-030

2-(6-Aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one

Thionyl chloride (2.2 mL, 30 mmol) was added to a stirred solution of 2-amino-6-methylbenzoic acid (1.51 g, 10 mmol) in benzene (50 mL) and the mixture was heated at reflux for 18 h. cooled, the solvent was removed in vacuo and stripped down twice with benzene (25 mL). residue was dissolved in CHCl₃ (50 mL) and treated with o-toluidine (2.13 mL, 20 mmol). The slurry was then heated at reflux for 3 h. At that time TLC (50% EtOAc/hexane) indicated that the reaction was complete. After cooling to room temperature, the reaction mixture was poured atop a 4 cm plug of silica gel and flushed through with 20% EtOAc/hex-The product containing fractions were combined and concentrated in vacuo. The residue was dissolved in HOAc (50 mL) and treated with chloroactyl chloride (1.6 mL, 20 mmol) and the mixture was heated at reflux for 18 h. The reaction was cooled and concentrated in vacuo. The remaining HOAc was removed by azeotroping with toluene (25 mL) three The residue was dissolved in toluene (10 mL) and poured through a 4 cm plug of silica gel, flushing through with 20 % EtOAc/hexane. product containing fractions were identified by LCMS [MS (ES): m/z 299 (M+)), and concentrated in vacuo to afford 476 mg (16%) as a white foam. The white foam chloride (470 mg, 1.57 mmol) was dissolved in DMF (10 mL) and treated with adenine (423 mg, 3.14 mmol) and K_2CO_3 (433 mg, 3.14 mmol) and the mixture

was stirred overnight at room temperature. The suspension was then poured into 200 mL of H2O, stirred at room temperature for 30 min then chilled in the refrigerator for 30 min. The resultant solid was collected by vacuum filtration and recrystallized from EtOH to afford 123 mg (20%) of an off white solid. mp 281.5-282.7°C (decomposes). 1H NMR $(DMSO-d_6)$ δ : 8.07 (s, 1H); 8.05 (s, 1H); 7.61 (t, J=7.8 Hz, 1H), 7.48 (m, 4H), 7.25 (m, 3H), 5.09 (d, J=17.4 Hz, 1H), 4.76 (d, J=17.4 Hz, 1H), 2.73 (s, 3H), 2.18 (s, 3H). 13 C NMR (DMSO- d_6) ppm: 156.2, 152.8, 151.4, 150.0, 148.5, 142.2, 140.9, 136.1, 135.4, 134.3, 131.7, 130.1, 130.0, 129.0, 128.0, 125.8, 119.2, 118.5, 44.8; 22.9, 17.4. MS (ES): m/z 398.2 (M+). Anal. calcd. for $C_{22}H_{19}N_7O$: 66.49; H, 4.82; N, 24.67. Found: C, 66.29; H, 4.78; N, 24.72.

Compound D-031

3-(2-Fluorophenyl)-5-methyl-2-(9H-purin-6-yl-sulfanylmethyl)-3H-quinazolin-4-one

Thionyl chloride (2.2 mL, 30 mmol) was added to a stirred solution of 2-amino-6-methyl-benzoic acid (1.51 g, 10 mmol) in benzene (50 mL) and the mixture was heated at reflux for 18 h. Once cooled, the solvent was removed in vacuo and stripped down twice with benzene: (25 mL). The residue was dissolved in CHCl₃ (50 mL) and treated with 2-fluoroaniline (1.93 mL, 20 mmol). The slurry was then heated at reflux for 3 h. At that time TLC (50% EtOAc/hexane) indicated that the reaction was complete. After cooling to room temperature, the

reaction mixture was poured atop a 4 cm plug of silica gel and flushed through with 20% EtOAc/hex-The product containing fractions were combined and concentrated in vacuo. The residue was dissolved in HOAc (50 mL) and treated with chloroactyl chloride (1.6 mL, 20 mmol) and the mixture was heated at reflux for 18 h. The reaction was cooled and concentrated in vacuo. The remaining HOAc was removed by azeotroping with toluëne (25 mL) three The residue was dissolved in toluene (10 mL) and poured through a 4 cm plug of silica gel, flushing through with 20 % EtOAc/hexane. The product containing fractions were identified by LCMS [MS (ES): m/z 303 (M+)), and concentrated in vacuo to afford 1.12 g (37%) as a white foam. The white foam chloride (455 mg, 1.50 mmol) was dissolved in DMF (10 mL) and treated with 6-mercaptopurine monohydrate (510 mg, 3.0 mmol) and K_2CO_3 (414 mg, 3.0 mmol) and the mixture was stirred overnight at room temperature. The suspension was then poured into 200 mL of water, stirred at room temperature for 30 min then chilled in the refrigerator for 30 min. The resultant solid was collected by vacuum filtration and recrystallized from EtOH to afford 487 mg (77%) of an off white solid. mp 151.9-152.2°C. NMR (DMSO- $d_{\rm s}$) δ : 8.48 (s, 1H0, 8.44 (s, 1H), 7.70 (m, 2H), 7.48 (m, 2H), 7.33 (m, 3H), 4.55 (d, J=15.1)Hz, 1H), 4.48 (d, J=15.1 Hz, 1H), 2.73 (s, 3H). 13 C NMR (DMSO- d_6) ppm: 161.3, 157.8 (d, J=249.1 Hz), 156.9, 152.8, 151.5, 149.6, 148.6, 143.6, 140.9, 134.7, 131.9 (d, J=8.0 Hz), 131.4, 130.2, , 125.6 (d, J=3.6 Hz), 125.5, 124.4 (d, J=13.5 Hz), 118.8,116.6 (d, J=19.6 Hz), 56.4, 22.9. MS (ES): m/z

- 152 -

419.5 (M+). Anal. calcd. for C₂₁H₁₅FN₆OS•0.15 C₂H₆O: C, 60.14; H, 3.77; F, 4.47; N, 19.76; S, 7.54. Found: C,59.89; H,3.88; F,4.42; N,19.42; S,7.23.

Compound D-032

2-(6-Aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazolin-4-one

Prepared according to Procedure C using 2j (200 mg, 0.626 mmol), adenine (93 mg, 0.689 mmol), K_2CO_3 (95 mg, 0.689 mmol), and DMF (3 mL). The crude product was chromatographed in MeOH/CH2Cl2 to provide 101 mg of an off-white solid (39%), mp 262.0-266.5°C. ¹H NMR (DMSO-d₆) δ : 8.08 (s, 1H); 8.07 (s, 1H); 7.70 (t, J=8.0 Hz, 1H); 7.58 (dd, J=0.6, 7.9 Hz, 1H); 7.43-7.57 (m, 4H); 7.36 (dd, J=0.7, 8.0 Hz, 1H); 7.26 (br s, 2H); 5.12 (d, J=18 Hz, 1H); 4.78 (d, J=18 Hz, 1H); 2.20 (s, 3H). ¹³C NMR (DMSO-d_c) ppm: 158.7, 156.2, 152.9, 152.7, 150.0, 149.4, 142.1, 136.1, 135.1, 135.0, 133.2, 131.8, 130.3, 130.1, 128.9, 128.1, 127.2, 118.5, 117.9, 44.9, 17.4. MS (ES): m/z 418.1 (M+). Anal. calcd. for $C_{21}H_{16}ClN_7O \cdot 0.1H_2O \cdot 0.05KCl:$ C, 59.57; H, 3.86; Cl, 8.79; N, 23.16. Found: C, 59.65; H, 3.80; Cl, 8.70; N, 22.80.

- 153 -

Compound D-033

2-(6-Aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-phenyl)-3H-quinazolin-4-one

Prepared according to Procedure C using 21 (250 mg, 0.746 mmol), adenine (111 mg, 0.821 mmol), K₂CO₃ (113 mg, 0.821 mmol), and DMF (4 mL). crude product was chromatographed in MeOH/CH2Cl2 and recrystallized from EtOH to provide 124 mg of a brown solid (38%), mp 257.0-257.1°C. ¹H NMR (DMSO d_{s}) δ : 8.06 (s, 1H); 8.01 (s, 1H); 7.71 (t, J=8.0 Hz, 1H); 7.57 (dd, J=0.9, 7.9 Hz, 1H); 7.52-7.59 (m, 1H); 7.50 (dd, J=1.6, 7.8 Hz, 1H); 7.38 (dd, J=1.1, 8.2 Hz, 1H); 7.27 (dd, J=0.6, 8.3 Hz, 1H); 7.24 (br s, 2H); 7.17 (dt, J=0.9, 7.6 Hz, 1H); 5.07 (d, J=17 Hz, 1H); 4.97 (d, J=17 Hz, 1H); 3.79 (s, 3H). 13 C NMR (DMSO-d₆) ppm: 158.8, 156.2, 154.7, 153.2, 152.8, 150.1, 149.3, 142.0, 135.1, 133.2, 131.8, 130.1, 130.1, 127.2, 123.8, 121.6, 118.4, 117.9, 113.1, 56.2, 44.8. MS (ES): m/z 434.0 (M+). Anal. calcd. for C₂₁H₁₆ClN₇O₂•0.5H₂O•0.04KCl: C, 56.57; H, 3.84; Cl, 8.27; N, 21.99. Found: C, 56.29; H, 3.75; Cl, 8.21; N, 21.61.

The following compounds were made generally in accordance with the above-described methods and serve to further illustrate specific embodiments of the compounds of the invention:

3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one (D-034)

3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one (D-035)

- 154 -

```
3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one (D-036)
3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one (D-037)
3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one (D-038)
3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
quinazolin-4-one, acetate salt (D-039)
3-(3-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one (D-040)
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one (D-041)
2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
quinazolin-4-one (D-042)
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one (D-043)
3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one, acetate salt (D-044)
[5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
quinazolin-3-yl]acetic acid ethyl ester (D-045)
3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one (D-046)
3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one (D-047)
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one (D-048)
2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
quinazolin-4-one (D-049)
2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
one (D-050)
2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-
quinazolin-4-one, acetate salt (D-051)
```

3-(4-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-052).

Additional compounds of the present invention were prepared by the following synthetic procedures.

The following intermediates were prepared by the above-described Procedure A.

3a R=cyclopropyl

3b R=cyclopropylmethyl

3c R=phenethyl

3d R=cyclopentyl

3e R=3-(2-chloro)pyridyl

3f R=4-(2-methyl)benzoic acid

3g R=4-nitrobenzyl

3h R=cyclohexyl

3i R=E-(2-phenyl)cyclopropyl

Additional compounds of the present invention (D-053 through D-070) having the following core structure are discussed in the following Experimental Section. All were prepared following Procedure C.

Core structure:

Compound No.	R	R'
D-053	cyclopropyl	C .
D-054	cyclopropylmethyl	В
D-055	cyclopropylmethyl	A
D-056	cyclopropylmethyl	С
D-057	phenethyl	В
D-058	phenethyl	С
D-059	cyclopentyl	В
D-060	cyclopentyl	A
D-061	3-(2-chloro)pyridyl	В .
D-062	3-(2-chloro)pyridyl	A
D-063	4-(2-methyl)benzoic acid	В
D-064	cyclopropyl	В
D-065	cyclopropyl	A
D-066	4-nitrobenzyl	В
D-067	cyclohexyl .	В
D-068	cyclohexyl	Α .
D-069	cyclohexyl	С
D-070	E-(2-phenyl)cyclopropyl	В

Α

·B

C

2-(2-Amino-9H-purin-6-ylsulfanylmethyl)-3cyclopropyl-5-methyl-3H-quinazolin-4-one (D-053)

Prepared according to procedure C using 3a (100mg, 0.4 mmol), 2-amino-6-mercaptopurine (80 mg, 0.48 mmol), and K_2CO_3 (77 mg, 0.56 mmol). The product was purified by trituration from H_2O . ¹H NMR (DMSO- d_6) δ : 7.89 (d, J=0.9 Hz, 1H); 7.54 (t, J=7.4 Hz, 1H); 7.34 (d, J=8.1 Hz, 1H); 7.19 (d, J=7.2 Hz, 1H); 6.28 (s, 2H); 4.94 (s, 2H); 2.70 (s, 3H); 1.24 (d, J=6.5 Hz, 2H); 0.91 (s, 2H). MS (ES): m/z 380 (M+H), 190.

3-Cyclopropylmethyl-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-054)

Prepared according to procedure C using 3b (300mg, 1.14 mmol), 6-mercaptopurine monohydrate (214 mg, 1.26 mmol), and K_2CO_3 (189 mg, 1.37 mmol). The product was purified by trituration from H_2O , followed by recrystallization from MeOH. ¹H NMR (DMSO- d_6) δ : 13.60 (br s, 1H); 8.72 (s, 1H); 8.48 (s, 1H); 7.63 (t, J=7.8 Hz, 1H); 7.42 (d, J=8.0 Hz, 1H); 7.28 (d, J=7.3 Hz, 1H); 5.01 (s, 2H); 4.11 (d, J=6.8 Hz, 2H); 2.78 (s, 3H); 1.35 (quint, J=6.2 Hz, 1H); 0.44-0.59 (m, 4H). MS (ES): m/z 379 (M+H), 325.

- 159 -

2-(6-Aminopurin-9-ylmethyl)-3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one (D-055)

Prepared according to procedure C using 3b (300mg, 1.14 mmol), adenine (170 mg, 1.26 mmol), and K_2CO_3 (189 mg, 1.37 mmol). The product was purified by trituration from H_2O , followed by recrystallization from MeOH. ¹H NMR (DMSO- d_6) δ : 8.21 (s, 1H); 8.10 (s, 1H); 7.52 (t, J=7.7 Hz, 1H); 7.18-7.31 (m, 3H); 7.06 (d, J=8.1 Hz, 1H); 5.68 (s, 2H); 4.14 (d, J=6.8 Hz, 2H); 2.77 (s, 3H); 1.34 (quint, J=6.4 Hz, 1H); 0.45-0.60 (m, 4H). MS (ES): m/z 362 (M+H), 308.

2-(2-Amino-9H-purin-6-ylsulfanylmethyl)-3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one (D-056)

Prepared according to procedure C using 3b (280mg, 1.1 mmol), 2-amino-6-mercaptopurine (200 mg, 1.2 mmol), and K_2CO_3 (180 mg, 1.3 mmol). The product was purified by trituration from MeOH. ¹H NMR (DMSO- d_6) δ : 12.70 (br s, 1H); 7.95 (s, 1H); 7.64 (t, J=7.8 Hz, 1H); 7.44 (d, J=7.9 Hz, 1H); 7.28 (d, J=7.4 Hz, 1H); 6.41 (s, 2H); 4.91 (s, 2H); 4.05 (d, J=6.8 Hz, 2H); 2.78 (s, 3H); 1.26-1.43 (m, 1H); 0.36-0.56 (m, 4H). MS (ES): m/z 394 (M+H), 340.

5-Methyl-3-phenethyl-2-(9H-purin-6-ylsulfanyl-methyl)-3H-quinazolin-4-one (D-057)

Prepared according to procedure C using 3c (750mg, 2.4 mmol), 6-mercaptopurine monohydrate (442 mg, 2.6 mmol), and K_2CO_3 (398 mg, 2.9 mmol). The product was purified by trituration from H_2O . ¹H NMR

(DMSO- d_6) δ : 13.61 (s, 1H); 8.71 (s, 1H); 8.48 (s, 1H); 7.65 (t, J=7.7 Hz, 1H); 7.44 (d, J=7.9 Hz, 1H); 7.16-7.35 (m, 6H); 4.89 (s, 2H); 4.29 (br t, J=7.9 Hz, 2H); 3.08 (br t, J=7.8 Hz, 2H); 2.81 (s, 3H). MS (ES): m/z 429 (M+H), 105.

2-(2-Amino-9H-purin-6-ylsulfanylmethyl)-5-methyl-3-phenethyl-3H-quinazolin-4-one (D-058)

Prepared according to procedure C using 3c (750mg, 2.4 mmol), 2-amino-6-mercaptopurine (435 mg, 2.6 mmol), and K_2CO_3 (398 mg, 2.9 mmol). The product was purified by trituration from H_2O . ¹H NMR (DMSO- d_6) δ : 12.61 (s, 1H); 7.95 (s, 1H); 7.65 (t, J=7.7 Hz, 1H); 7.45 (d, J=7.9 Hz, 1H); 7.14-7.32 (m, 6H); 6.44 (s, 2H); 4.81 (s, 2H); 4.24 (br t, J=7.9 Hz, 2H); 3.04 (br t, J=7.8 Hz, 2H); 2.81 (s, 3H). MS (ES): m/z 444 (M+H), 340.

3-Cyclopentyl-5-methyl-2-(9H-purin-6-ylsulfanyl-methyl)-3H-quinazolin-4-one (D-059)

Prepared according to procedure C using 3d (100mg, 0.36 mmol), 6-mercaptopurine monohydrate (73 mg, 0.43 mmol), and K_2CO_3 (100 mg, 0.72 mmol). The product was purified by recrystallization from MeOH. ¹H NMR (DMSO- d_6) δ : 13.62 (br s, 1H); 8.77 (s, 1H); 8.48 (s, 1H); 7.62 (t, J=7.7 Hz, 1H); 7.42 (d, J=7.8 Hz, 2H); 7.26 (d, J=7.4 Hz, 1H); 5.03 (s, 2H); 4.80 (quint, J=8.0 Hz, 1H); 2.76 (s, 3H); 2.12-2.31 (m, 2H); 1.79-2.04 (m, 4H); 1.44-1.58 (m, 2H). MS (ES): m/z 393 (M+H), 325.

- 161 -

2-(6-Aminopurin-9-ylmethyl)-3-cyclopentyl-5-methyl-3H-quinazolin-4-one (D-060)

Prepared according to procedure C using 3d (100mg, 0.36 mmol), adenine (58 mg, 0.43 mmol), and K_2CO_3 (100 mg, 0.72 mmol). The product was purified by recrystallization from MeOH. ¹H NMR (DMSO- d_6) δ : 8.15 (s, 1H); 8.11 (s, 1H); 7.52 (t, J=7.7 Hz, 1H); 7.16-7.31 (m, 3H); 7.10 (d, J=8.0 Hz, 2H); 5.68 (s, 2H); 4.78 (quint, J=8.3 Hz, 1H); 2.74 (s, 3H); 2.09-2.32 (m, 2H); 1.86-2.04 (m, 2H); 1.68-1.86 (m, 2H); 1.43-1.67 (m, 2H). MS (ES): m/z 376 (M+H), 308, 154.

3-(2-Chloro-pyridin-3-yl)-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-061)

Prepared according to procedure C using 3e (500mg, 1.6 mmol), 6-mercaptopurine monohydrate (289 mg, 1.7 mmol), and K_2CO_3 (262 mg, 1.9 mmol). The product was purified by trituration from H_2O . MS (ES): m/z 436 (M+H), 200.

2-(6-Aminopurin-9-ylmethyl)-3-(2-chloro-pyridin-3-yl)-5-methyl-3H-quinazolin-4-one (D-062)

Prepared according to procedure C using 3e (500mg, 1.6 mmol), adenine (230 mg, 1.7 mmol), and K_2CO_3 (262 mg, 1.9 mmol). The product was purified by trituration from H_2O . ¹H NMR (DMSO- d_6) δ : 8.59 (dd, J=1.7, 4.8 Hz, 1H); 8.22 (dd, J=1.7, 7.8 Hz, 1H): 8.025 (s, 1H); 8.017 (s, 1H); 7.60-7.72 (m, 2H); 7.35 (t, J=8.2 Hz, 2H); 7.22 (s, 2H); 5.12 (d,

- 162 -

J=17.0 Hz, 1H); 5.02 (d, J=17.0 Hz, 1H); 2.72 (s, 3H). MS (ES): m/z 419 (M+H).

3-Methyl-4-[5-methyl-4-oxo-2-(9H-purin-6-ylsulfanyl-methyl)-4H-quinazolin-3-yl]-benzoic acid (D-063)

Prepared according to procedure C using 3f (400mg, 1.17 mmol), 6-mercaptopurine monohydrate (219 mg, 1.29 mmol), and K_2CO_3 (226 mg, 1.64 mmol). The product was purified by recrystallization from MeOH. ¹H NMR (DMSO- d_6) δ : 13.54 (br s, 1H); 8.44 (s, 1H); 8.42 (s, 1H); 7.80 (s, 2H); 7.71 (t, J=7.7 Hz, 1H); 7.59 (d, J=8.6 Hz, 1H); 7.52 (d, J=7.9 Hz, 1H); 7.34 (d, J=7.4 Hz, 1H); 4.46 (d, J=15.4 Hz, 1H); 4.34 (d, J=15.7 Hz, 1H); 3.17 (d, J=4.4 Hz, 1H); 2.73 (s, 3H); 2.17 (s, 3H). MS (ES): m/z 459 (M+H).

3-Cyclopropyl-5-methyl-2-(9H-purin-6-ylsulfanyl-methyl)-3H-quinazolin-4-one (D-064)

Prepared according to procedure C using 3a (100mg, 0.40 mmol), 6-mercaptopurine monohydrate (90 mg, 0.53 mmol), and K_2CO_3 (97 mg, 0.7 mmol). The product was purified by trituration from H_2O . ¹H NMR (DMSO- d_6) δ : 8.69 (d, J=0.8 Hz, 1H); 8.47 (s, 1H); 7.57 (d, J=7.9 Hz, 1H); 7.37 (d, J=8.1 Hz, 1H); 7.23 (d, J=7.3 Hz, 1H); 5.08 (s, 2H); 3.06-3.18 (m, 1H); 2.74 (s, 3H); 1.14-1.36 (m, 2H); 0.92-1.06 (m, 2H).

2-(6-Aminopurin-9-ylmethyl)-3-cyclopropyl-5-methyl-3H-quinazolin-4-one (D-065)

Prepared according to procedure C using 3a (100mg, 0.40 mmol), adenine (94 mg, 0.7 mmol), and K_2CO_3 (121 mg, 0.88 mmol). The product was purified by trituration from H_2O . ¹H NMR (DMSO- d_6) δ : 8.19 (d, J=0.9 Hz, 1H); 8.09 (d, J=1.0 Hz, 1H); 7.48 (t, J=7.8 Hz, 1H); 7.13-7.29 (m, 3H); 7.04 (d, J=8.1 Hz, 1H); 5.74 (s, 2H); 3.00-3.13 (m, 1H); 2.73 (s, 3H); 1.18-1.38 (m, 2H); 0.94-1.09 (m, 2H).

5-Methyl-3-(4-nitro-benzyl)-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one (D-066)

Prepared according to procedure C using 3g (200mg, 0.58 mmol), 6-mercaptopurine monohydrate (148 mg, 0.87 mmol), and K_2CO_3 (160 mg, 1.16 mmol). The product was purified by trituration from MeOH. ¹H NMR (DMSO- d_6) δ : 13.44 (br s, 1H); 8.50 (s, 1H); 8.31 (s, 1H); 8.03 (d, J=8.6 Hz, 2H); 7.58 (t, J=7.9 Hz, 1H); 7.37 (d, J=8.3 Hz, 3H); 7.22 (d, J=7.5 Hz, 1H); 5.44 (s, 2H); 4.70 (s, 2H); 2.66 (s, 3H). MS (ES): m/z 460 (M+H).

3-Cyclohexyl-5-methyl-2-(9H-purin-6-ylsulfanyl-methyl)-3H-quinazolin-4-one (D-067)

Prepared according to procedure C using 3h (150mg, 0.52 mmol), 6-mercaptopurine monohydrate (97 mg, 0.57 mmol), and K_2CO_3 (86 mg, 0.62 mmol). The product was purified by trituration from MeOH. ¹H NMR (DMSO- d_6) δ : 13.66 (br s, 1H); 8.82 (s, 1H); 8.50 (s, 1H); 7.62 (t, J=7.7 Hz, 1H); 7.42 (d, J=8.0 Hz,

- 164 -

1H); 7.26 (d, J=7.3 Hz, 1H); 5.01 (s, 2H); 4.11 (br s, 1H); 2.75 (s, 3H); 2.38-2.65 (m, 2H); 1.58-1.90 (m, 4H); 1.37-1.57 (m, 1H); 0.71-1.26 (m, 3H). MS (ES): m/z 407 (M+H), 325.

2-(6-Aminopurin-9-ylmethyl)-3-cyclohexyl-5-methyl-3H-quinazolin-4-one (D-068)

Prepared according to procedure C using 3h (150mg, 0.52 mmol), adenine (77 mg, 0.57 mmol), and K_2CO_3 (86 mg, 0.62 mmol). The product was purified by trituration from MeOH. ¹H NMR (DMSO- d_6) δ : 8.15 (s, 2H); 7.54 (t, J=7.9 Hz, 1H); 7.06-7.35 (m, 4H); 5.65 (s, 2H); 4.09 (br s, 1H); 2.73 (s, 3H); 1.41-1.90 (m, 6H); 0.99-1.34 (m, 4H). MS (ES): m/z 390 (M+H), 308.

2-(2-Amino-9H-purin-6-ylsulfanylmethyl)-3-cyclohexyl-5-methyl-3H-quinazolin-4-one (D-069)

Prepared according to procedure C using 3h (150mg, 0.52 mmol), 2-amino-6-mercaptopurine (95 mg, 0.57 mmol), and K_2CO_3 (86 mg, 0.62 mmol). The product was purified by reversed-phase HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220). MS (ES): m/z 422 (M+H), 340, 170.

5-Methyl-3-(E-2-phenyl-cyclopropyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-070)

Prepared according to procedure C using 3i and 6-mercaptopurine monohydrate). The product was

purified by reversed-phase HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220). MS (ES): m/z 441.

Additional compounds of the invention follow, together with the synthetic route to compounds D-071 to D-118.

- 167 -

Procedure D: A mixture of amide 4a or 4b, FMOC-glycyl-chloride, and glacial acetic acid was heated to 120°C for 1 to 4 hours. The resulting mixture was concentrated in vacuo and purified by flash chromatography to provide the protected, cyclized amine. This material was combined with 10 equivalents octanethiol and a catalytic amount of DBU in THF and stirred at ambient temp until consumption of starting material was indicated by The reaction was poured directly onto a flash column (equilibrated in CH2Cl2) and eluted with 0-5% MeOH/CH₂Cl₂ to provide the free amine, 5a or 5b. Compound 5c was prepared in an analogous manner using (±) FMOC-alanyl-chloride in place of FMOCglycyl chloride.

Procedure E: Equimolar amounts of 5a or 5b, the appropriate 6-chloropurine, and DIEA were combined with EtOH in a small vial and heated to 80°C. The reaction was monitored regularly by LCMS and purified as stated.

Procedure F: A mixture of amide 4b, acetoxyacetyl chloride, and glacial acetic acid was heated to 120°C and stirred for 2 hours. The cooled reaction was filtered and the solids washed with CH₂Cl₂ to provide the cyclized acetate as a white solid. This material was combined with K₂CO₃ in aqueous methanol and stirred for one hour, then concentrated in vacuo. The resulting solids were triturated from H₂O to provide 6a as a white solid.

3-(2-Chlorophenyl)-5-fluoro-2-[(9H-purin-6-ylamino)-methyl]-3H-quinazolin-4-one (D-072)

Prepared according to procedure E using 5b (50 mg, 0.165 mmol) and 6-chloropurine (26 mg, 0.165 mmol) in 1 mL EtOH. After 5 days, reaction purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ). ¹H NMR (DMSO- d_6) δ : 12.99 (br s, 1H); 8.14 (br s, 1H); 8.12 (s, 1H); 7.85 (dt, J=5.7, 8.1 Hz., 1H); 7.68-7.79 (m, 3H); 7.57 (t, J=6.2 Hz., 1H); 7.57 (d, J=7.7 Hz., 1H); 7.50 (d, J=8.1 Hz., 1H); 7.35 (dd, J=8.4, 10.7 Hz., 1H); 4.15-4.55 (m, 2H). MS (ES): m/z 422 (M+H), 211.

- 169 -

2-[(2-Amino-9H-purin-6-ylamino)methyl]-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one (D-074)

Prepared according to procedure E using 5b (50 mg, 0.165 mmol) and 2-amino-6-chloropurine (28 mg, 0.165 mmol) in 1 mL EtOH. After 5 days, reaction purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220λ). ¹H NMR (DMSO-d₆) δ: 12.13 (br s, 1H); 7.86 (dt, J=5.6, 8.2 Hz., 1H); 7.76-7.83 (m, 2H); 7.68 (br s, 1H); 7.61 (t, J=5.7 Hz., 1H); 7.61 (d, J=7.2 Hz., 1H); 7.53 (d, J=8.2 Hz., 1H); 7.35 (dd, J=8.2, 10.9 Hz., 1H); 5.66 (br s, 2 H); 4.16-4.50 (m, 1H); 4.09 (q, J=5.3 Hz., 2H). MS (ES): m/z 437 (M+H), 219.

5-Methyl-2-[(9H-purin-6-ylamino)methyl]-3-o-tolyl-3H-quinazolin-4-one (D-071)

Prepared according to procedure E using 6-chloropurine (11 mg, 0.072 mmol) and 5a (20 mg, 0.072 mmol). After 5 days, the reaction was quenched with water and the resulting suspension filtered. The solids were purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at

18 min, detector at 220 λ). ¹H NMR (DMSO- d_6) δ : 12.98 (br s, 1H); 8.14 (br s, 1H); 8.10 (s, 1H); 7.58-7.79 (m, 2H); 7.37-7.48 (m, 4H); 7.26-7.36 (m, 2H); 3.93-4.39 (m, 2H); 2.75 (s, 3H); 2.18 (s, 3H). MS (ES): m/z 398 (M+H), 199.

2-[(2-Amino-9H-purin-6-ylamino)methyl]-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-073)

Prepared according to procedure E using 5a (189 mg, 0.677 mmol) and 2-amino-6-chloropurine (115 mg, 0.677) in 3 mL EtOH. After 3 days, the reaction was filtered to remove excess purine and the filtrate purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) to provide 7 mg of the product as the TFA salt. ¹H NMR (DMSO- d_6) δ : 8.88 (br s, 1H); 8.21 (s, 1H); 7.71 (t, J=7.7 Hz., 1H); 7.45-7.56 (m, 2H); 7.38-7.44 (m, 3H); 7.35 (d, J=7.5 Hz., 1H); 7.30 (br s, 1H); 4.40 (dd, J=4.5, 17.5 Hz., 1H); 4.27 (dd, J=5.3, 17.4 Hz., 1H); 2.75 (s, 3H); 2.09 (s, 3H). MS (ES): m/z 413 (M+H), 207, 163.

171 -

2-[(2-Fluoro-9H-purin-6-ylamino)methyl]-5-methyl-3o-tolyl-3H-quinazolin-4-one (D-076)

Prepared according to procedure E using 5a (20 mg, 0.072 mmol) and 2-fluoro-6-chloropurine (16 mg, 0.094 mmol) in 1 mL EtOH. After 18 hours, the reaction was purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220A) and subsequently recrystallized from EtOH to provide 14 mg of the product as a yellow solid. NMR (DMSO- d_6) δ : 13.12 (br s, 1H); 8.40 (br s, 1H); 8.15 (s, 1H); 7.66 (t, J=7.7 Hz, 1H); 7.35-7.49 (m, 4H); 7.31 (d, J=7.2 Hz., 1H); 4.00-4.22 (m, 2H); 3.17 (s, 1H); 2.74 (s, 3H); 2.18 (s, 3H). MS (ES): m/z 416 (M+H), 208.

- 172 -

(2-Chlorophenyl)-dimethylamino-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-075)

D-015 (100 mg, 0.228 mmol) was combined with ammonium hydroxide (28-30%, 1 mL) in DMF (2 mL) and heated to 80°C. After 2 days, the reaction was purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) to provide the product as a yellow solid, ~2mg. ¹H NMR (DMSO- d_6) δ : 13.52 (br s, 1H); 8.46 (s, 1H); 8.42 (s, 1H); 7.69 (dd, J=2.1, 7.3 Hz, 1H); 7.62 (dd, J=1.6, 7.6 Hz., 1H); 7.61 (t, J=8.0 Hz., 1H); 7.37-7.48 (m, 2H); 7.05 (d, J=7.9 Hz., 1H); 6.96 (d, J=7.8 Hz., 1H); 4.32-4.45 (m, 2H); 2.80 (s, 6H). MS (ES): m/z 464 (M+H), 232.

5-(2-Benzyloxyethoxy)-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-078)

To a solution of 2-benzyloxyethanol (0.3 mL) in DMF (1.0 mL) was added NaH (50 mg, 2.08 mmol). After stirring for 5 minutes, 0.5 mL was added to a solution of IC-87185 (50 mg, 0.114

- 173 -

mmol) in anhydrous DMF (0.75 mL). The reaction was heated to 50°C and stirred for 3 days. Purification by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) provided the product as a heterogenous solid, 150 µg. MS (ES): m/z 571 (M+H), 481.

6-Aminopurine-9-carboxylic acid 3-(2-chlorophenyl)-5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethyl ester (D-079)

To a solution of 3b (20 mg, 0.066 mmol) in CH_2Cl_2 (500 µL) at 0°C was added phosgene (2M/toluene, 36 µL, 0.072 mmol), followed by adenine (10 mg, 0.072 mmol), and DIEA (25 µL, 0.145 mmol). The reaction was allowed to attain ambient temperature and stir for 8 days. Purification by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) provided the product as a mixture. ¹H NMR (DMSO- d_6) δ : 11.04 (br s, 1H); 8.61 (s, 1H); 8.40 (s, 1H); 7.85-7.95 (m, 1H); 7.76 (dd, J=5.4, 9.6 Hz, 1H); 7.70-7.78 (m, 1H); 7.52-7.63 (m,

3H); 7.38 (dt, J=8.3, 10.6 Hz., 1H); 4.76-4.89 (m, 2H). MS (ES): m/z 466 (M+H), 331, 305.

N-[3-(2-Chloropheny1)-5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethy1]-2-(9H-purin-6-ylsulfany1)-acetamide (D-077)

(9H-Purin-6-ylsulfanyl)-acetic acid (63 mg, 0.296 mmol), 5b (108 mg, 0.355 mmol), EDC (68 mg, 0.355 mmol), HOBT (48 mg, 0.355 mmol), DIEA (62 μL , 0.355 mmol), and DMF (1 mL) were combined in a flask and stirred at ambient temperature for one The reaction was diluted with EtOAc (20 mL) and washed with dilute brine (2 x 13 mL). organic phase was concentrated in vacuo and chromatographed in 5% MeOH/CH2Cl2 to provide the 91 mg of the product as a viscous, peach foam. ¹H NMR · (DMSO d_6) δ : 12.88 (br s, 1H); 8.72 (s, 1H); 8.62 (t, J=5.0 Hz, 1H); 8.49 (s, 1H); 7.88 (dt, J=5.6, 8.2 Hz, 1H); 7.73-7.78 (m, 1H); 7.67-7.72 (m, 1H); 7.57-7.65 (m, 2H); 7.38 (d, J=8.1 Hz., 1H); 7.36 (dd, J=8.3, 11.1 Hz., 1H); 4.11-4.24 (m, 2H); 3.96 (dd,

J=5.0, 17.4 Hz, 1H); 3.78 (dd, J=5.2, 17.4 Hz, 1H). MS (ES): m/z 496 (M+H), 248.

2-[1-(2-Fluoro-9H-purin-6-ylamino)ethyl]-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-080)

Prepared according to procedure E using 5c (50 mg, 0.17 mmol) and 2-fluoro-6-chloropurine (35 mg, 0.204 mmol) in 1.2 mL EtOH. Purification by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) provided two atropisomers as white solids. Data for one of these follows: ¹H NMR (DMSO- d_6) δ : 8.48 (br d, J=6.4 Hz, 1H); 8.17 (s, 1H); 7.69 (t, J=7.8 Hz, 1H); 7.53 (d, J=7.8 Hz, 1H); 7.44 (d, J=7.8 Hz, 2H); 7.33 (d, J=7.2 Hz, 2H); 7.07 (br t, J=7.2 Hz, 1H); 4.80 (br t, J=6.8 Hz, 1H); 2.74 (s, 3H); 2.09 (s, 3H); 1.38 (d, J=6.7 Hz, 3H). MS (ES): m/z 430 (M+H), 215.

5-Methyl-2-[1-(9H-purin-6-ylamino)ethyl]-3-o-tolyl-3H-quinazolin-4-one (D-081)

Prepared according to procedure E using 5c (50 mg, 0.17 mmol) and 6-chloropurine (32 mg, 0.204 mmol) in 1.2 mL EtOH. Purification by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ) provided two atropisomers as yellow solids. Data for one of these follows: ¹H NMR (DMSO- d_6) δ : 8.39 (br s, 1H); 8.34 (s, 1H); 8.18 (s, 1H); 7.71 (t, J=7.7 Hz, 1H); 7.56 (d, J=7.9 Hz, 1H); 7.49 (d, J=6.9 Hz, 1H); 7.28 -7.43 (m, 3H); 7.20 (br s, 1H); 5.06 (br s, 1H); 2.73 (s, 3H); 2.04 (s, 3H); 1.51 (d, J=6.6 Hz, 3H). MS (ES): m/z 412 (M+H), 206.

$$\begin{array}{c|c} XH & & \\ X_2CO_3 & \\ DMF & & X \end{array}$$

The following compounds of the present invention (D-082 through D-109) were prepared as outlined in Procedure C, using 2-chloromethyl-5-methyl-3-o-tolyl-3H-quinazolin-4-one (10 mg), the appropriate nucleophile XH (20 mg, excess), and potassium carbonate (10 mg) in DMF (0.25 mL). The reaction mixture was stirred 16 h at room temperature, quenched with water, and the crude solid product was collected by filtration and air dried. The crude material was dissolved in 0.5 mL of DMSO and purified by reversed-phase HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% aceto-nitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\(\lambda\)). Appropriate fractions were concentrated in vacuo to yield the final products.

2-(6-Dimethylaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-082)

Yield: 8.1 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.13 (s, 1H), 8.11 (s, 1H), 7.60 (t, J=7.8 Hz, 1H), 7.54-7.38 (m, 4H), 7.30 (d, J=7.4 Hz, 1H), 7.20 (d, J=8.1 Hz, 1H), 5.11 (d, J=17.4 Hz, 1H), 4.76 (d, J=17.4 Hz, 1H), 3.33 (s, 6H), 2.73 (s, 3H), 2.20 (s, 3H). LRMS (ES pos.) m/z = 426 (M+1).

WO 01/81346

5-Methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-7-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-083)

Yield: 3.3 mg

¹H NMR (300 MHz, d_6 -DMSO) δ : 12.06 (s, 1H), 8.12 (s, 1H), 7.60 (t, J=7.8 Hz, 1H), 7.55-7.38 (m, 4H), 7.30 (d, J=7.4 Hz, 1H), 7.15 (d, J=7.9 Hz, 1H), 5.26 (d, J=17.4 Hz, 1H), 4.94 (d, J=17.4 Hz, 1H), 2.73 (s, 3H), 2.32 (s, 3H), 2.24 (s, 3H). Alkylation at purine N₇ assigned arbitrarily based on downfield shift of methylene protons due to the carbonyl group.

LRMS (ES pos.) m/z = 413 (M+1).

- 179 -

5-Methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-9-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-084)

$$X = \bigvee_{N \to N} \bigvee_{N \to N}$$

Purified from same reaction mixture as D-083. Yield: 3.6 mg.

¹H NMR (300 MHz, d_6 -DMSO) 12.17 (s, 1H), 7.96 (s, 1H), 7.63 (t, J=7.8 Hz, 1H), 7.57-7.39 (m, 4H), 7.32 (d, J=7.4 Hz, 1H), 7.26 (d, J=8.1 Hz, 1H), 5.08 (d, J=17.2 Hz, 1H), 4.70 (d, J=17.2 Hz, 1H), 2.73 (5, 3H), 2.27 (s, 3H), 2.17 (s, 3H).

LRMS (ES pos.) m/z = 413 (M+1).

2-(Amino-dimethylaminopurin-9-ylmethyl)-5-methyl-3o-tolyl-3H-quinazolin-4-one (D-085)

$$X = N$$
 H_2N

Yield: 6.7 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 7.66 (s, 1H0, 7.61 (d, J=7.8 Hz, 1H), 7.55-7.40 (m, 4H), 7.32-7.26 (m, 2H), 6.74 (s, 2H), 4.94 (d, J=17.2 Hz, 1H), 4.63 (d, J=17.2 Hz, 1H), 4.63 (d, J=17.2 Hz, 1H), 2.97 (s, 6H), 2.73 (s, 3H), 2.17 (s, 3H), 2.08 (s, 3H). LRMS (ES pos.) m/z = 441 (M+1).

2-(2-Amino-9H-purin-6-ylsulfanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-086)

Yield: 9.5 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 12.54 (s, 1H), 7.89 (s, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.34 = 7.26 (m, 4H), 6.16 (s, 2H), 4.32 (AB quartet, J_{AB} =14.8 Hz, Δ n=23.7), 2.74 (s, 3H), 2.09 (s, 3H). LRMS (ES pos.) m/z = 430 (M+1).

2-(4-Amino-1,3,5-triazin-2-ylsulfanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-087)

Yield: 5.8 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.10 (s, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.58 (s, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.48-7.26 (m, 6H), 4.08 (s, 2H), 2.73 (s, 3H), 2.09 (s, 3H).

LRMS (ES pos.) m/z = 391 (M+1).

5-Methyl-2-(7-methyl-7H-purin-6-ylsulfanylmethyl)-3o-tolyl-3H-quinazolin-4-one (D-088)

Yield: 3.1 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.52 (s, 1H), 8.49 (s, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.50 (d, J=7.8 Hz, 1H), 7.45 (d, J=7.1 Hz, 1H), 7.35-7.20 (m, 4H), 4.41 (AB quartet, J_{AB} =15.3 Hz, Δv =19.2 Hz), 4.08 (s, 3H), 2.73 (s, 3H), 2.12 (s, 3H). LRMS (ES pos.) m/z = 406 (M+1).

5-Methyl-2-(2-oxo-1,2-dihydro-pyrimidin-4-ylsul-fanylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-089)

Yield: 2.4 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 11.49 (s, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.60 (brt, J=6.0 Hz, 1H), 7.53-7.48 (m, 2H), 7.46-7.28 (m, 4H), 6.31 (d, J=6.7 Hz, 1H), 4.05 (s, 2H), 2.73 (s, 3H), 2.12 (s, 3H). LRMS (ES pos.) m/z = 391 (M+1).

5-Methyl-2-purin-7-ylmethyl-3-o-tolyl-3H-quinazolin-4-one (D-090)

¹H NMR (300 MHz, d_6 -DMSO) δ : 9.04 (s, 1H), 8.97 (s, 1H), 8.48 (s, 1H), 7.65-7.54 (m, 2H), 7.53-7.39 (m, 3H), 7.31 (d, J=7.4 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 5.31 (d, J=17.6 Hz, 1H), 5.16 (d, J-17.6 Hz, 1H), 2.73 (s, 3H), 2.09 (s, 3H). Alkylation at purine N7 was determined by NOE enhancement between the purine 6-position proton and methylene protons on the linker between the purine and quinazolinone groups. LRMS (ES pos.) m/z = 383 (M+1).

5-Methyl-2-purin-9-ylmethyl-3-o-tolyl-3H-quinazolin-4-one (D-091)

From same reaction that produced D-090.
¹H NMR (300 MHz, d_6 -DMSO) δ : 9.17 (s, 1H), 8.86 (s, 1H), 8.55 (s, 1H), 7.59 (t, J-7.8 Hz, 1H), 7.55-7.42 (m, 4H), 7.30 (d, J=7.4 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 5.26 (d, J=17.5 Hz, 1H), 4.92 (d, J=17.5 Hz, 1H), 2.73 (s, 3H), 2.19 (s, 3H). Alkylation at

purine N9 suggested by the lack of NOE enhancement

- 183 -

between purine 6-position protons and the linker methylene protons.

LRMS (ES pos.) m/z = 383 (M+1).

5-Methyl-2-(9-methyl-9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-092)

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.52 (s, 1H), 8.42 (s, 1H), 7.69 (t, J=7.7 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.44 (d, J=7.6 Hz, 1H), 7.36-7.27 (m, 4H), 4.38 (AB quartet, J_{AB} =15.5 Hz, $\Delta \nu$ =21.0 Hz), 3.80 (s, 3H), 2.73 (s, 3H), 2.12 (s, 3H).

LRMS (ES pos.) m/z = 429 (M+1).

2-(2,6-Diamino-pyrimidin-4-ylsulfanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-093)

$$X = \bigvee_{NH_2}^{NH_2}$$

¹H NMR (300 MHz, d_6 -DMSO) δ: 7.70 (t, J=7.7 Hz, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.45-7.27 (m, 5H), 6.22 (br s, 1H), 5.80 (br s, 1H), 3.99 (AB quartet, J_{AB} =14.6 Hz, ΔV =26.9 Hz, 2H), 2.73 (s, 3H), 2.08 (s, 3H). LRMS (ES pos.) m/z = 405 (M+1).

- 184 -

5-Methyl-2-(5-methyl-[1,2,4]triazolo[1,5-a]pyri-midin-7-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-094)

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.57 (s, 1H), 7.73 (t, J=7.8 Hz, 1H), 7.55-7.35 (m, 4H), 7.18 (s, 1H), 4.27 (s, 2H), 2.74 (s, 3H0, 2.55 (s, 3H), 2.08 (s, 3H). LRMS (ES pos.) m/z = 429 (M+1).

5-Methyl-2-(2-methylsulfanyl-9H-purin-6-ylsulfanyl-methyl)-3-o-tolyl-3H-quinazolin-4-one (D-095)

$$X = \bigcup_{N \in \mathbb{N}} \bigcup_{N \in \mathbb{N}} S$$

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.30 (s, 1H), 8.29 (s, 1H), 7.72 (t, J=7.8 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.47 9d, J=6.3 Hz, 1H), 7.38-7.26 (m, 4H), 4.34 (AB quartet, J_{AB} =16.1 Hz, ΔV =23.6 Hz, 2H), 2.74 (s, 3H), 2.32 (s, 3H), 2.10 (s, 3H). LRMS (ES pos.) m/z = 461 (M+1).

2-(2-Hydroxy-9H-purin-6-ylsulfanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-096)

$$X = \bigvee_{N \in N} OH$$

¹H NMR (300 MHz, d_6 -DMSO) δ: 8.08 (s, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.50 (brd, J=t.8 Hz, 2H), 7.33-7.50 (m, 4H), 4.28 (AB quartet, J_{AB} =15.5 Hz, $\Delta \nu$ =21.3 Hz, 2H), 2.74 (s, 3H), 2.12 (s, 3H). LRMS (ES pos.) m/z = 431 (M+1).

5-Methyl-2-(1-methyl-1H-imidazoI-2-ylsulfanyl-methyl)-3-o-tolyl-3H-quinazolin-4-one (D-097)

¹H NMR (300 MHz, d_6 -DMSO) δ : 7.69 t, J=7.8 Hz, 1H), 7.46-7.37 (m, 5H), 7.32 (d, J=7.3 Hz, 1H), 7.20 (d, J=1.0 Hz, 1H), 6.48 (d, J=1.0 Hz), 3.83 (AB quartet, J_{AB} =15.0 Hz, Δv =18.8 Hz, 1H), 3.55 (s, 3H), 2.73 (s, 3H), 2.09 (s, 3H). LRMS (ES pos.) m/z = 364 (M+1).

5-Methyl-3-o-tolyl-2-(1H-[1,2,4]triazol-3-ylsul-fanylmethyl)-3H-quinazolin-4-one (D-098)

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.98 (s, 1H), 8.47 (s, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.49 (d, J=7.9 Hz, 1H), 7.44-7.31 (m, 5H), 4.04 (AB quartet, J_{AB} =15.5 Hz, Δv =19.1 Hz, 1H), 2.74 (s, 3H), 2.10 (s, 3H). LRMS (ES pos.) m/z = 364 (M+1).

2-(2-Amino-6-chloro-purin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-099)

$$X = \bigvee_{N \to N} \bigvee_{N \to N}$$

LRMS (ES pos.) 432 (M+1).

2-(6-Aminopurin-7-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-100)

$$X = \bigvee_{N = 1}^{N + 1} \bigvee_{N = 1}^{N + 2} \bigvee_{N =$$

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.19 (s, 3H), 7.66 (t, J=7.8 Hz, 1H), 7.59-7.43 (m, 5H), 7.34 9d, J=7.4 Hz, 1H), 7.23 (d, J=8.0 Hz, 1H), 6.90 (s, 2H), 5.21 (AB quartet, J_{AB} =17.4 Hz, $\Delta \nu$ =22.1 Hz, 2H), 2.72 (s, 3H), 1.93 (s, 3H). Alkylation at purine N7 was confirmed by NOE enhancements between the following protons:

1) Exocyclic amine and methylene protons; 2) Exocyclic amine and toluyl methyl protons.

LRMS (ES pos.) m/z = 398 (M+1).

2-(7-Amino-1,2,3-triazolo[4,5-d]pyrimidin-3-yl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-101)

$$X = \bigvee_{H_2N}^{N} \bigvee_{N}^{N}$$

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.43 (br s, 1H), 8.19 (s, 1H), 8.10 (br s, 1H), 7.62 (t, J=7.8 Hz, 1H), 7.49-7.28 (m, 5H), 7.22 (d, J=8.1 Hz, 1H), 5.49 (d, J=17.0 Hz, 1H), 5.19 (d, J=17.0 Hz, 1H), 2.73 (s, 3H), 2.11 (s, 3H). Alkylation at purine N7

determined by similarity to nmr spectrum of D-030. LRMS (ES pos.) m/z = 399 (M+1).

2-(7-Amino-1,2,3-triazolo[4,5-d]pyrimidin-1-yl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-102)

From same reaction mixture as D-101.

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.27 (s, 1H), 8.20 (br s, 1H), 8.05 (br s. 1H), 7.70 (t, J=7.8 Hz, 1H), 7.47-7.26 (m, 6H), 5.61 (AB quartet, J_{AB} =16.0 Hz, Δv =20.7 Hz, 2H), 2.75 (s, 3H), 1:98 (s, 3H)). Alkylation at purine N7 determined by similarity to nmr spectrum of D-100.

LRMS (ES pos.) m/z = 399 (M+1).

2-(6-Amino-9H-purin-2-ylsulfanylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-103)

¹H NMR (300 MHz, d_6 -DMSO) δ : 12.62 (s, 1H), 7.93 (s, 1H), 7.69 (t, J=7.7 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.42 (dd, J=7.6,1.7 Hz, 1H), 7.35-7.15 (m, 6H), 4.12

- 189 -

(AB quartet, J_{AB} =14.5 Hz, Δv =18.2 Hz, 2H), 2.73 (s, 3H), 2.10 (s, 3H). LRMS (ES pos.) m/z = 430 (M+1).

2-(2-Amino-6-ethylamino-pyrimidin-4-ylsulfanyl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-104)

¹H NMR (300 MHz, d_6 -DMSO) δ : 7.70 (T, J=7.8 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 7.44-7.31 (m, 5H), 6.69 (br s, 1H), 5.83, (br s, 2H), 5.61 (s, 1H), 4.03 (d, J=14.6 Hz, 1H), 3.95 (d, J=14.6 Hz, 1H), 3.22-3.11 (m, 2H), 2.73 (s, 3H), 2.08 (s, 3H), 1.06 (t, J=7.1 Hz, 3H).

LRMS (ES pos.) m/z = 433 (M+1).

2-(3-Amino-5-methylsulfanyl-1,2,4-triazol-1-yl-methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-105)

$$X = \bigvee_{N \to N} S$$

Yield: 5.0 mg.

¹H NMR (300 MHz, d_4 -MeOH) δ : 7.67 (t, J=7.8 Hz, 1H), 7.55-7.37 (m, 4H), 7.35-7.27 (m, 2H), 4.77 (d, J=17.1Hz, 1H), 4.60 (d, J=17.1 Hz, 1H), 2.80 (s, 3H), 2.43 (s, 3H), 2.14 (s, 3H). LRMS (ES pos.) m/z = 393 (M+1).

2-(5-Amino-3-methylsulfanyl-1,2,4-triazol-1-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-106)

$$X = H_2 N N N$$

Yield: 0.6 mg.

LRMS (ES pos.) m/z = 393 (M+1).

PCT/US01/13315

5-Methyl-2-(6-methylaminopurin-9-ylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-107)

$$X = \bigvee_{N = -N}^{N} \bigvee_{N = -N}^{N}$$

Yield: 5.0 mg 1 H NMR (300 MHz, d_4 -MeOH) δ : 8.17 (s, 1H), 8.03 (s, 1H), 7.54-7.43 (m 4H), 7.31-7.23 (m, 2H), 5.14 (d, J=17.5 Hz, 1H), 4.90 (d, J=17.5 Hz, 1H), 3.14 (br s, 3H), 2.79 (s, 3H), 2.22 (s, 3H). LRMS (ES pos.) m/z = 412 (M+1).

2-(6-Benzylaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-108)

Yield: 6.7 mg.

¹H NMR (300 MHz, d_4 -MeOH) δ : 8.13 (s, 1H), 8.04 (s, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.51-7.21 (m, 11H), 5.15 (d, J=17.5 Hz, 1H), 4.91 (d, J=17.5 Hz, 1H), 4.83 (s, 2H, under H₂O Peak), 2.79 (s, 3H), 2.22 (s, 3H).

LRMS (ES pos.) m/z = 488 (M+1).

2-(2,6-Diaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (D-109)

$$X = \bigvee_{N \to N} \bigvee_{N \to N} \bigvee_{N \to 1} \bigvee_{N \to 1}$$

Doubled the amounts of all reactants. Yield: 14 mg.

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.53 (br s, 2H), 8.01 (s, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.53-7.40 (m, 4H), 7.33 (d, J=7.4 Hz, 1H), 7.27 9d, J=7.9 Hz, 1H), 4.96 (d, J=17.5 Hz, 1H), 4.64 (d, J=17.5 Hz, 1H), 2.74 (s, 3H), 2.17 (s, 3H).

LRMS (ES pos.) m/z = 413 (M+1).

Compounds D-110 through D-115 of the following general structure were prepared from the following Intermediates E-1 through E-3.

Intermediate E-1.

5-Methyl-2-(9H-purin-6-ylsulfanylmethyl)-3,1-benzoxazin-4-one

Intermediate E-1

Step 1. A suspension of 6-methylanthranilic acid (2 g, 13.2 mmol) in chloroacetyl chloride (12 mL, large excess) was stirred at 115°C in a sealed vial for 30 min. The resulting solution was cooled to room temperature and treated with ether (~5 mL). After cooling at 4°C overnight, the re-

- 194 -

sulting tan precipitate was collected by filtration, washed with ether, and dried *in vacuo* to yield the chloro intermediate (1.39 g, 50%).

¹H NMR (300 MHz, CDCl₃) δ : 7.67 (t, J=7.8 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 7.35 (d, J=7.6 Hz, 1H), 4.39 (s, 2H), 2.81 (s, 3H).

LRMS (ES pos.) m/z = 210, (M+1).

step 2. A mixture of the chloro intermediate (50 mg, 0.25 mmol), 6-mercaptopurine monohydrate (43 mg, 0.25 mmol), and potassium carbonate (25 mg, 0.25 mmol) in dry DMF (0.5 mL) was stirred at room temperature for 30 min. The mixture was poured into ethyl acetate (20 mL) and all insoluble material was filtered off and discarded. The filtrate was concentrated in vacuo to remove all ethyl acetate, and the residue was treated with ether, resulting in a light orange precipitate. The precipitate was collected by filtration, washed with ether, and dried in vacuo to afford Intermediate E-1 (41 mg, 51%).

¹H NMR (300 MHz, d_6 -DMSO) δ : 8.64 (s, 1H), 8.39 (s, 1H), 7.73 (t, J=7.8 Hz, 1H), 7.44-7.37 (m, 2H), 4.69 (s, 2H), 2.69 (s, 3H).

LRMS (ES pos.) m/z = 326 (M+1).

Intermediate E-2

A solution of 2-nitroacetanilide (1.0 g, 5.6 mmol) in EtOH was purged with nitrogen, treated with Pd(OH)₂ (20% by wt. on C, 200 mg, cat.), and shaken for 2 h under H₂ (20 psi). The catalyst was removed by filtration through a 0.22 um cellulose acetate membrane (Corning), and the filtrate was concentrated in vacuo to afford the white crystalline solid product (800 mg, 96%).

¹H NMR (300 MHz, d_6 -DMSO) δ : 9.12 (s, 1H), 7.14 (dd, J=7.8, 1.3 Hz, 1H), 6.88 (dt, J=7.6, 1.5 Hz, 1H), 6.70 (dd, J=8.0, 1.3 Hz, 1H), 6.52 (dt, J=7.5, 1.4 Hz, 1H), 4.85 (br s, 2H), 2.03 (s, 3H). LRMS (ES pos.) m/z = 151 (M+1).

Intermediate E-3

A mixture of 2-fluoro-nitrobenzene (1.41 g, 10 mmol) and NaHCO $_3$ in EtOH (20 mL) was treated with (N,N,N'-trimethyl)-1,2-diaminoethane (1.1 g, 11

mmol) and was stirred 16 h at 80°C. Solvent was removed in vacuo, residue was treated with 0.1 M NaOH (120 mL), and the mixture was extracted with ethyl acetate (2 x 50 mL). The organic layers were combined and washed with 20 mL of water (1x) and brine (2x), dried with sodium sulfate, and concentrated in vacuo to an orange liquid (2.2 g, 100%; ESMS: m/z = 224, M+1).

This intermediate was dissolved in EtOH, the solution was purged with nitrogen, treated with Pd(OH)₂ (20% by wt. on C, 180 mg, cat.), and shaken for 2 h under H₂ (50 psi): The catalyst was removed by filtration through a 0.22 um cellulose acetate membrane (Corning), and the filtrate was concentrated in vacuo to afford the red liquid product E-3 (1.8 g, 95%).

¹H NMR (300 MHz, CDCl₃) δ: 8.64 (s, 1H), 7.03 (dd, J=8.3, 1.4 Hz, 1H), 6.91 (ddd, J=7.6, 7.2, 1.4 Hz, 1H), 6.73-6.67 (m, 2H), 4.20 (br s, 2H), 2.95 (t, J=6.7 Hz, 2H), 2.68 (s, 3H), 2.41 (t, J=6.7 Hz, 1H), 2.26 (s, 6H). LRMS (ES pos.) m/z=194 (M+1).

Compounds D-110 through D-115 were prepared as follows:

5-Methyl-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one (D-110)

A mixture of Intermediate E-1 (40 mg) and o-toluidine (0.3 mL, large excess) was warmed at 100°C in a sealed vial for 16 h. The reaction mixture was cooled, treated with 1N HCl (2 mL) and ether (2 mL), and the resulting gray precipitate was collected by filtration, washed with ether, and air dried (19 mg crude). The crude solid was dissolved in 0.5 mL DMSO and purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\lambda). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid (4 mg).

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.52 (s, 1H), 8.47 (s, 1H), 8.43 (s, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.50 (d, J=7.9 Hz, 1H), 7.46-7/43 (m, 1H), 7.37-7.25 (m, 4H), 4.37 (AB quartet, J_{AB} =15.4 Hz, ΔV =22.4 Hz, 2H), 2.74 (5, 3H), 2.12 (5, 3H).

LRMS (ES pos.) m/z = 415 (M+1).

3-Isobutyl-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-111)

A mixture of Intermediate E-1 (40 mg) and isobutylamine (0.4 mL, large excess) was warmed at 120°C in a sealed vial for 16 h. Excess isobutylamine was allowed to evaporate, residue was dissolved in 1 mL DMSO and purified in two portions by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\lambda). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid (4 mg).

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.75 (br s, 1H), 8.73 (s, 1H), 8.50 (s, 1H), 7.63 (t, J=7.7 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.28 (d, J=7.3 Hz, 1H), 4.96 (s, 2H), 4.00 (d, J=7.5 Hz, 2H), 2.77 (s, 3H), 2.30-2.15 (m, 1H), 0.98 (d, J=6.7 Hz, 1H).

LRMS (ES pos.) m/z = 381 (M+1).

- 199 -

N-{2-[5-Methyl-4-oxo-2-(9H-purin-6-ylsulfanyl-methyl)-4H-quinazolin-3-yl]-phenyl}-acetamide (D-112)

A mixture of Intermediate E-1 (80 mg, 0.25 mmol) and Intermediate E-2 (75 mg, 0.5 mmol, 2 eq) was warmed until melted in a sealed vial using a heat gun. reaction mixture was triturated with ether and the solids were collected by filtration. The crude material was dissolved in 1 mL DMSO and purified in two portions by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid. ¹H NMR (300 MHz, d_{e} -DMSO) δ : 13.52 (s, 1H), 9.52 (s, 1H), 8.48 (s, 3H), 8.42 (s, 3H), 8.02 (d, J=8.0 Hz, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.51 (d, J=7.9 Hz, 1H), 7.45-7.37 (m, 2H), 7.31 (d, J=7.3 Hz, 1H), 7.19 (t, J=7.5 Hz, 1H), 4.38 (s, 2H), 2.74 (s, 3H), 1.93 (s, 3H).

LRMS (ES pos.) m/z = 458 (M+1).

- 200 -

5-Methyl-3-(E-2-methyl-cyclohexyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-113)

A mixture of Intermediate E-1 (80 mg, 0.25 mmol) and trans-2-methyl-1-aminocyclohexane (0.25 mL, large excess) was warmed in a sealed at 100°C for 16 h. The reaction mixture was triturated with ether and the solids were collected by filtration. The crude material was dissolved in 0.5 mL DMSO and purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220A). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid (1.5 mg). ¹H NMR (300 MHz, d_6 -DMSO) δ : 13.5 (br s, 1H), 8.82 (s, 1H), 8.51 (s, 1H), 7.63 (t, J=7.7 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.27 (d, J=7.4 Hz, 1H), 5.11 (d,J=14.5 Hz, 1H), 3.78-3.69 (m, 1H), 2.73 (s, 3H),2.55-2.40 (m, 3H), 1.88-1.46 (m, 4H), 1.31-1.11 (m, 1H), 0.90-0.65 (m, 1H), 0.74 (d, J=6.7 Hz, 3H). LRMS (ES pos.) m/z = 421 (M+1).

- 201 -

2-[5-Methyl-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-quinazolin-3-yl]-benzoic acid (D-114)

A mixture of Intermediate E-1 (80 mg, 0.25 mmol) methyl anthranilate (0.25 mL, large excess) was warmed in a sealed vial at 100°C for 16 h. The reaction mixture was triturated with ether and the solids were collected by filtration. The crude material was dissolved in 0.5 mL DMSO and purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\lambda). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid (8 mg). ¹H NMR (300 MHz, d_6 -DMSO) δ : 13.51 (s, 1H), 8.51 (s, 1H), 8.42 (s, 1H), 8.11 (dd, J=7.4, 1.1 Hz, 1H), 7.88 (dt, J=7.7, 1.4 Hz, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.57 (t, J=7.2 Hz, 1H), 7.49-7.35 (m, 3H), 4.58(d, J=15.5 Hz, 1H), 4.35 (d, J=15.5 Hz, 1H), 2.44 (s, 3H).

LRMS (ES pos.) m/z = 445 (M+1).

3-{2-[(2-Dimethylamino-ethyl)-methyl-amino]-phenyl}-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-115)

A mixture of Intermediate E-1 (40 mg, 0.25 mmol) Intermediate E-3 (0.2 mL, large excess) was warmed in a sealed vial at 100°C for 16 h. The reaction mixture was triturated with ether and the solids were collected by filtration. The crude material was dissolved in 1 mL DMSO and purified by HPLC in two portions (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, 0.05% TFA in all solvents, detector at 220\(\lambda\)). Appropriate fractions were concentrated in vacuo to yield the final product as the TFA salt (11 mg).

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.4 (br s, 1H), 9.27 (s, 1H), 8.52 (s, 1H), 8.44 (s, 1H), 7.72 (t, J=7.8 Hz, 1H), 7.53 (d, J=7.9 Hz, 1H), 7.40-7.33 (m, 4H), 7.10-7.04 (m, 1H), 4.42 (s, 3H), 3.5 (m, 2H), 3.23-3.03 (m, 3H), 2.75 (s, 3H), 2.68-2.56 (m, 8H). LRMS (ES pos.) m/z = 501 (M+1).

- 203 -

Compounds D-116 through D-118 were prepared as follows:

3-(2-Chlorophenyl)-5-methoxy-2-(9H-purin-6-ylsul-fanylmethyl)-3H-quinazolin-4-one (D-116)

(R = Me, X = O)

A mixture of D-015 (25 mg) in 0.5 M NaOMe (2 mL in MeOH; large excess) was stirred at 50°C for 16 h in a sealed vial. The reaction mixture was cooled to room temperature, treated with water (5 mL), and the resulting precipitate was collected by filtration, washed with water, and air dried. The crude material was dissolved in 0.5 mL DMSO and purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220\lambda). Appropriate fractions were concentrated in vacuo to yield the final product as a white solid (5.3 mg).

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.52 (s, 1H), 8.48 (s, 1H), 8.44 (br s, 1H), 7.77 (t, J=8.2 Hz, 1H), 7.71-7.60 (m, 2H), 7.51-7.34 (m, 2H), 7.23 (d, J=8.2 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 4.39 (AB quartet, J_{AB} =5.2 Hz, Δv =23.2 Hz, 2H), 3.85 (s, 3H). LRMS (ES positive) m/z = 451 (M+1).

3-(2-Chlorophenyl)-5-(2-morpholin-4-yl-ethylamino)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-117)

A mixture of D-015 (25 mg) and 4-(aminoeth-2-yl)-morpholine (650 mg, large excess) was stirred at 50°C for 16 h. The crude reaction mixture was purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220 λ). Appropriate fractions were concentrated in vacuo to yield the final product.

¹H NMR (300 MHz, d_6 -acetone) δ : 8.57 (br s, 1H), 8.47 (s, 1H), 8.37 (s, 1H), 7.72 (dd, J=7.7, 1.6 Hz, 1H), 7.65 (dd, J=8.0, 1.2 Hz, 1H), 7.57 (t, J=8.1 Hz, 1H), 7.49 (dt, J=7.7,1.6 Hz, 1H), 7.40 (dt, J=7.7,1.5 Hz, 1H), 6.86 (d, J=7.4 Hz, 1H), 6.82 (d, J=8.3 Hz, 1H), 4.55 (d, J=15.0 Hz, 1H), 4.42 (d, J=15.1 Hz, 1H), 4.05-3.90 (m, 4H), 3.90 (t, J=6.9 Hz, 2H), 3.75-3.4 (m, 4H), 3.54 (t, J=6.9 Hz, 2H). LRMS (ES positive) m/z = 549 (M+1).

3-Benzyl-5-methoxy-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one (D-118)

A mixture of D-043 (25 mg) in 0.5 M NaOMe (2 mL in MeOH; large excess) was stirred at 50°C for 16 h in a sealed vial. The reaction mixture was treated with 1 N HCl (1 mL) and aliquots of this solution (0.5 mL each) were purified by HPLC (C18 Luna column, 4.6 x 250 mm, 4.7 mL/min, 10-75% acetonitrile/water over 15 min, 100% acetonitrile at 18 min, detector at 220λ). Appropriate fractions were concentrated *in vacuo* to yield the final product as a white solid (6.6 mg).

¹H NMR (300 MHz, d_6 -DMSO) δ : 13.57 (s, 1H), 8.60 (S, 1H), 8.45 (s, 1H), 7.72 (t, J=8.1 Hz, 1H), 7.42-7.30 (m, 2H), 7.30-7.19 (m, 3H), 7.15 (d, J=8.0 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H), 5.43 (s, 2H), 4.80 (s, 2H), 3.87 (s, 3H).

LRMS (ES positive) m/z = 431 (M+1).

- 206 -

Compound D-999 (comparative)

3-(2-Chlorophenyl)-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanylmethyl)-3H-quinazolin-4-one

An analog compound, 3-(2-chlorophenyl)-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanylmethyl)-3H-quinazolin-4-one, also was synthesized generally in accordance with the described methods, except that a 4-mercapto-1H-pyrazolo[3,4-d]pyrimidine was substituted for the mercaptopurine in the final step.

EXAMPLE 11

A. Biochemical Assay using 20 µM ATP

Using the method described in Example 2, above, compounds of the invention were tested for inhibitory activity and potency against PI3K δ , and for selectivity for PI3K δ versus other Class I PI3K isozymes. In Table 2, IC₅₀ values (μ M) are given for PI3K α ("Alpha"), PI3K β ("Beta"), PI3Y ("Gamma"), and PI3K δ ("Delta"). To illustrate selectivity of the compounds, the ratios of the IC₅₀ values of the compounds for PI3K α , PI3K β , and PI3K γ relative to PI3K δ are given, respectively, as "Alpha/Delta Ratio," "Beta/Delta Ratio," and "Gamma/Delta Ratio."

The initial selectivity assays were done identically to the selectivity assay protocol in Example 2, except using 100 µL Ecoscint for radiolabel detection. Subsequent selectivity assays were done similarly using the same 3X substrate stocks except they contained 0.05 mCi/mL y[32P]ATP and 3 mM

PIP₂. Subsequent selectivity assays also used the same 3X enzyme stocks, except they now contained 3 nM of any given PI3K isoform.

For all selectivity assays, the test compounds were weighed out and dissolved into 10-50 mM stocks in 100% DMSO (depending on their respective solubilities) and stored at -20°C. Compounds were thawed (to room temperature or 37°C), diluted to 300 µM in water from which a 3-fold dilution series into water was done. From these dilutions, 20 µL was added into the assay wells alongside water blanks used for the enzyme (positive) control and the no enzyme (background) control. The rest of the assay was essentially done according to the selectivity assay protocol in Example 2.

For those cases in which the greatest concentration used in the assay, i.e., 100 μ M, did not inhibit activity of the enzyme by at least 50%, the table recites the percent activity remaining at that concentration (i.e., at 100 μ M). In these cases, the true activity ratio(s) for the compounds cannot be calculated, since one of the required IC₅₀ values is missing. However, to provide some insight into the characteristics of these compounds, a hypothetical activity ratio is calculated using 100 μ M substituted for the missing value. In such cases, the selectivity ratio must in fact be greater than the hypothetical value, and this is indicated by use of a greater than (>) symbol.

			Table	le 2			
		,			Alpha/Delta	Beta/Delta	Gamma/Delta
Compound	Alpha ICso	Beta ICso	Delta IC50	Gamma IC50	Ratio	Ratio	Ratio
D-000	898	877	0.33	7.7	>302	>302	23
D-001	838	45	. 89	·	>1.5	0.66	
D-002	888	\$8 <i>L</i> ·	44		>2.3	>2.3	
D-003	92	538	4		22	>24	
D-004	938	868	64	•	. 2<.	>1.6	
D-005	868	46	0.8		>121	56	
D-006	78\$	9	0.15		>652	38	
D-007	828	30	0.16	•	>619	188	
D-008	82\$	68	1.2		>85	57	
D-009	82	9 .	0.12		683	50	
D-010	48	11	0.06	0.70	800	183	12
D-011	728	55	0.10	1.0	>1,000	. 550	. 10
D-012	869	11	0.17		>588	. 65	
D-013	718	13	0.05	2.1	>2,000	260	42
D-014	8 29	3.6	0.06	0.56	>1,667	60	9.3
D-015	829	69¥	0.21	3.6	>480	>480	17
D-016	918	818	40		>2.5	>3	

			Table	9.2			
		٠			Alpha/Delta	Beta/Delta	Gamma/Delta
Compound	Alpha ICso	Beta, ICso	Delta IC50.	Gamma ICso	Ratio	Ratio	Ratio
D-017	868	108%	. 12		>8	>8	
D-018	888	938	4.2		>24	>24	
D-019	29	105	4		- 10 -	15 .	
D-020	. \$69	. \$69	1.9	,	>53	>53	
D-021	100	ÖTT	1.6		62	68	
D-022	818	110	8.0	40	>125	137.50	50
D-023	838	% T6	26		. >4	>3.9	
D-024	100	%9 L	2.6	•	38	>38	
D-025	73\$	% T9	0.11	1.5	>909	< 806	14
D-026	÷ 899 ·	548	80.0	1.7	>1,250	>1,250	21
D-027	598	58	9.0		. >169	97	
D-028	678	13	0.18		>556	69	
D-029	49	3.0	90.0		882	54 .	
D~030	50	. 2	0.07		758	70	
D-031	74	10	0.12		>833 .	.83.	
D-034	1.9	ΤΙ	0.15		131	74	
D-035	6	3	0.05		199	65	
				,			

			Table	le 2			
					Alpha/Delta	Beta/Delta	Gamma/Delta
Compound	Alpha IC ₅₀	Beta IC ₅₀	Delta ICso	Germa ICso	Ratio	Ratio	. Ratio .
D-036	638	31	0.4		>226	69	
D-037	648	08	0.8	,	>125	100	
. D-039	. 778	899	. 6.0	. 8£	>111	>111	. 42
D-038	778	\$ £9	9.0	9	. >167	>170	100
D-040	778	879	1.7		>61	>61	
D-041	819	\$ 59	4		>25	>25	
D-042	%02	25 .	3		>32	8	
D-043	838	877	2.1	•		>47	
D-044	105	61	4.2		25	1.5	·
D-045	. 886	748	9:4	·	>13 "	>13	
D-046	648	56	6		>11	11:	
D-047	30	6	60.0	0.5	333	100	5.6
D-048	7.0	14	0.16	-	449.	90	
. D-049	110%	30	1.0		>100	30	
D-050	&66·	. 41	1.6	•	>63	. 26.	
D-051	89%	578	3.3		>31	>31	
D-052	0.7	698	8		60.0	>13	

-			Tabl	Table 2	•		
			-		Alpha/Delta	Beta/Delta	Gamma/Delta
. Compound	Alpha IC50	Beta IC ₅₀	. Delta IC50	Gamma ICso	Ratio	Ratio.	Ratio
D-121	869	804	0.48		>211	>211	
D-999	105	718	47	60	2.2	2.1	1.3
LY294002	1.2	0.4	0.23		5.3	1.7	·

Compound D-121 is 3-phenyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

B. Biochemical Assay using 200 µM ATP

In Part A, above, compounds of the invention were tested to establish their IC_{50} for inhibition of the alpha, beta, delta, and gamma isoforms of PI3K using 20 μ M ATP. A further screen was performed to establish the IC_{50} for inhibition of the four PI3K isoforms at a final concentration of 200 μ M ATP, 10-fold greater, and substantially closer to the normal physiological concentration of ATP in cells. This selectivity protocol is identical to that described above, except the 3X stock ATP concentration was 600 μ M. Data from this assay are summarized in Table 3, below. The observed sensitivity to ATP concentration suggests that these PI3K δ inhibitor compounds act as ATP competitors.

			Table	Le 3			
Compound	Alpha IC50	Beta IC ₅₀	Delta ICso	Gamma ICso	Alpha/Delta Ratio	Beta/Delta Ratio	Gamma/Delta Ratio
D-000	91±18	84±2%	2±1	32∓32	16	84	18
D-005	104%	828	11	816	5 0	. 16	17
D-006	104±18	44±5	0.92±0.1	87±33	. 326	. 48	56
D-007	92±11%	72±12	0.73±0.2	88±4	252	66	121
D-009	. 70%	18	0.7	53	200	26	94
D-010	74±18%	33∓4	0.23±0.2	6±3	859	144	27
D-011	88±4%	105±35	0.25±0.2	61±70	700	420	244
D-012	70±48	108±4	1.3±0.4	. 50±0	107	83	38
D-013	117±8%	73±24%	0.51±0.6	12±1	461	289	24
D-014	100±68	13±0	0.5±0.4	5±3	398	26	10
D-015.	95±22\$	81±3%	1.1±0.5	83±37%	180	154	160
D-019	100%	100	30	33	7	3	1
D-022	888	1018	4.2	608	42'	48	29
D-025	89±11%	77±68	0.32±0.3	7.8±3	556	478	24
D-026	83±18	77±8\$	0.38±0.2	13±10	443	411	34
D-027	748	110	4	60	37	. 28	15
D-028	100%	818	1.6	29	125	101	18
D-029	1101128	34±4	0.34±0.08	13±0.7	653	101	37

			Table	le 3		,	
ניוניסמווטט	Alpha IC.	Bets IC.	Delta IC.	Garma IC	Alpha/Delta Ratio	Beta/Delta Ratio	Gamma/Delta Ratio
D-030	95±11\$	80±14	0.53±0.05	31±10	362	152	59
D-031	87±10%	137±23	0.2±0.01	155±60	903	707	802
D-034	92±11\$	103±4	. 1.2±0.3	34±1	153	85	28
D-035	9 1 56	34±6	0.49±0.1	6.8±1	. 193	69	14
D-036	866	738	4.1	72	48	36	18
D-037	1128	588	3.5	45	79	33	13
D-038	869	748	1.8	52	7.7	82	31
D-039 ·	828	. \$59	2.6	\$ <i>L</i> 5.	. 59 .	50	. 4·4·
D-047	818	30	0.2	4.5	810	150	23
D-048	. 72±06	95±7	1.4±0.9	123±40	<i>-</i> 67	7.0	91
D-121	718	628	6.0	618	158	138	136
0-999	628	718	75	06	2	. 2	П
LY294002	23±5	3.7±2	.2.1±1.5	29±13	11	2	13

- 215 -

EXAMPLE 12

Cell-Based Assay Data for . <u>Inhibitors of PI3Kō Activity</u>

Using the methods described in Examples 3-5, above, compounds of the invention were tested for inhibitory activity and potency in assays of stimulated B and T cell proliferation, neutrophil (PMN) migration, and neutrophil (PMN) elastase release. Data from these assays are set forth in Table 4, below. In Table 4, the values shown are effective concentrations of the compound (EC $_{50}$; μ M). Where no value is given, no assay was performed.

Table 4						
Compound	Mouse BCR Stim (EC ₅₀)	Mouse TCE Stim (EC ₅₀)	Human PMN Elastase (EC ₅₀)	Human PMN Migration (EC ₅₀)		
D-000	0.9±0.4	5.5±4	2.2±2	1-5		
D-003	3.9	5.7				
D-005	0.7±0.1	3.9	4.3±1			
D-006	0.2±0.1	5.3	0.3±0.1			
D-007	0.3±0.1	4.2	0.4			
D-008	1.0					
D-009	0.3±0.2		10.5			
D-010	0.2±0.1		0.3±0.3			
D-011	0.3±0.1		0.9±0.7			
D-012	0.3±0.2		0.3			
D-013	1.4					
D-014	0.2±0.1	4.3		·		
D-015	1.2±0.2	1.8	1.3±0.4	2.0		
D-019	0.9±0.01	0.9				
D-021	1.8	3.5				
D-022	. 1.8	2.3				
D-024			2.9			
D-025	0.3±0.1	4.4±0.6	0.3±0.2	0.3±0.3		
D-026	0.3±0.1	3.5	0.2±0.2	0.3±0.3		
D-027	>2		· 2 ·	·		
D-028	0.4±0.2		1			
D-029	0.1±0.03	3.4±2	0.5±0.6	0.3		
D-030	0.1±0.1	6	0.4±0.5	0.2		
D-031	0.2±0.1		0.7±0.1			
D-034	0.6±0.4	· .				
D-035	0.2±0.1	2.9±0.7	0.3±0.1			
D-036	0.9±0.04	4.1	5.5±5	0.2		
D-037	1.2±0.4		1.3±0.4	2.0		
D-038	.1.4±0.1	2.9	5			

- 217 -

Table 4					
Compound	Mouse BCR Stim (EC ₅₀)	Mouse TCE Stim (EC ₅₀)	Human PMN Elastase (EC ₅₀)	Human PMN Migration (EC ₅₀)	
D-039	0.9±0.1		5 :		
D-043	1.4	2.6	. :		
D-045			. 9.0		
D-047	`0.3±01.		0.5±0.2		
D-048	·0.4±0.2	. 5	. 0.9±0:2		
D-049	2.0	6.3	5.0		
D-121	1.4				
D-999	3.1±0.7	5.9	>20 [:]	1	
LY294002	0.9±0.5	,	,		

- 218 -

EXAMPLE 13

Assay of Inhibitors of PI3Kδ Activity in Cancer Cells

The effect of compounds of the invention on cancer cell proliferation was evaluated by testing one of the compounds against a panel of Chronic Myeloid Leukemia (CML) cell lines, including KU812, RWLeu4, K562, and MEG-01.

The inhibitory activity of the compound (D-000, dissolved in DMSO) was determined as follows. The tested compound was added in a series of concentrations (0.001 µM to 20 µM) to 96-well microtiter plates with cells (1000 to 5000 cells/-well). Plates were incubated for five days at 37°C during which the control cultures without test compound were able to undergo at least two cell-division cycles. Cell growth was measured by incorporation of [3H]-thymidine for eighteen hours added at days three, four, and five. Cells were transferred to a filter, washed and the radioactivity counted using a Matrix 96 beta counter (Packard). The percentage of cell growth was measured as follows:

- 219 -

(average counts of cells incubated with a given inhibitor concentration) x 100

% Cell growth =

(average counts of the cells without inhibitor)

The EC₅₀ value in these experiments was determined by the concentration of the test compound that resulted in a radioactivity count 50% lower than that obtained using the control without inhibitor. The D-000 compound exhibited inhibitory activity with an EC₅₀ of approximately 2 μ M for the KU812 and RWLeu4 lines. The compound was not found to exhibit an effect in the K562 and MEG-01 lines.

PI3K δ inhibitors of the invention appear to inhibit CML cell growth and therefore could be useful in the treatment of benign or malignant PI3Kδ expression has been demonstrated so far mostly in cells of hematopoietic origin. ever, it could be present in a broader variety of proliferating cells. Therefore, the compounds of the invention could be used to induce tumor regression and to prevent the formation of tumor metastasis in both leukemia and solid tumor or in proliferation of nontumoral origin. In addition, the compounds could be used both alone and in combination with other pharmacologically active compounds or in combination with radiation as a sensitizing agent.

- 220 -

EXAMPLE 14

Measurement of elastase exocytosis in mouse air pouch lavage

The effect of D-030 on leukocyte influx and neutrophil elastase exocytosis in animal models was tested. The six-day air pouch model is an in vivo inflammation model that histologically resembles a joint synovium. A lining of organized mononuclear cells and fibroblasts develops that closely resembles a synovial cavity. The model represents an "acute" model of a chronic disease (e.g., rheumatoid arthritis). This model allows for the in vivo evaluation of agents to block cellular influx into the air pouch under the influence of an inflammatory stimulus.

The test was performed as follows: on day zero, groups of rats were shaved and 10 ml of air was injected subcutaneously on the back of each,

forming a pouch. On day three, 10 ml of air was reinjected. Six hours prior to TNF challenge on day six, one group of rats (n=6) received D-030 (100 mg/kg in PEG 400 vehicle) orally, and another group (n=12) received vehicle alone orally. Six hours following dosing, the air pouches of both groups received 2.5 ng of TNF. Twelve hours following dosing, the pouches were washed with saline, and the resulting lavage fluid was analyzed for leukocyte counts and neutrophil elastase activity. In addition, blood was drawn to determine the levels of D-030 in circulation. The results were as follows: rats that received D-030 for twelve hours had an average of 8.7 µM of compound in circulation and had an 82% reduction in total leukocytes in the lavage fluid compared to vehicle controls. Reductions in specific leukocyte counts were as follows: phils (90%), eosinophils (66%), and lymphocytes (70%). Quantitation of neutrophil elastase showed that D-030-treated rats had elastase levels that were somewhat reduced (15%) versus vehicle controls.

In another test, an area of the mouse back was shaved using clippers, and an air pouch was created by injecting 3 ml air subcutaneously. On day three, the air injection was repeated. On day six, the animals were dosed with either D-030 (32 mg/kg in LABRAFIL®) or LABRAFIL® only one hour before and two hours after challenge with TNF- α (0.5 ng in 1 ml PBS), or PBS only. PBS is phosphate buffered saline. Four hours after TNF challenge, the animals were anesthetized and the pouches were lavaged with 2 mL of 0.9% saline with 2 mM EDTA. The lavages were centrifuged at 14,000 rpm in a

- 222 -

microcentrifuge. Fifty microliters of the supernatant was used to measure elastase exocytosis according to the procedure described above.

As shown in Figure 9, TNF challenge induced a high level of elastase exocytosis compared to PBS challenged animals. However, when the TNF challenged animals were treated with D-030, a significant decrease in the elastase activity in the air pouch lavages was observed.

All publications and patent documents cited in this specification are incorporated herein by reference for all that they disclose.

While the present invention has been described with specific reference to certain preferred embodiments for purposes of clarity and understanding, it will be apparent to the skilled artisan that further changes and modifications can be practiced within the scope of the invention as it is defined in the claims set forth below. Accordingly, no limitations should be placed on the invention other than those specifically recited in the claims.

- 223 -

WHAT IS CLAIMED IS:

- 1. A method of disrupting leukocyte function comprising contacting leukocytes with a compound that selectively inhibits phosphatidylinositol 3-kinase delta (PI3K δ) activity in said leukocytes relative to other Type I phosphatidylinositol 3-kinase (PI3K) isoforms in a cell-based assay.
- 2. The method of claim 1 wherein said leukocytes comprise cells selected from the group consisting of neutrophils, B lymphocytes, T lymphocytes, and basophils.
- 3. The method of claim 1 wherein said leukocytes comprise neutrophils, and wherein said method comprises disrupting at least one neutrophil function selected from the group consisting of stimulated superoxide release, stimulated exocytosis, and chemotactic migration.
- 4. The method of claim 3 wherein bacterial phagocytosis or bacterial killing by said neutrophils is substantially undisrupted.
- 5. The method of claim 1 wherein said leukocytes comprise B lymphocytes, and wherein said method comprises disrupting proliferation of said B lymphocytes or antibody production by said B lymphocytes.

- 6. The method of claim 6 wherein said method comprises disrupting proliferation of said T lymphocytes.
- 7. The method of claim 1 wherein said leukocytes comprise basophils, and wherein said method comprises disrupting histamine release by the basophils.
- 8. The method of claim 1 wherein said compound exhibits at least about a 10-fold selectivity for inhibition of PI3K δ relative to other Type I PI3K isoforms in a cell-based assay.
- 9. The method of claim 8 wherein said compound exhibits at least about a 20-fold selectivity for inhibition of PI3K δ relative to other Type I PI3K isoforms in a cell-based assay.
- 10. The method of claim 9 wherein said compound exhibits at least about a 50-fold selectivity for inhibition of PI3K δ relative to other Type I PI3K isoforms in a biochemical assay.

11. The method of claim 1 wherein said compound has the structure:

wherein Y is selected from the group consisting of null, S, and NH;

 ${
m R}^7$ is selected from the group consisting of H, halo, OH, OCH₃, CH₃, and CF₃;

 R^8 is selected from the group consisting of is H, OCH $_3$, and halogen;

or R⁷ and R⁸ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6membered aromatic ring optionally containing one or more O, N, or S atoms;

 $$\rm R^9$$ is selected from the group consisting of $\rm C_1\text{-}C_6alkyl,$ phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0)- $\rm OC_2H_5$, and morpholinyl;

 R^4 , independently, is selected from the group consisting of NH_2 , halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, $NH(C_{1-3}$ alkyl), $N(C_{1-3}$ alkyl)₂, $NH(C_{1-3}$ alkylenephenyl);

PCT/US01/13315

- 226 -

q is 1 or 2,

and pharmaceutically acceptable salts and solvates thereof,

provided that at least one of R^7 and R^8 is different from 6-halo or 6,7-dimethoxy groups, and that R^9 is different from 4-chlorophenyl.

- 227 -

```
The method of claim 11 wherein the
          12.
compound is selected from the group consisting of
3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-yl-
sulfanylmethyl) - 3H-quinazolin-4-one;
5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-
3H-quinazolin-4-one;
5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-y-ylsulfan-
ylmethyl-3H-quinazolin-4-one;
3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-yl-
sulfanylmethyl) - 3H-quinazolin-4-one;
3-(2-chlorophenyl)-6-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-(3-methoxyphenyl-2-(9H-purin-6-ylsulfanylmethyl-
3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
quinazolin-4-one, acetate salt;
```

- 228 -

```
8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
fanylmethyl) - 3H-quinazolin-4-one;
3-(2-methoxyphenyl-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
trifluoromethyl-3H-quinazolin-4-one;
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one, acetate salt;
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
[5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
quinazolin-3-yl]acetic acid ethyl ester;
3-(2,4-dimethoxyphenyl)-2-(9H-purin-6-ylsulfanyl-
methyl)-3H-quinazolin-4-one;
3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
methyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
chloro-3H-quinazolin-4-one;
```

```
5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsul-
fanylmethyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
fluoro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
one;
2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-
fluoro-3H-quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-phenyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-isopropyl-
phenyl) - 3H-quinazolin-4-one; and
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-
```

quinazolin-4-one.

13. A method for disrupting leukocyte function comprising contacting leukocytes with a compound having a structure

$$\mathbb{R}^1$$
 \mathbb{R}^3
 \mathbb{R}^2
 \mathbb{R}^3
 \mathbb{R}^3

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHR^b , CH_2CHR^b , and $CH=C\left(R^b\right)$;

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=O), OC(=O), C(=O)O, and NHC(=O)CH₂S;

R¹ and R², independently, are selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, halo, NHC(=0)C₁₋₃alkyleneN(R^a)₂, NO₂, OR^a, OCF₃, N(R^a)₂, CN, OC(=0)R^a, C(=0)R^a, C(=0)OR^a, arylOC₁₋₃alkylene-N(R^a)₂, arylOC(=0)R^a, C₁₋₄alkylene-C(=0)OR^a, OC₁₋₄alkylene-N(R^a)₂, arylOC(=0)R^a, C₁₋₄alkylene-C(=0)OR^a, OC₁₋₄alkylene-C(=0)OR^a, C(=0)-NR^aSO₂R^a, C₁₋₄alkyleneO(R^a)₂, C₂₋₆alkenyleneN(R^a)₂, C(=0)NR^aC₁₋₄alkyleneOR^a, C(=0)NR^aC₁₋₄alkyleneHet, OC₂₋₄alkyleneN(R^a)₂, OC₁₋₄alkyleneCH(OR^b)CH₂N(R^a)₂, OC₁₋₄alkyleneHet, OC₂₋₄alkyleneOR^a, OC₂₋₄alkylene-NR^aC(=0)OR^a, NR^aC₁₋₄alkyleneN(R^a)₂, NR^aC(=O)R^a, NR^aC₁₋₄alkyleneN(R^a)₂, NR^aC₁₋₄alky

 $SO_2N(R^a)_2$, OSO_2CF_3 , C_{1-3} alkylenearyl, C_{1-4} alkyleneHet, C_{1-6} alkyleneOR^b, C_{1-3} alkyleneN($R^a)_2$, $C(=0)N(R^a)_2$, NHC(=0) C_1 - C_3 alkylenearyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, arylOC₁₋₃alkyleneN($R^a)_2$, arylOC(=0) R^b , NHC(=0) C_{1-3} alkyleneC₃₋₈heterocycloalkyl, NHC(=0) C_{1-3} -alkyleneHet, OC_{1-4} alkyleneOC₁₋₄alkyleneC(=0) OR^b , $C(=0)C_{1-4}$ alkyleneHet, and NHC(=0)haloC₁₋₆alkyl;

or R¹ and R² are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R3 is selected from the group consisting of optionally substituted hydrogen, C1-6alkyl, C3-8cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-4} alkylenecycloalkyl, $\text{C}_{2\text{-}6}\text{alkenyl}\text{, }\text{C}_{1\text{-}3}\text{alkylenearyl}\text{, arylC}_{1\text{-}3}\text{alkyl}\text{, }\text{C(=O)}\,\text{R}^{\text{a}}\text{,}$ aryl, heteroaryl, $C(=0)OR^a$, $C(=0)N(R^a)_2$, $C(=S)N(R^a)_2$, SO_2R^a , $SO_2N(R^a)_2$, $S(=0)R^a$, $S(=0)N(R^a)_2$, $C(=0)NR^aC_{1-4}$ alkyleneOR^a, C(=O)NR^aC₁₋₄alkyleneHet, C(=O)C₁₋₄alkylenearyl, C(=0)C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl substituted with one or more of SO₂N(Ra)₂, N(Ra)₂, $C(=0) OR^a$, $NR^aSO_2CF_3$, CN, NO_2 , $C(=0)R^a$, OR^a , $C_{1-4}alkyl$ eneN(Ra)2, and OC1-4alkyleneN(Ra)2, C1-4alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=0)C₁₋₄alkylenearyl, C_{1-4} alkyleneC(=0) C_{1-4} alkyleneheteroaryl, C_{1-4} alkyleneC(=0)Het, C_{1-4} alkyleneC(=0)N(R^a)₂, C_{1-4} alkylene OR^a , C_{1-4} alkylene NR^aC (=0) R^a , C_{1-4} alkylene OC_{1-4} alkyleneORa, C_{1-4} alkyleneN(Ra), C_{1-4} alkyleneC(=0)ORa, and C₁₋₄alkyleneOC₁₋₄alkyleneC(=0)OR^a;

 $$\rm R^a$$ is selected from the group consisting of hydrogen, $\rm C_{1-6}alkyl$, $\rm C_{3-8}cycloalkyl$, $\rm C_{3-8}heterocycloalkyl$, $\rm C_{1-3}alkyleneN\left(R^a\right)_2$, aryl, arylC₁₋₃alkyl, $\rm C_{1-3}alkylenearyl$, heteroaryl, heteroarylC₁₋₃alkyl, and C₁₋₃alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

 R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and C_{1-3} alkylenearyl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0) OR^a ;

and pharmaceutically acceptable salts and solvates,

in an amount sufficient to inhibit phosphatidylinositol 3-kinase delta activity in said leukocytes.

- 233 -

The method according to claim 13 wherein the compound is selected from the group consisting of 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7dimethoxy-3H-quinazolin-4-one 2-(6-aminopurin-o-ylmethyl)-6-bromo-3-(2-chlorophenyl)-3H-quinazolin-4-one 2-(6-aminopurin-o-ylmethyl)-3-(2-chlorophenyl)-7fluoro-3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-6-chloro-3-(2-chlorophenyl) -3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5fluoro-3H-quinazolin-4-one 2-(6-aminopurin-o-ylmethyl)-5-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5methyl-3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chlorophenyl)-3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5chloro-3H-quinazolin-4-one 5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-one 5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluorophenyl)-3H-quinazolin-4-one 3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one 5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one 3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

```
3-(2-chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-
ylsulfanylmethyl) -3H-quinazolin-4-one
6-bromo-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-8-trifluoromethyl-2-(9H-purin-6-
ylsulfanylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-benzo[g] quinazolin-4-one
6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-7-nitro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-yl-
sulfanylmethyl) -3H-quinazolin-4-one
3-(2-chlorophenyl)-6-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
```

- 235 -

```
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-
quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-
phenyl) -3H-quinazolin-4-one
2-(2-amino-9H-purin-6-ylsulfanylmethyl)-3-cycloprop-
yl-5-methyl-3H-quinazolin-4-one
3-cyclopropylmethyl-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-cyclopropylmethyl-5-
methyl-3H-quinazolin-4-one
2-(2-amino-9H-purin-6-ylsulfanylmethyl)-3-cyclo-
propylmethyl-5-methyl-3H-quinazolin-4-one
5-methyl-3-phenethyl-2-(9H-purin-6-ylsulfanyl-
methyl) -3H-quinazolin-4-one
2-(2-amino-9H-purin-6-ylsulfanylmethyl)-5-methyl-3-
phenethyl-3H-quinazolin-4-one
3-cyclopentyl-5-methyl-2-(9H-purin-6-ylsulfanyl-
methyl) -3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-cyclopentyl-5-methyl-
3H-quinazolin-4-one
3-(2-chloropyridin-3-yl)-5-methyl-2-(9H-purin-6-
ylsulfanylmethyl) -3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-(2-chloropyridin-3-
yl)-5-methyl-3H-quinazolin-4-one
3-methyl-4-[5-methyl-4-oxo-2-(9H-purin-6-ylsulfanyl-
methyl) -4H-quinazolin-3-yl]-benzoic acid
3-cyclopropyl-5-methyl-2-(9H-purin-6-ylsulfanyl-
methyl) -3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-cyclopropyl-5-methyl-
3H-quinazolin-4-one
5-methyl-3-(4-nitrobenzyl)-2-(9H-purin-6-ylsulfanyl-
methyl) -3H-quinazolin-4-one
```

```
3-cyclohexyl-5-methyl-2-(9H-purin-6-ylsulfanyl-
methyl) -3H-quinazolin-4-one
2-(6-aminopurin-9-ylmethyl)-3-cyclohexyl-5-methyl-
3H-quinazolin-4-one
2-(2-amino-9H-purin-6-ylsulfanylmethyl)-3-cyclo-
hexyl-5-methyl-3H-quinazolin-4-one
5-methyl-3-(E-2-phenylcyclopropyl)-2-(9H-purin-6-
ylsulfanylmethyl) -3H-quinazolin-4-one
3-(2-chlorophenyl)-5-fluoro-2-[(9H-purin-6-ylamino)-
methyl]-3H-quinazolin-4-one
2-[(2-amino-9H-purin-6-ylamino)methyl]-3-(2-chloro-
phenyl)-5-fluoro-3H-quinazolin-4-one
5-methyl-2-[(9H-purin-6-ylamino)methyl]-3-o-tolyl-
3H-quinazolin-4-one
2-[(2-amino-9H-purin-6-ylamino)methyl]-5-methyl-3-o-
tolyl-3H-quinazolin-4-one
2-[(2-fluoro-9H-purin-6-ylamino)methyl]-5-methyl-3-
o-tolyl-3H-quinazolin-4-one
(2-chlorophenyl) -dimethylamino-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one
5-(2-benzyloxyethoxy)-3-(2-chlorophenyl)-2-(9H-
purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one
6-aminopurine-9-carboxylic acid 3-(2-chlorophenyl)-
5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethyl
ester
N-[3-(2-chlorophenyl)-5-fluoro-4-oxo-3,4-dihydro-
quinazolin-2-ylmethyl]-2-(9H-purin-6-ylsulfanyl)-
acetamide
2-[1-(2-fluoro-9H-purin-6-ylamino)ethyl]-5-methyl-3-
o-tolyl-3H-quinazolin-4-one
5-methyl-2-[1-(9H-purin-6-ylamino)ethyl]-3-o-tolyl-
3H-quinazolin-4-one
```

PCT/US01/13315

```
2-(6-dimethylaminopurin-9-ylmethyl)-5-methyl-3-o-
toly1-3H-quinazolin-4-one
5-methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-7-
ylmethyl)-3-o-tolyl-3H-quinazolin-4-one
5-methyl-2-(2-methyl-6-oxo-1,6-dihydro-purin-9-
ylmethyl)-3-o-tolyl-3H-quinazolin-4-one
2-(amino-dimethylaminopurin-9-ylmethyl)-5-methyl-3-
o-tolyl-3H-quinazolin-4-one
2-(2-amino-9H-purin-6-ylsulfanylmethyl)-5-methyl-3-
o-tolyl-3H-quinazolin-4-one
2-(4-amino-1,3,5-triazin-2-ylsulfanylmethyl)-5-
methyl-3-o-tolyl-3H-quinazolin-4-one
5-methyl-2-(7-methyl-7H-purin-6-ylsulfanylmethyl)-3-
o-tolyl-3H-quinazolin-4-one
5-methyl-2-(2-oxo-1,2-dihydro-pyrimidin-4-ylsulfan-
ylmethyl)-3-o-tolyl-3H-quinazolin-4-one
5-methyl-2-purin-7-ylmethyl-3-o-tolyl-3H-quinazolin-
4-one
5-methyl-2-purin-9-ylmethyl-3-o-tolyl-3H-quinazolin-
4-one
5-methyl-2-(9-methyl-9H-purin-6-ylsulfanylmethyl)-3-
o-tolyl-3H-quinazolin-4-one
2-(2,6-Diamino-pyrimidin-4-ylsulfanylmethyl)-5-
methyl-3-o-tolyl-3H-quinazolin-4-one
5-methyl-2-(5-methyl-[1,2,4]triazolo[1,5-a]pyri-
midin-7-ylsulfanylmethyl)-3-o-tolyl-3H-quinazolin-4-
one
5-methyl-2-(2-methylsulfanyl-9H-purin-6-ylsulfanyl-
methyl)-3-o-tolyl-3H-quinazolin-4-one
2-(2-hydroxy-9H-purin-6-ylsulfanylmethyl)-5-methyl-
3-o-tolyl-3H-quinazolin-4-one
```

```
5-methyl-2-(1-methyl-1H-imidazol-2-ylsulfanyl-
methyl)-3-o-tolyl-3H-quinazolin-4-one
5-methyl-3-o-tolyl-2-(1H-[1,2,4]triazol-3-ylsulfan-
ylmethyl) -3H-quinazolin-4-one
2-(2-amino-6-chloro-purin-9-ylmethyl)-5-methyl-3-o-
toly1-3H-quinazolin-4-one
2-(6-aminopurin-7-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one
2-(7-amino-1,2,3-triazolo[4,5-d]pyrimidin-3-yl-
methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one
2-(7-amino-1,2,3-triazolo[4,5-d]pyrimidin-1-yl-
methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one
2-(6-amino-9H-purin-2-ylsulfanylmethyl)-5-methyl-3-
o-tolyl-3H-quinazolin-4-one
2-(2-amino-6-ethylamino-pyrimidin-4-ylsulfanyl-
methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one
2-(3-amino-5-methylsulfanyl-1,2,4-triazol-1-yl-
methyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one
2-(5-amino-3-methylsulfanyl-1,2,4-triazol-1-
ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one
5-methyl-2-(6-methylaminopurin-9-ylmethyl)-3-o-
toly1-3H-quinazolin-4-one
2-(6-benzylaminopurin-9-ylmethyl)-5-methyl-3-o-
toly1-3H-quinazolin-4-one
2-(2,6-diaminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-
3H-quinazolin-4-one
5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-
3H-quinazolin-4-one
3-isobutyl-5-methyl-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one
N-\{2-[5-Methyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-0-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-purin-6-ylsulfanyl-4-oxo-2-(9H-
methyl) -4H-quinazolin-3-yl]-phenyl}-acetamide
```

- 239 -

5-methyl-3-(E-2-methyl-cyclohexyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

2-[5-methyl-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)4H-quinazolin-3-yl]-benzoic acid

3-{2-[(2-dimethylaminoethyl)methylamino]phenyl}-5methyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

3-(2-chlorophenyl)-5-methoxy-2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one

3-(2-chlorophenyl)-5-(2-morpholin-4-yl-ethylamino)2-(9H-purin-6-ylsulfanylmethyl)-3H-quinazolin-4-one
3-benzyl-5-methoxy-2-(9H-purin-6-ylsulfanylmethyl)3H-quinazolin-4-one.

- 15. A method of ameliorating a medical condition mediated by PI3Kδ activity in leukocytes comprising administering to an animal in need thereof a therapeutically effective amount of a compound that selectively inhibits phosphatidylinositol 3-kinase delta activity in said leukocytes relative to other Type I PI3K isoforms in a cellbased assay.
- 16. The method of claim 15 wherein said medical condition is characterized by an undesirable neutrophil function selected from the group consisting of stimulated superoxide release, stimulated exocytosis, and chemotactic migration.
- 17. The method of claim 16 wherein phagocytic activity or bacterial killing by said neutrophils is substantially unaffected.

- 240 -

18. A method of disrupting a function of osteoclasts comprising contacting osteoclasts with a compound that selectively inhibits phosphatidylinositol 3-kinase delta activity in said osteoclasts relative to other Type I PI3K isoforms in a cell-based assay.

19. The method of claim 18 wherein said compound has a structure

wherein Y is selected from the group consisting of null, S, and NH;

 ${
m R}^7$ is selected from the group consisting of H, halo, OH, OCH3, CH3, and CF3;

 $$\rm R^8$$ is selected from the group consisting of is H, OCH3, and halogen;

or R⁷ and R⁸ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6-membered aromatic ring optionally containing one or more O, N, or S atoms;

 R^9 is selected from the group consisting of C_1 - C_6 alkyl, phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0)- OC_2H_5 , and morpholinyl;

 R^d , independently, is selected from the group consisting of NH₂, halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, NH(C_{1-3} alkyl), N(C_{1-3} alkyl)₂, NH(C_{1-3} alkylenephenyl);

q is 1 or 2,

and pharmaceutically acceptable salts and solvates thereof,

provided that at least one of R⁷ and R⁸ is different from 6-halo or 6,7-dimethoxy groups, and further provided that R⁹ is different from 4-chlorophenyl.

- 20. The method of claim 18 wherein said compound comprises a moiety that binds to bone.
- 21. A method of ameliorating a bone-resorption disorder in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound that inhibits phosphatidylinositol 3-kinase delta (PI3K δ) activity in osteoclasts of the animal relative to other Type I PI3K isoforms in a cell-based assay.
- 22. The method of claim 21 wherein said bone-resorption disorder is osteoporosis.
- 23. A method of inhibiting the growth or proliferation of chronic myelogenous leukemia cells comprising contacting the cells with a compound that selectively inhibits phosphatidylinositol 3-kinase delta activity in the cancer cells relative to other Type I PI3K isoforms in a cell-based assay.

24. The method of claim 23 wherein said compound has a structure

wherein R^7 is selected from the group consisting of H, halogen, OH, OCH₃, CH₃, and CF₃;

 $$\rm R^{8}$$ is selected from the group consisting of H, OCH3, and halogen;

or R⁷ and R⁸ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6-membered aromatic ring optionally containing one or more O, N, or S atoms;

 R^9 is selected from the group consisting of C_1 - C_6 alkyl, phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, acetic acid ethyl ester, and morpholinyl;

X is NH or S; and

pharmaceutically acceptable salts and solvates thereof,

provided that at least one of R^7 and R^8 is different from 6-halo or 6,7-dimethoxy groups, and further provided that R^9 is different from 4-chlorophenyl.

25. A method of inhibiting kinase activity of a phosphatidylinositol 3-kinase delta polypeptide comprising contacting the polypeptide with a compound having a structure

$$R^1$$
 R^3
 R^2
 R^2
 R^3
 R^3

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHR^b , CH_2CHR^b , and $CH=C\left(R^b\right)$;

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=O), OC(=O), C(=O)O, and NHC(=O)CH₂S;

 R^1 and R^2 , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, halo, NHC(=0) C_{1-3} alkyleneN(R^a)₂, NO₂, OR^a, OCF₃, N(R^a)₂, CN, OC(=0) R^a , C(=0) R^a , C(=0)OR^a, aryloR^b, Het, NR^aC(=0) C_{1-3} alkyleneC(=0)OR^a, aryloC₁₋₃alkylene-

N(Ra)2, aryloC(=0)Ra, C1-4alkyleneC(=0)ORa, OC1-4alkyleneC(=0)ORa, C1-4alkyleneC(=0)ORa, C1-4alkyleneOC1-4alkyleneC(=0)ORa, C(=0)-NRaSO2Ra, C1-4alkyleneN(Ra)2, C2-6alkenyleneN(Ra)2, C(=0)NRaC1-4alkyleneORa, C(=0)NRaC1-4alkyleneHet, OC2-4alkyleneN(Ra)2, OC1-4alkyleneCH(ORb)CH2N(Ra)2, OC1-4alkyleneHet, OC2-4alkyleneHet, OC2-4alkyleneORa, OC2-4alkylene-NRaC(=0)ORa, NRaC1-4alkyleneN(Ra)2, NRaC(=0)Ra, NRaC(=0)N(Ra)2, N(SO2C1-4alkyl)2, NRaC(=0)Ra, NRaC(=0)N(Ra)2, N(SO2C1-4alkyl)2, NRa(SO2C1-4alkyl), SO2N(Ra)2, OSO2CF3, C1-3alkylenearyl, C1-4alkyleneHet, C1-6alkyleneORb, C1-3alkyleneN(Ra)2, C(=0)N(Ra)2, NHC(=0)C1-C3alkylenearyl, C3-6cycloalkyl, C3-8heterocycloalkyl, aryloC1-3alkyleneN(Ra)2, aryloC(=0)Rb, NHC(=0)C1-3alkyleneC3-8heterocycloalkyl, NHC(=0)C1-3alkyleneC3-8heterocycloalkyl, NHC(=0)C1-4alkyleneHet, and NHC(=0)haloC1-6alkyl;

or R¹ and R² are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R³ is selected from the group consisting of optionally substituted hydrogen, C₁₋₆alkyl, C₃₋₈cyclo-alkyl, C₃₋₈heterocycloalkyl, C₁₋₄alkylenecycloalkyl, C₂₋₆alkenyl, C₁₋₃alkylenearyl, arylC₁₋₃alkyl, C(=0)R³, aryl, heteroaryl, C(=0)OR³, C(=0)N(R³)₂, C(=S)N(R³)₂, SO₂R³, SO₂N(R³)₂, S(=0)R³, S(=0)N(R³)₂, C(=0)NR³C₁₋₄-alkyleneOR³, C(=0)NR³C₁₋₄alkyleneHet, C(=0)C₁₋₄alkylenearyl optionally substituted with one or more of halo, SO₂N(R³)₂, N(R³)₂, C(=0)OR³, NR³SO₂CF₃, CN, NO₂, C(=0)R³, OR³, C₁₋₄alkyleneN(R³)₂, and OC₁₋₄alkyleneN(R³)₂, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkylene-C(=0)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=0)Het, C₁₋₄alkyleneC(=0)-

 $N(R^a)_2$, C_{1-4} alkylene OR^a , C_{1-4} alkylene NR^aC (=0) R^a , C_{1-4} -alkylene OC_{1-4} alkylene OR^a , C_{1-4} alkylene $O(R^a)_2$, C_{1-4} alkylene $O(R^a)_3$, and $O(R^a)_4$ alkylene $O(R^a)_4$ alkylene $O(R^a)_4$;

 R^a is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneN(R^a)₂, aryl, aryl C_{1-3} alkyl, C_{1-3} -alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

R^b is selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkylenearyl, and C₁₋₃alkylenearyl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0)OR^a;

and pharmaceutically acceptable salts and solvates thereof.

26. The method of claim 25 wherein R^1 is selected from the group consisting of H, halo, OH, OCH₃, CH₃, and CF₃; and

 R^3 is selected from the group consisting of C_1 - C_6 alkyl, phenyl, halophenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0) C_2 H_5 , and morpholinyl;

wherein at least one of R^1 and R^2 is different from 6-halo or 6,7-dimethoxy, and R^3 is different from 4-chlorophenyl.

27. A compound having a structure

wherein Y is selected from the group consisting of null, S, and NH;

 R^4 is selected from the group consisting of H, halogen, NO_2 , OH, OCH₃, CH₃, and CF₃;

 $$\rm R^{5}$$ is selected from the group consisting of H, OCH, and halo;

or R⁴ and R⁵ together with C-6 and C-7 of the quinazoline ring system define a 5- or 6membered aromatic ring optionally containing one or more O, N, or S atoms;

 $$\rm R^6$$ is selected from the group consisting of $\rm C_1\text{-}C_6alkyl,$ phenyl, halophenyl, alkoxyphenyl, alkylphenyl, biphenyl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=O)OC_2H_5, and morpholinyl;

 R^d , independently, is selected from the group consisting of NH₂, halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OH, NH(C_{1-3} alkyl), N(C_{1-3} alkyl)₂, NH(C_{1-3} alkylenephenyl), and

q is 1 or 2; and pharmaceutically acceptable salts and solvates thereof,

provided that at least one of R^4 and R^5 is other than H when R^6 is phenyl or 2-chlorophenyl.

- 249 -

```
The compound of claim 27 selected
from the group consisting of:
3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsul-
fanylmethyl)-3H-quinazolin-4-one;
5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-
3H-quinazolin-4-one;
5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-(2-methoxyphenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-
fanylmethyl) -3H-quinazolin-4-one;
3-(2-chlorophenyl)-6-fluoro-2-(9h-purin-6-ylsulfan-
ylmethyl)-3h-quinazolin-4-one;
5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
quinazolin-4-one, acetate salt;
```

```
8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
fanylmethyl)-3H-quinazolin-4-one;
3-(3-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one; .
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
quinazolin-4-one;
3-(2-chlorophenyl)-8-trifluoromethyl-2-(9H-purin-6-
ylsulfanylmethyl)-3H-quinazolin-4-one;
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one, acetate salt;
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
[5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
quinazolin-3-yl]acetic acid ethyl ester;
3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
methyl)-3H-quinazolin-4-one;
5-chloro-3-(2-methoxyphenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
```

```
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
chloro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl) -3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-
fluoro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-
one;
2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-
fluoro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-6-chloro-3-(2-chloro-
phenyl) - 3H-quinazolin-4-one;
3-(4-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-(2-chlorophenyl)-6,7-dimethoxy-2-(9H-purin-6-
ylsulfanylmethyl) - 3H-quinazoline - 4-one;
3-(2-chlorophenyl)-7-nitro-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-6-bromo-3-(2-chlorophen-
yl)-3H-quinazolin-4-one;
```

- 252 -

2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one;
6-bromo-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-3H-benzo[g]quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazolin-4-one; and
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-methoxy-phenyl)-3H-quinazolin-4-one.

- 253 -

29. The compound of claim 27 wherein R4 is selected from the group consisting of H, halo, OH, OCH3, CH3, and CF3;

 R^6 is selected from the group consisting of C_1 - C_6 alkyl, phenyl, halophenyl, alkylphenyl, biphen-yl, benzyl, pyridinyl, 4-methylpiperazinyl, C(=0)- OC_2H_5 , and morpholinyl; wherein (a) R^4 and R^5 , independently, are different from 6-halo or 6,7-dimethoxy groups;

- (b) R^6 is different from 4-chlorophenyl; and
- (c) at least one of R^4 and R^5 is different from H when R^6 is phenyl or 2-chlorophenyl and X is S.

```
30.
               The compound of claim 28 is selected
from the group consisting of
3-(2-isopropylphenyl)-5-methyl-2-(9H-purin-6-ylsul-
fanylmethyl)-3H-quinazolin-4-one;
5-chloro-2-(9H-purin-6-ylsulfanylmethyl)-3-o-tolyl-
3H-quinazolin-4-one;
5-chloro-3-(2-fluorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-(2-fluorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl) -3H-quinazolin-4-one;
3-(2,6-dichlorophenyl)-5-methyl-2-(9H-purin-6-ylsul-
fanylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-6-fluoro-2-(9h-purin-6-ylsulfan-
ylmethyl)-3h-quinazolin-4-one;
5-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-methyl-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-(2-chlorophenyl)-5-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-benzyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-butyl-2-(9H-purin-6-ylsulfanylmethyl)-3H-quin-
azolin-4-one;
3-(2-chlorophenyl)-7-fluoro-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one;
3-morpholin-4-yl-2-(9H-purin-6-ylsulfanylmethyl)-3H-
quinazolin-4-one, acetate salt;
8-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-(2-chlorophenyl)-6,7-difluoro-2-(9H-purin-6-ylsul-
fanylmethyl) -3H-quinazolin-4-one;
```

- 255 -

```
6-chloro-3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
3-(3-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)
3H-quinazolin-4-one;
2-(9H-purin-6-ylsulfanylmethyl)-3-pyridin-4-yl-3H-
quinazolin-4-one;
3-(2-chlorophenyl)-2-(9H-purin-6-ylsulfanylmethyl)-
trifluoromethyl-3H-quinazolin-4-one;
3-benzyl-5-fluoro-2-(9H-purin-6-ylsulfanylmethyl)-
3H-quinazolin-4-one;
3-(4-methylpiperazin-1-yl)-2-(9H-purin-6-ylsulfan-
ylmethyl)-3H-quinazolin-4-one, acetate salt;
3-(2-chlorophenyl)-6-hydroxy-2-(9H-purin-6-ylsulfan-
ylmethyl) - 3H-quinazolin-4-one;
[5-fluoro-4-oxo-2-(9H-purin-6-ylsulfanylmethyl)-4H-
quinazolin-3-yl]acetic acid ethyl ester;
3-biphenyl-2-yl-5-chloro-2-(9H-purin-6-ylsulfanyl-
methyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-isopropylphenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-
quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-biphenyl-2-yl-5-
chloro-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-3-(2-fluorophenyl)-5-
methyl-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-fluoro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-8-chloro-3-(2-chloro-
phenyl)-3H-quinazolin-4-one;
2-(6-aminopurin-9-ylmethyl)-5-chloro-3-(2-chloro-
phenyl)-3H-quinazolin-4-one;
```

- 256 -

- 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-methyl-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-5-fluoro-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-benzyl-5-fluoro-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-butyl-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-morpholin-4-yl-3H-quinazolin-4-one;
- 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-7-fluoro-3H-quinazolin-4-one; and
- 2-(6-aminopurin-9-ylmethyl)-5-chloro-3-o-tolyl-3H-quinazoline-4-one.

31. A compound having a general structural formula

$$R^{1}$$
 R^{2}
 N
 R^{3}
 $X-Y A$

wherein A is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;

X is selected from the group consisting of CHRb, CH2CHRb, and CH=C(Rb);

Y is selected from the group consisting of null, S, SO, SO₂, NH, O, C(=O), OC(=O), C(=O)O, and NHC(=O)CH₂S;

R¹ and R², independently, are selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, halo, NHC(=0)C₁₋₃alkyleneN(R^a)₂, NO₂, OR^a, OCF₃, N(R^a)₂, CN, OC(=0)R^a, C(=0)R^a, C(=0)OR^a, aryloR^b, Het, NR^aC(=0)C₁₋₃alkyleneC(=0)OR^a, aryloC₁₋₃alkylene-N(R^a)₂, aryloC(=0)R^a, C₁₋₄alkyleneC(=0)OR^a, OC₁₋₄alkylene-N(R^a)₂, aryloC(=0)R^a, C₁₋₄alkyleneOC₁₋₄alkyleneC(=0)OR^a, C(=0)-NR^aSO₂R^a, C₁₋₄alkyleneN(R^a)₂, C₂₋₆alkenyleneN(R^a)₂, C(=0)NR^aC₁₋₄alkyleneOR^a, C(=0)NR^aC₁₋₄alkyleneHet, OC₂₋₄alkyleneOH(OR^b)CH₂N(R^a)₂, OC₁₋₄alkyleneOH(OR^b)CH₂N(R^a)₂, OC₁₋₄alkyleneOR^a, OC₂₋₄alkylene-NR^aC(=0)OR^a, NR^aC₁₋₄alkyleneN(R^a)₂, NR^aC(=0)R^a, NR^aC(=0)N(R^a)₂, N(SO₂C₁₋₄alkyl)₂, NR^a(SO₂C₁₋₄alkyl), SO₂N(R^a)₂, OSO₂CF₃, C₁₋₃alkylenearyl, C₁₋₄alkyleneHet,

 C_{1-6} alkyleneOR^b, C_{1-3} alkyleneN(R^a)₂, C(=O)N(R^a)₂, NHC(=O)C₁-C₃alkylenearyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, arylOC₁₋₃alkyleneN(R^a)₂, arylOC(=O)R^b, NHC(=O)C₁₋₃alkyleneC₃₋₈heterocycloalkyl, NHC(=O)C₁₋₃-alkyleneHet, OC₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^b, C(=O)C₁₋₄alkyleneHet, and NHC(=O)haloC₁₋₆alkyl;

or R¹ and R² are taken together to form a 3- or 4-membered alkylene or alkenylene chain component of a 5- or 6-membered ring, optionally containing at least one heteroatom;

R3 is selected from the group consisting of optionally substituted hydrogen, C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, C1-4alkylenecycloalkyl, C_{2-6} alkenyl, C_{1-3} alkylenearyl, aryl C_{1-3} alkyl, C(=0) \mathbb{R}^a , aryl, heteroaryl, $C(=0)OR^a$, $C(=0)N(R^a)$, $C(=S)N(R^a)$, SO_2R^a , $SO_2N(R^a)_2$, $S(=0)R^a$, $S'(=0)N(R^a)_2$, $C(=0)NR^aC_{1-4}$ alkylene OR^a , $C(=0)NR^aC_{1-4}$ alkyleneHet, $C(=0)C_{1-4}$ alkylenearyl, $C(=0)C_{1-4}$ alkyleneheteroaryl, C_{1-4} alkylenearyl optionally substituted with one or more of halo, $SO_2N(R^a)_2$, $N(R^a)_2$, $C(=O)OR^a$, $NR^aSO_2CF_3$, CN, NO_2 , $C(=O)R^a$, ORa, C₁₋₄alkyleneN(Ra)₂, and OC₁₋₄alkyleneN(Ra)₂, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkylene-C(=0)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=0)C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneC(=0)Het, C₁₋₄alkyleneC(=0)- $N(R^a)_2$, C_{1-4} alkylene OR^a , C_{1-4} alkylene $NR^aC(=0)R^a$, C₁₋₄alkyleneOC₁₋₄alkyleneOR^a, C₁₋₄alkyleneN(R^a), C₁₋₄alkyleneC(=0)OR^a, and C₁₋₄alkyleneOC₁₋₄alkylene- $C(=0)OR^a;$

 $$\rm R^a$$ is selected from the group consisting of hydrogen, $\rm C_{1-6}alkyl,$ $\rm C_{3-8}cycloalkyl,$ $\rm C_{3-8}heterocycloalkyl,$ $\rm C_{1-3}alkyleneN(R^a)_2,$ aryl, arylC₁₋₃alkyl, $\rm C_{1-3}alkylenearyl,$ heteroaryl, heteroarylC₁₋₃alkyl, and C₁₋₃alkyleneheteroaryl;

or two R^a groups are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

 R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and C_{1-3} alkylenearyl;

Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C_{1-4} alkyl or C(=0)ORa;

and pharmaceutically acceptable salts and solvates thereof,

with the provisos that if X-Y is CH_2S , then R^3 is different from

and if X-Y is CH_2S , then R^3 is different from $-CH_2CH(OH)\,CH_2OH$ substituted phenyl.

- 261 -

- 32. The compound of claim 31 wherein X is selected from the group consisting of CH_2 , CH_2CH_2 , CH=CH, $CH(CH_3)$, $CH_2CH(CH_3)$, and $C(CH_3)_2$.
- 33. The compound of claim 31 wherein Y is selected from the group consisting of null, S, and NH.
- 34. The compound of claim 31 wherein the A ring system is selected from the group consisting of imidazolyl, pyrazolyl, 1,2,3-triazolyl, pyridizinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, 1H-indazolyl, and benzimidazolyl.

35. The compound of claim 31 wherein the A ring system is selected from the group consisting of

, and

36. The compound of claim 31 wherein the A ring system is substituted with one to three substituents selected from the group consisting of $N(R^a)_2$, halo, C_{1-3} alkyl, $S(C_{1-3}$ alkyl), OR^a , halo, and

WO 01/81346

37. The compound of claim 31 wherein the A ring system is substituted with one to three substituents selected from the group consisting of NH_2 , $NH(CH_3)$, $N(CH_3)_2$, $NHCH_2C_6H_5$, $NH(C_2H_5)$, Cl, F, CH_3 , SCH_3 , OH, and

38. The compound of claim 31 wherein R^1 and R^2 , independently, selected from the group consisting of hydrogen, OR^a , halo, C_{1-6} alkyl, CF_3 , NO_2 , $N(R^a)_2$, NR^aC_{1-3} alkyleneN($R^a)_2$, and OC_{1-3} alkyleneOR^a. Specific substituents include, but are not limited to, H, OCH_3 , Cl, Br, F, CH_3 , CF_3 , NO_2 , OH, $N(CH_3)_2$,

and O(CH₂)₂OCH₂C₆H₅.

39. The compound of claim 31 wherein R^1 and R^2 are taken together to form a five- or six-membered ring.


40. The compound of claim 31 wherein R^3 is selected from the group consisting of C_{1-6} alkyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C(=0)OR a , C_{1-4} alkyleneHet, C_{1-4} alkylenecycloalkyl, C_{1-4} alkylenearyl, C_{1-4} alkyleneC(=0) C_{1-4} alkylenearyl, C_{1-4} alkyleneC(=0) C_{1-4} alkyleneC(=0) C_{1-4} alkyleneC(=0) C_{1-4} alkyleneC(=0) C_{1-4} alkyleneC(=0) C_{1-4} alkyleneC(=0) C_{1-4} alkyleneNraC-eneC(=0) C_{1-4} alkyleneNraC-(=0) C_{1-4} alkylene

41. The compound of claim 31 wherein R^3 is selected from the group consisting of OR^a , C_{1-6} alkyl, aryl, heteroaryl, NO_2 , $N(R^a)_2$, $NR^aC(=0)R^a$, $C(=0)OC_2H_5$, $CH_2CH(CH_3)_2$,













and

- 268 -

- 42. The compound of claim 31 wherein R^3 is substituted with a substituent selected from the group consisting of halo, OR^a , C_{1-6} alkyl, aryl, heteroaryl, NO_2 , $N(R^a)_2$, $NR^aSO_2CF_3$, $NR^aC(=0)R^a$, $C(=0)OR^a$, $SO_2N(R^a)_2$, CN, $C(=0)R^a$, C_{1-4} alkyleneN(R^a)₂, OC_{1-4} alkyleneN(R^a)₂, and OR_1 0, and OR_2 1, and OR_2 2.
- 43. The compound of claim 31 wherein R^3 is substituted with a substituent selected from the group consisting of Cl, F, CH₃, CH(CH₃)₂, OCH₃, C₆H₅, NO₂, NH₂, NHC(=O)CH₃, CO₂H, and N(CH₃)CH₂CH₂N(CH₃)₂.









FIGURE 2























FIGURE'










FIGURE 9

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 1 November 2001 (01.11.2001)

PCT

(10) International Publication Number WO 01/81346 A3

- (51) International Patent Classification⁷: C07D 473/38, 473/34, 473/00, 473/24, 473/16, 473/40, 473/30, 403/12, 487/04, A61K 31/517, 31/52, A61P 7/00, 29/00, 19/10 // (C07D 487/04, 249:00, 239:00)
- (21) International Application Number: PCT/US01/13315
- (22) International Filing Date: 24 April 2001 (24.04.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/199,655 60/238,057 25 April 2000 (25.04.2000) US 5 October 2000 (05.10.2000) US

- (71) Applicant: ICOS CORPORATION [US/US]; 22021 20th Avenue S.E., Bothell, WA 98021 (US).
- (72) Inventors: SADHU, Chanchal; 903 223rd Street SE, Bothell, WA 98012 (US). DICK, Ken; 22517 1st Place West, Bothell, WA 98021-8321 (US). TREIBERG, Jennifer; 19411 Grannis Road, Bothell, WA 98012 (US). SOWELL, C., Gregory; 9423 61st Avenue W., Makilteo, WA 98275 (US). KESICKI, Edward, A.; 2504 208th Place SE, Bothell, WA 98021 (US). OLIVER, Amy; 23123 15th Avenue, S.E., Bothell, WA 98021 (US).

- (74) Agent: NAPOLI, James, J.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPl patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 21 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A

(54) Title: INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA

(57) Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compound s to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

INTERNATIONAL SEARCH REPORT rnational Application No rCT/US 01/13315 A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D473/38 C07D C07D473/34 CO7D473/00 C07D473/24 C07D473/16 C07D473/40 C07D473/30 CO7D403/12 C07D487/04 A61K31/517 A61K31/52 A61P7/00 A61P29/00 A61P19/10 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) CO7D IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A WO 94 17090 A (GLAXO GROUP LTD; GREGSON 1,2,13, MICHAEL (GB); AYRES BARRY EDWARD (GB); EW) 15,19, 4 August 1994 (1994-08-04) 24,25, 27,31 page 1, line 3 - line 29; claims 1,14-16 CARNERO A ET AL: "Wortmannin, an 1,15,18 inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM, NL, vol. 422, no. 2, 30 January 1998 (1998-01-30), pages 155-159, XP004261794 ISSN: 0014-5793 page 155, abstract Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but 'A' document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention 'E' earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone document of particular relevance; the claimed invention citation or other special reason (as specified)

- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed
- cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of mailing of the international search report

Fax: (+31-70) 340-3016

Date of the actual completion of the international search

15 November 2001

Name and mailing address of the ISA

European Palent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

21/12/2001

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

ernational Application No PCT/US 01/13315

A. CLASSIF IPC 7	//(C07D487/04,249:00,239:00)		
According to	International Patent Classification (IPC) or to both national classifica	tion and IPC	
B. FIELDS			
	cumentation searched (classification system followed by classification	n symbols)	
Documentat	on searched other than minimum documentation to the extent that so $$	uch documents are included in the fields se	arched .
Electronic d	ata base consulted during the international search (name of data base	e and, where practical, search terms used)	
			•
		·	
	•		
0.000100	THE ACHIOPERED TO BE DELEVANT		
	ENTS CONSIDERED TO BE RELEVANT		Colouret to daim his
Category *	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
A	CHANTRY D ET AL: "P110DELTA, A N PHOSPHATIDYLINOSITOL 3-KINASE CAT SUBUNIT THAT ASSOCIATES WITH P85 EXPRESSED PREDOMINANTLY IN LEUKOO	ALYTIC AND IS	1
·	JOURNAL OF BIOLOGICAL CHEMISTRY, SOCIETY OF BIOLOGICAL CHEMISTS, E MD, US, vol. 272, no. 31,	AMERICAN	
	1 August 1997 (1997-08-01), pages 19236-19241, XP002059998 ISSN: 0021-9258 cited in the application		
ł	the whole document	•	
		-/	
٠.		•	
			·
X Furt	ner documents are listed in the continuation of box C.	X Patent family members are listed	in annex.
Special ca	tegories of cited documents:	*T* later document published after the inte	ernational filling date
consid	ent defining the general state of the art which is not lered to be of particular relevance	or priority date and not in conflict with cited to understand the principle or th invention	the application but
filing (ent which may throw doubts on priority claim(s) or	*X* document of particular relevance; the cannot be considered novel or canno involve an inventive step when the do	t be considered to
O docum	is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"Y" document of particular relevance; the cannot be considered to involve an indocument is combined with one or management and combined with one or management.	ventive step when the ore other such docu-
P docum	means ent published prior to the international filing date but nan the priority date claimed	ments, such combination being obvio in the art. *&* document member of the same patent	
Date of the	actual completion of the international search	Date of mailing of the international se	arch report
	5 November 2001		
Name and	nalling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer	•
	Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Hass, C	

1

INTERNATIONAL SEARCH REPORT

rnational Application No PCT/US 01/13315

C.(Continua	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 46688 A (LUDWIG INST CANCER RES; VANHASEBROECK BART (GB); WATERFIELD MICHAE) 11 December 1997 (1997-12-11) cited in the application abstract	1
A	WO 96 04923 A (PRO NEURON INC) 22 February 1996 (1996-02-22) claims 1-4,7,8	27,31
A	EP 0 675 124 A (JAPAN ENERGY CORP) 4 October 1995 (1995-10-04) claims	27,31
Α .	WO 99 34804 A (UNIV VIRGINIA) 15 July 1999 (1999-07-15) claims 3,4	27,31
A	WO 98 33802 A (CALVERT ALAN HILARY; UNIV NEWCASTLE VENTURES LTD (GB); CURTIN NICO) 6 August 1998 (1998-08-06) claim 1	27,31
A	WO 97 41097 A (REDDY RESEARCH FOUNDATION; REDDY CHEMINOR INC (US)) 6 November 1997 (1997-11-06) examples 12-15,22,23,28,39-43	27,31
A	WO 99 08501 A (REDDY RESEARCH FOUNDATION; REDDY CHEMINOR INC (US)) 25 February 1999 (1999-02-25) examples 1-26,49-62	27,31
A .	US 3 984 555 A (AMSCHLER HERMANN ET AL) 5 October 1976 (1976-10-05) table VI	27,31
A	US 4 183 931 A (RATHMAN TERRY L ET AL) 15 January 1980 (1980-01-15) example 2	27,31
Ä.	US 3 322 756 A (HANS HILMER ET AL) 30 May 1967 (1967-05-30) columns 7, 8, table	27,31

1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-10, 15-18, 21-23 (all partly)

Present claims 1-10, 15-18, 21-23 relate to methods for treatment of the human or animal body with compounds that are defined by reference to a desirable characteristic or property, namely their activity as selective inhibitors of phosphatidylinositol 3-kinase delta activity in leukocytes relative to other Type I phosphatidylinositol 3-kinase isoforms. The claims cover all methods and compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds being suitable for such methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds/methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods and compounds which are concretely mentioned in the claims and the description (claims 11-14, 19, 20, 24-43 and the examples and concrete disclosures of compounds and structures in the description).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

rnational Application No PCT/US 01/13315

Patent docur cited in search		Publication date		Patent family member(s)	Publication date
WO 941709		04-08-1994	Α̈́P	457 A	01-02-1996
WU 341/U	U . ^	04-00-1994	AT	164849 T	15-04-1998
			AU	679714 B2	10-07-1997
			AU	5885194 A	15-08-1994
			CA	2153688 A1	04-08-1994
			CN	1119440 A ,B	27-03-1996
			CZ	9501879 A3	17-01-1996
			DE	69409503 D1	14-05-1998
			DE	69409503 T2	06-08-1998
		•	DK	680488 T3	25-01-1999
			WO	9417090 A1	04-08-1994
			EP	0680488 A1	08-11-1995
			ES	2117249 T3	01-08-1998
	•		FI	953489 A	13-09-1995
					30-10-1995
			HU	9500514 A3 108372 A	15-06-1998
			IL		
•			JP	8505864 T	25-06-1996
			NO	952872 A	13-09-1995
			NZ	259880 A	26-11-1996
			PL	309975 A1	13-11-1995
			RU	2129561 C1	27-04-1999
			SI	9400021 A	30-09-1994
			SK	91895 A3	03-04-1996
			US	5925624 A	20-07-1999
			บร	5889178 A	30-03-1999
			ZA	9400335 A	24-10-1994
WO 97466	38 A	11-12-1997	AU	719354 B2	04-05-2000
			AU	2970597 A	05-01-1998
			CN	1220701 A	23-06-1999
		•	EP	0914448 A1	12-05-1999
			WO	9746688 A1	11-12-1997
			JP	2000517165 T	26-12-2000
WO 96049	23 A	22-02-1996	AU	712835 B2	18-11-1999
			AU	3278495 A	07-03-1996
			CA	2197205 A1	22-02-1996
•			EP	0771204 A1	07-05-1997
			FI	970588 A	11-04-1997
			JP	10507441 T	21-07-1998
		•	NO.	970631 A	11-04-1997
			WO	9604923 A1	22-02-1996
			US	6054441 A	25-04-2000
		•	US	6060459 A	09-05-2000
EP 06751	24 A	04-10-1995	 ЈР	7316157 A	05-12-1995
Ei 00/21	_+ A	04-10-1332	JP	7316157 A 7316158 A	05-12-1995
			CA	7316158 A 2145443 A1	29-09-1995
					29-09-1995 04-10-1995
			EP	0675124 A2	
			FI	951367 A	29-09-1995
			NO US	951165 A 5602140 A	29-09-1995 11-02-1997
		1P 07 1000			
WO 99348	04 A	15-07-1999	AU	2108299 A	26-07-1999
			EP	1044004 A1	18-10-2000
			WO	9934804 A1	15-07-1999

INTERNATIONAL SEARCH REPORT

information on patent family members

rnational Application No rCT/US 01/13315

	atent document d in search report		Publication date		Patent family member(s)	Publication date
CHEC	In Search report		Gate		interriber(s) .	Odie
WO	9833802	Α		EP	0966476 A1	29-12-1999
				WO	9833802 A1	06-08-1998
				JP	2001511776 T	14-08-2001
	•			US	6156739 A	05-12-2000
MO.	9741097	Α	06-11-1997	AU	3719897 A	19-11-1997
	3, 1203,	••	•••	BR	9711098 A	08-03-2000
		•		CA	2258949 A1	06-11-1997
				CN	1275982 A	06-12-2000
				CZ	9803850 A3	14-04-1999
				EP	0958296 A1	24-11-1999
	•					
			•	NO	986055 A	22-12-1998
				PL	342608 A1	18-06-2001
				WO	9741097 A2	06-11-1997
				US	6114526 A	05-09-2000
			•	บร	6310069 B1	30-10-2001
	•			US	2001031759 A1	18-10-2001
				US-	5985884 A	16-11-1999
WO	9908501	Α	25-02-1999	AU	1120599 A	08-03-1999
				CN	1280571 T	17-01-2001
			•	ΕP	1073643 A2	07-02-2001
				WO	9908501 A2	25-02-1999
US	3984555	Α	05-10-1976	DE	2027645 A1	09-12-1971
				AT	318628 B	11-11-1974
				AT	317899 B	25-09-1974
			•	AT	318615 B	11-11-1974
	₩.			BE	768137 A1	06-12-1971
			•	CA	951319 A1	16-07-1974
				CH	558374 A	31-01-1975
				CH	569732 A5	28-11-1975
				CH	557829 A	15-01-1975
				FR	2100726 A5	24-03-1972
	•			GB	1331522 A	26-09-1973
•				LU	63267 A1	23-08-1972
				NL	7107695 A	07-12-1971
US	4183931	Α	15-01-1980	NONE		
US	3322756	Α	30-05-1967	BE	648093 A	19-11-1964
				CH	447181 A	30-11-1967
				CH	447182 A	30-11-1967
	•			CH	447183 A	30-11-1967
	•		•	DE	1231705 B	
				DE	1249281 B	
				FR	3806 M	
				FR	1404524 A	10-11-1965
				GB	1053063 A	
				NL	6405448 A	19-11-1964
			•	SE	314074 B	01-09-1969
				SE	314075 B	01-09-1969
				SE	314076 B	01-09-1969